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Abstract 
A major contributor to mortality in patients with plasma cell dyscrasias (PCDs); i.e., multiple 
myeloma, light chain deposition disease and AL amyloidosis is the deposition as insoluble 
aggregates of monoclonal immunoglobulin light chain proteins (LC) in the kidneys and other 
organs.  Currently anti-plasma cell chemotherapies are used to reduce LC synthesis, and slow 
deposition.  While effective, these treatments are toxic, non-specific, expensive, and might not be 
appropriate in all cases, making the identification of an alternate means of reducing toxic LC 
species desirable.  To this end, we have investigated whether RNA interference (RNAi) could 
achieve these goals. 
 Human (RPMI 8226, Bur) and transfected mouse myeloma (SP2/O-lambda 6) cells which 
produce measureable quantities of human LC protein were used as model systems for testing the 
efficacy of both synthetic small interfering RNAs (siRNAs) and short hairpin RNA (shRNA) 
expression vectors in reducing LC synthesis.  Sequencing of LC genes provided the basis for 
design of siRNA duplexes targeting either the variable (V) or joining (J) regions of individual LCs, 
or the constant (C) region of either kappa or lambda LC isotypes.  Myeloma lines were transfected 
with siRNAs using lipid-based transfection media.  Cells receiving non-silencing siRNAs served as 
controls.  Exposure of myeloma lines to siRNAs was well tolerated and no cytotoxicity was 
observed.  LC mRNA expression was shown to be reduced ≥40% in 8226 and SP2/O- lambda 6 
cell lines receiving siRNA treatment as compared with untreated controls.  Exposure to siRNAs 
was also effective in significantly reducing both intracellular and secreted LC protein levels in cell 
lines tested as evidenced by flow cytometry or enzyme-linked immunosorbent assays (ELISAs).   
 Effective siRNA nucleotide sequences were used to generate shRNA cassettes which were 
ligated into lentiviral expression vectors under the control of the RNA polymerase III promoter, 
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U6.  These expression systems were used to generate replication incompetent lentiviral particles.  
Exposure of 8226 to lentiviral particles resulted in significant knockdown of LC mRNA and 
protein both in vitro and in xenograft tumor bearing immune compromised mice.  These results 
provide positive evidence for the ability of RNAi based approaches to reduce LC secretion in 
models of PCD. 
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Chapter 1 
Review of the Literature 
1.1 Post transcriptional gene silencing by RNA interference 
Recently, new light was shed on the process by which eukaryotic cells moderate the expression 
of genes following transcription (post-transcriptional gene silencing; PTGS). This process, 
namely, RNA interference (RNAi) is enacted by a conserved family of proteins that, upon 
activation by the presence of short double stranded RNA sequences, abrogate translation of 
messenger RNA (mRNA) in a sequence dependant manner.   
The process of RNA mediated conditional gene silencing was first posited in the early nineties 
with observations made in plants which were infected with viral constructs designed to express 
short mRNAs encoding the chalcone synthase gene, with the intended goal of enhancing petal 
colors in petunias by overexpression of the gene product.  Results from these experiments were 
contradictory to this hypothesis as transgenic plants generated in these experiments exhibited 
either a total or a variegated loss of pigment within the petals (1).  This loss of pigment was 
found to correlate with suppressed levels of both endogenous and exogenous chalcone synthase 
mRNAs, thus the process was originally termed co-suppression (1).  Following these 
observations, a series of studies were enacted to determine if co-suppression was present in other 
organisms  (2) (3).  In 1997 two American researchers Andrew Fire and Craig Mello 
demonstrated that small double stranded RNAs (dsRNA) were the initiating factors of RNA 
interference in the invertebrate C. elegans in a nature publication and were later awarded the 
nobel prize for this work (4). 
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The process of RNAi is highly conserved among eukaryotes and has been posited to have arisen 
as part of a cellular innate immune defense to viral infection and harmful transposable genetic 
elements (5).   Similarly, endogenous siRNAs may be produced which are used to modulate 
normal gene expression.  These so-called microRNAs (miRNAs) were first identified in 
developmental models and were originally termed short-temporal RNAs due to their pattern of 
expression, and have since been shown to mediate tissue and cell cycle specific post 
transcriptional regulation of self proteins (6-9).   
 
Overview of RNA interference 
Initation of the RNAi pathway coincides with the introduction of short dsRNA molecules to the 
cytoplasm of a eukaryotic cell which act as guides for silencing (10) (figure 1.1).  Also known as 
a short interfering RNAs (siRNAs), these molecules are palindromic, double stranded 21-28 bp 
RNA sequences showing either complete or nearly complete complimentarity and possessing a 
characteristic 2-4 nucleotide overhang on the 3’end of each strand  (11, 12).  Generation of 
siRNAs is the result of a multi-protein complex, whose enzymatically active member, known as 
Dicer belongs to the RNase III family of proteins.  Dicer is capable of generating double strand 
endonucleic cleavages along longer dsRNA transcripts produce the characteristic siRNAs 
described above (13).  Dicer, along with mature siRNAs, then acts as a nucleus which triggers 
the association of several specialized proteins into a larger multi-protein complex known as the 
RNA Induced Silencing Complex (RISC). As the RISC assembles Dicer transfers the siRNA to a 
protein belonging to the Argonaute (Ago) family (of which there are four in humans), and the 
siRNA is cleaved into its component nucleotide “guide” and “passenger” strands, with the strand 
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showing the lowest thermodynamic stability at the 5’ end being preferentially transferred (14, 
15).  Proteins of the Ago family (Ago 2 in humans) have been found to have both an RNA 
binding domain (PAZ) as well as an active RNase site (PIWI) and are thought to be the 
enzymatically active portion of RISC, details of which are summarized in (Figure 1.2) (14).  
Using the guide strand to locate target mRNA molecules by complimentary bp binding RISC 
prevents translation and protein synthesis in several ways;  In the case of siRNAs, the perfect 
pairing of guide to target triggers allows cleavage of the mRNA by the PIWI domain of the Ago 
protein (579).  The guide strand also acts in concert with Ago as a “molecular ruler”, generating 
cleavage sites which are defined in relation to the siRNA 3’ end, occurring between the 10th and 
11th nucleotide of the bound portion of the mRNA strand (16).  Imperfect base among partner 
RNA strands may induce silencing as well, as is the case with another class of interfering RNA 
molecules, the miRNAs.  These act along a parallel pathway as siRNAs, however, bulges 
generated by imperfect pairing prevent cleavage by RISC. Silencing generated by miRNAs is a 
result of inhibition of translation by the bound RISC complex.  These bound mRNAs may also 
be removed to cytoplasmic storage centers called “processing bodies” (p-bodies) for degradation 
or future release (15). 
 
Endogenous interfering RNAs 
Endogenous short dsRNA sequences are transcribed from stretches of non-coding DNA by either 
RNA pol-II in the case of miRNAs or RNA pol-III enzymes as with shRNA molecules. Of the 
endogenous silencing RNAs, ShRNAs are perhaps the simplest consisting of two complimentary 
21-28nt sequences which are separated by an intervening stretch of non-complimentary nucleo- 
 Figure 1.1 Outline of RNA interference.
hairpin RNA molecules with 2nt 3’ overhangs, while RNA polymerase II enzymes synthesize 
longer primary miRNAs (pri-miRNA). Pri
to mature miRNAs containing hairpin loops and 2nt 3’ overhangs.  Structural recognition of the 
3’ end overhang by the nuclear export protein exportin 5 allows transfer of the nucleic acid
cytoplasm.  Processing by nuclease enzyme Dicer removes loop portion, leaving short dsRNA 
molecules upon which the RNA induced silencing complex (RISC) forms.  Further processing 
removes passenger strand RNA while the guide strand remains associate
identifies target mRNA strands.  Perfect homology results in cleavage of target sequence, while 
imperfect pairing results in inhibition of translat
from (17).  
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Figure 1.2 Schematic depiction of the model for siRNA-guided mRNA cleavage by Ago. 
Within the Ago protein (Red, Green, Purple, Blue) the siRNA (yellow) binds with its 3’ end in 
the PAZ cleft (red) and is directed along a groove which facilitates duplex binding between PAZ 
and the RNase domain PIWI (purple).  The 5’ phosphate group interacts with a second site on 
PAZ to stabilize the interaction between siRNA and Ago, as well as to produce the crucial 
binding region for target mRNA loading, known as a “seed region” this area corresponds to 
nucleotides 2 through 8.  Target mRNA is introduced between the amino terminal (blue) and 
PAZ, exiting between PAZ and the middle domain (green).  Cleavage of target mRNA occurs at 
a conserved site containing two aspartate and single histadine residue (scissors) found within the 
PIWI domain (purple). Taken and summarized from (14).  
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tides.  Upon transcription, shRNA gene products self-anneal to generate a stem-loop structure 
with a short overhanging sequence found at the 3’ terminus.  Recognition of the overhang region 
by the protein Exportin-5 facilitates transfer from the nucleus to the cytoplasm (18-21).   
Initial transcription of miRNA genes produce longer (up to several kilobases) primary-miRNAs 
(pri-miRNA) which are processed by the RNase III-like enzyme Drosha to ~70 nt shRNAs 
complete with 3’ overhang (22-24).  In contrast with shRNAs, miRNAs contain short regions of 
mismatch between strands causing bulges to form during folding.  As with shRNAs the nuclear 
export protein, Exportin-5, recognizes the 3’ overhang and transports the nucleic acid to the 
cytoplasm where it is processed by Dicer and incorporates to RISC as above (21).  Schematic 
representations of each species are illustrated in Figure 1.3. 
 
Exogenous siRNAs 
Since their discovery over a decade ago countless studies have utilized the phenomenon of RNAi 
as a means to probe gene function within the laboratory and have postulated their use in the 
clinical setting to target gene products associated with a variety of pathologies (25).  Design of 
these molecules has been optimized based on the characteristics of naturally occurring siRNAs, 
shRNAs, and miRNAs to allow efficient incorporation to the RNAi pathway (26, 27).  
Introduction of functional interfering RNAs has been shown possible using a variety of 
transfection methods each with their own strengths and weaknesses (Table 1.1).  These user 
generated siRNAs may be synthesized and pre-annealed siRNAs and introduced to the cytoplasm  
 Figure 1.3 Structural differences between interfering RNA species.
by RNase enzyme Dicer removes hairpin loop generating B) a 21
Cropping of longer pri-miRNA sequences by the nuclear enz
miRNAs, which will be further processed by the Dicer enzyme to form D) mature miRNAs.   
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Table 1.1 Strategies for delivery of interfering RNAs 
Class Method Advantages Disadvantages Examples 
     
Physical Direct injection 
Electroporation 
Laser Irradiation 
Sonoporation 
Magnetic nanoparticle 
Not cell type 
specific, 
Physical relocation 
of nucleic acid to 
cell, no vector, 
single cell 
transfection 
Laborious, high level of 
skill required, costly 
equipment 
Gene gun, 
amaxa 
nucleofector, 
microneedle 
Chemical Cationic Polymer 
Ca++ Phosphate 
Cationic Lipid 
No need for vector, 
high- efficiency, 
commercially 
available, no size 
limit for cargo 
Transfection efficiency 
can vary, cytotoxicity, 
some cell types hard to 
transfect 
Lipofectamine, 
invivofectamine, 
HiPerFect, 
DOTAP, DEAE 
dextran  
Biological Virus Mediated High-efficiency, 
simple to 
administer, may be 
used in vivo 
Biosafety concern, 
insertional mutagenesis, 
immunogenicity, limited 
package size, costly 
production, fragility of 
viral particles 
Lentivirus, 
Herpesvirus, 
Adenovirus, 
Adeno-
associated virus, 
vaccinia virus, 
sindbis virus  
Adapted from (28) 
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physically or chemically, or incorporated into viral vectors capable of nuclear expression of gene 
transcripts encoding siRNA precursors such as shRNAs or pre-miRNAs (28-31). Table 1.2 
summarizes the compatibilities of these systems and refers to selected studies in which they have 
been used. 
 
1.2 Introduction to the plasma cell 
The plasma cell is a functionally active and terminally differentiated lymphocyte arising from the 
b-cell lineage. The b-cell repertoire within higher vertebrates contains an astounding collection 
of cells whose immunoglobulin (Ig) products are capable of recognizing a multitude of unique 
antigens.  The amount of diversity seen in the Ig complement comes from the ability of the B-
cell to recombine and mutate the germline genes which encode the Ig products.   Plasma cells 
arise from a series of activation and selection events stemming from the interaction of a 
specialized b-cell receptor with antigen, engulfment of the receptor antigen complex, and 
expression of antigen proteins on major histocompatibility complexes leading to activation by 
helper t-cells.  Under normal circumstances these activation events lead to a controlled 
monoclonal expansion of b-cells capable of producing Ig proteins that interact with the given 
antigen.  This expansion of a single b-cell subgroup, paired with the almost unlimited variability 
of the Ig product allows plasma cells to recognize an exceedingly wide variety of antigens and 
makes them an integral component of the adaptive immune system.   
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Table 1.2 Compatibility of synthetic interfering RNAs with various delivery systems 
Type of interfering RNA Route of 
introduction 
Cell compartment Refs 
    
siRNA/miRNA Physical cytoplasm  (30-34) 
 Chemical cytoplasm  (28) 
shRNA Physical cytoplasm (35) 
 
 
Chemical Cytoplasm (35) 
 Biological Cytoplasm/nucleus  
Pre-miRNA Physical Cytoplasm  
 Chemical Cytoplasm  
 
Biological Cytoplasm/Nucleus 
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Immunoglobulins 
Structurally the mature Ig product of the plasma cell is a 150 kDa molecular weight molecule 
composed of two 330-440aa 50 kDa regions, the heavy chain (HC), and two 100-110aa 25 kDa, 
the Ig light chain (LC) regions.  Amino acid sequencing of the Ig have yielded regions of 
homology in both the LC and HC chains representing the domains of each peptide class. Based 
on the extent of this homology these domains have been termed either the variable (V) or 
constant (C) domains.  Thus the LC is composed of one VL and one VC domain, while the IgHC 
is composed of one VH domain and 3-4 CH domains based on the Ig class (36). These 
polypeptide chains adapt a pleated beta sheet structure of alternating hydrophobic and 
hydrophilic residues with the individual domains held in conformation by the hydrophobic 
interactions and with a conserved disulfide bond (37).  The Ig molecule itself is encoded by 
multigene families located on separate chromosomes (37).  Each of the genetic loci contains a 
series of gene segments encoding regions of the HC or LC proteins.  Each of these gene 
segments are in turn flanked by specific sequence motifs that provide a recognition site for 
proteins encoded for by two distinct recombinase activating genes (RAG 1/2).  The 
recombination signal sequences are a conserved palindromic heptamer and AT- rich nonamer 
separated by a 12 or 23 base pair sequence (38). Recognition of these sites by RAG proteins 
allows for the formation of novel Ig proteins based on the rearrangement and splicing of the 
individual V and C regions within the LC DNA and the V, C, as well as the added diversifying 
(D) region within the HC (38).  This signal sequence also directs the rejoining of the cleaved 
DNA strands resulting in a directed recombination of the HC gene into the mature form which 
contains the V, (D), J, and C regions.  This process is repeated along the LC gene locus resulting 
in a b-cell which is unique at three separate levels; a) selection of V, D, J, and C segments, b) 
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selection of HC and LC sub-types, and c) insertions and deletions introduced during 
rearrangement.   
 Following the expression of a functional B-cell receptor (BCR) the maturing b-cell 
migrates from the bone marrow to lymphoid follicles.  Antigenic challenge of these follicles 
induces the formation of germinal centers which act as sites of selection and activation of b-cells 
through the binding of antigen displayed by follicular dendritic cells with the BCR. At this point 
the maturing Ig gene undergoes a form of secondary diversification in a unique process termed 
somatic hypermutation (SHM).  SHM is an enzymatic process involving Activation-Induced 
Cytidine Deaminase (AID) which introduces point mutations within key “hotspots” of the  HC 
and LC V regions (39).  These point mutations occur by the selective conversion of cytidine to 
uridine within single stranded DNA loops of transcription bubbles (40).  This mismatch lesion is 
then either carried on during replication to form an A:T substitution or is repaired by low fidelity 
polymerase enzymes which induce further substitutions and subversions to the genetic sequence 
(41).    
B-cell origin and differentiation 
Cells of the B-lineage arise from pluripotent hematapoetic stem cells within the fetal liver and 
the bone marrow in most mammals (42).  Identification of these cells have been carried out by 
immunologic methods based on the presence of conserved surface markers such as CD43, HSA, 
and cKIT.  Of these pluripotent cells a subset has been identified which gives rise to B and T 
lymphocytes as well as Natural Killer (NK) cells and are thus termed common lymphoid 
progenitor cells(43).  It is from this group that the early phase pro-B cell population originates, 
characterized by its expression of the b220 isoform of CD45 as well as terminal 
13 
 
deoxynucleotidyl transferase (TdT) in conjunction with the lack of CD19 expression (present in 
all further differentiated B-cell subsets).   At this point key genetic rearrangements occur, which 
give rise to the recombination of the Ig heavy chain gene locus HC through the activation of 
genes RAG 1/2 (44).  During recombination of the HC genes the protein products of the RAG-1 
and RAG-2 genes perform site specific double stranded cleavages of the genomic DNA strand 
using a unique signal sequence motif recognized by the enzymes (38).     
Because of the immense capacity of an activated b-cell to produce Ig protein the pathologic 
potential of unregulated expansion of a monoclonal b-cell population is compounded.  Indeed, a 
major contributing factor to the morbidity and mortality of patients diagnosed with plasma cell 
dyscrasias is the aggregation and deposition of the monoclonal Ig protein within the organs, the 
most commonly affected being the kidneys.  The chronic deposition of these proteins leads to 
progressive organ failure.  The potential of organ involvement by circulating Ig proteins poses a 
unique problem for the treatment of b-cell malignancies as a detectable expansion of monoclonal 
b-cells is not always required for pathology to occur.    
1.3 Plasma cell dyscrasias 
The following section will address plasma cell dyscrasias (PCD) starting with the pre-malignant 
condition known as monoclonal gammopathy of undetermined significance (MGUS) and the 
malignant condition multiple myeloma (MM). An overview of MM will be provided which will 
include; diagnosis, staging, epidemiology, and a summation of lytic bone lesions.  This will be 
followed by a discussion of pathologies arising from overproduction and deposition of 
immunoglobulin component proteins (i.e., LC) which, although often occurring concurrently to 
MM, may arise independent of a detectable malignant plasma cell compartment.  The final 
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portion of this section will provide a brief review of some of the therapeutic options that are 
currently used in treatment of MM and PCD.   
Plasma cell dyscrasias 
Plasma cell dyscrasias (i.e., MGUS, multiple myeloma, plasmacytoma, light chain amyloidosis, 
etc) represent a spectrum of pre-malignant and malignant states arising from the late B-cell 
compartment.  Dysregulation of cell processes result in the expansion of a monoclonal 
population of these antibody secreting cells, which home to the bone marrow microenvironment, 
inducing a variety of disorders ranging from the formation of lytic bone lesions, immuno- 
suppression, decreased hematopoesis, and organ dysfunciton.  A characteristic feature of PCD is 
the presence of the so called M-protein, which is a measurable spike in serum and urine protein 
levels, occurring from the overproduction of immunoglobulin (Ig), or immunoglobulin 
component (i.e., LC or HC) by the monoclonal cell population.  The overproduction of Ig, LC, or 
HC is of additional concern as the increased protein load may lead to pathologies apart from the 
primary neoplasia, occurring mainly by deposition and aggregation of protein in the organs and 
soft tissues.  Renal function is of particular susceptibility in PCDs, in part due to the role of the 
kidney in clearing small proteins such as LCs and HCs, and to Ig independent conditions which 
may occur during the course of PCD.   
 
Monoclonal gammopathy of undetermined significance 
A spike in monoclonal Ig (M protein) is perhaps the most common abnormalities upon 
hematologic examination, occurring in 3% of persons over 50 and in up to 7% of patients 
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seeking a medical evaluation (45).  LC M protein was first described by the English physician 
Henry Bence-Jones in Thomas Alexander McBean, a patient of Dr. William Macintyre, who 
referred to the curious properties of an “animal matter” that was present in the patients urine.  
Thus, the term Bence Jones Protein (BJP) was born into existence (46-48).   
Spikes in M protein in the serum and urine were recognized as an indicator of a potentially 
malignant condition early on, and are detected by agarose gel electrophoresis followed by 
immunofixation to determine M protein components (49).  M protein can be quantified by rate 
nephelometer (48).  The presence of a small protein spike without evidence of MM or other PCD 
has also been described, known as essential hyperglobulinemia, benign monoclonal 
gammopathy, or the modern MGUS (50, 51).  MGUS is described as a pre-malignant disorder 
characterized by limited plasma cell expansion without organ involvement (52).  MGUS is often 
described as a precursor to MM or other PCDs. Like MM risk increases with age, and 
Approximately 1% of patients diagnosed with MGUS will proceed to MM per year (53).      
 
 Multiple Myeloma 
Diagnosis of multiple myeloma 
Multiple myeloma is a clonal expansion arising from the plasma cell compartment with 
infiltrates detectable in the bone marrow microenvironment and to a limited extent other organs 
(extramedullary).  Patients most commonly seek medical attention due to bone pain (40-70%), 
weakness (20-60%), or recurrent infections (54).   
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Positive diagnosis of MM is based on several criteria: Presence of an elevated M protein in the 
sera or urine, greater than 10% monoclonal plasma cells detected in the bone marrow, and 
evidence of  end organ damage, as indicated by elevated calcium levels, renal insufficiency, 
anemia, and bone lesions present on radiograph (55, 56).   
The most direct consequence of expansion in monoclonal plasma cells is the presence of a 
monoclonal Ig protein spike (M-protein) in the serum and urine.  This spike was reported to be 
detectable in 82% of patients by electrophoresis, and in 93% of patients by immunofixation, 
while a portion of patients exhibit a monoclonal PC expansion absent M protein (47).  
Approximately 20% of myeloma patients are found to exhibit increased sera and urine LC levels, 
in absence of HC protein (57).  Anemia has been reported in 70% of patients, hypercalcemia in 
~25% of patients, and elevated serum creatinine levels in upwards of 50% of patients (57).  Lytic 
bone lesions and fractures are detectable in up to 80% of patients due to changes in the bone 
marrow microenvironment brought about by the presence of the monoclonal plasma cell 
population (58).   
 
Staging in multiple myeloma 
As with other malignancies, a standardized system of classification and prognosis for the severity 
and progression of MM is important.  However, as MM consists of diffuse collections of 
plasmacytoid cells, it has presented special challenges for the development of systemic 
classification of tumor burden in the patient.  As such, staging in multiple myeloma has 
undergone several evolutions since the initial scheme was proposed by Durie and Salmon in 
1975 (59).    These revised systems include; the Durie-Salmon plus, southwestern oncology 
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group, Mayo, and international staging systems, which were subsequently developed over the 
ensuing 35 years (59-62).    
As mentioned, initial efforts to stage myeloma cell burden were carried out in the mid-1970’s by 
Brian Durie and Sydney Salmon using sera and urine M-protein measured from 105 MM patients 
to estimate total MM cell numbers.  In this, the Durie-Salmon system (DS), monoclonal cell 
mass was shown to correlate both singly with serum and urine M protein levels and with 
clinically significant criteria (hemoglobin, serum calcium, and presence of bone lesions), when 
taken together, could be used to generate a 3 category staging system.  Each stage, representing a 
low, medium, or high myeloma cell mass.  In addition, Durie and Salmon also identified serum 
creatinine as a correlate to survival, and further modified the initial three tier system to include A 
and B sub-categories which made the system a more robust prognostic metric for not only 
survival, but response to therapy as well (60).  These results were confirmed by Alexanian et al. 
(63) in a similar study with the Southwestern Oncology Group (SWOG) which included a larger 
patient sample and proposed a similar staging system to that of Salmon and Durie.   
Following these initial efforts several subsequent studies reevaluated the metric for tumor mass 
and found that serum albumin and beta-2-microglobulin (β2M; a component of the MHC protein 
found on the MM cell surface, useful as an indicator of cell proliferation) were accurate 
predictors of overall survival (63-66).  Although these observations were made as early as 1982, 
they weren’t widely accepted until 2003 when SWOG proposed a revised 4-tiered staging system 
based on using β2M and serum albumin exclusively (59).  In the interim, a 1993 study by the 
Mayo clinic reviewed 107 patients and proposed staging of myeloma using a multivariate system 
measuring β2M and serum creatinine along with thymidine kinase and C-reactive protein (CRP) 
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as measures of proliferation and IL6 production, respectively.  This study also pressed for the 
inclusion of a plasma cell labeling index, in which plasma cells were identified by fluorescent 
immunohistochemical labeling for light chain production, and cell cycle determined by the 
incorporation of 5-bromo-deoxyuridine, indicating those in S-phase (61).      
As previously mentioned, the widespread acceptance of β2M as a metric of Myeloma cell 
proliferation occurred in 2003 with the publication of a review of 1,555 patients by the SWOG.  
In this study, again, several metrics were evaluated while β2M and serum albumin were shown to 
be the most powerful indicators of survival, again, measuring proliferation and IL6 production, 
respectively.  This study proposed a 4 tiered system, and demonstrated a close relationship in 
staging to that of the original DS system (59).  Most recently, the findings that β2M and serum 
albumin were perhaps the best (and most easily obtained) metrics for staging myeloma patients 
were confirmed by a multinational effort, leading to development of the International Staging 
System (ISS).  In this 2005 study 10,750 myeloma cases were reviewed in 17 centers across 
North America, Europe, and Asia, which served to confirm the observations made over 20 years 
prior (62). 
In summary, staging in MM seems to have made a single major change over the last 30 plus 
years, switching from a combination of M-protein, extent of bone lesions, and hemoglobin as the 
gold standard, to β2M and serum albumin.  The benefit of the latter seems to be the ease of 
sampling, while losing no advantage to the prior system.   
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Epidemiology of multiple myeloma 
The annual incidence of newly diagnosed cases of MM is reported as 0.4-5 new cases per 
100,000 people per year worldwide (67).  According to the most recent annual factsheet 
generated by the National Cancer Institute reviewing incidence and mortality data from the 
surveillance epidemiology and end results (SEER) database there were, in the United States, an 
estimated 20,180 new cases of MM in 2010, with 11,170 males and 9,010 females constituting 
these cases (68).  This represents an age adjusted incidence rate of 7.2 and 4.6 new cases of MM 
per 100,000 people per year in males and females, respectively (68).  On January 1, 2008 there 
were reported to be 64,165 people living, with a history of MM in the United States, while an 
estimated 10,650 died of the disease (68). MM also ranks in the top 15 cancers in the U.S. for 
males as reported in a recent sex selected, age adjusted survey of SEER data (69).   
Since as early as 1945 the incidence rate in MM has risen gradually.  In the U.S. population as a 
whole, incidence rate of MM in 1949 was reported as occurring in 0.8 per 100,000 persons per 
year.  This rose to 1.7 per 100,000 by 1963, and 3.2 per 100,000 persons by the end of the 1980’s  
(47). A similar trend was reported in a survey of residents of Olmsted County, MN spanning 
from 1945-1990.  In this report the initial incidence rate was significantly higher than that 
reported nationwide with a rate of 3.1 per 100,000 in the years spanning from 1945  to 1964 
while the trend towards increasing incidence persisted to the 1990 level  of 4.1 per 100,000 from 
1978-1990 (70).  Analysis of SEER data using the embedded faststats program confirmed this 
trend from 1975 until around 1992, when the reported incidence of MM seems to have plateaued 
(Figure 1.4 ). 
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Figure 1.4 Association of age and diagnosis of MM.  Data were taken from SEER Cancer 
Statistics, while the figure was generated using the online SEER FastStats program. 
(http://www.seer.cancer.gov/faststats ) 
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 Efforts have been made to determine risk factors for MM, examining the roles of age, 
genetic background, race, obesity, exposure to certain toxins, and exposure to ionizing radiation  
in MM pathogenesis.  Of these, age has shown consistently to be the strongest factor in risk for 
MM occurrence.  Taken from the 2008 SEER data, the median age of diagnosis for MM was 69 
years of age (68).  This trend was also reflected in a review of 1,027 newly diagnosed MM 
patients from the Mayo Clinic, and published in a 2003 article by Kyle et al (47).  Compared 
with the SEER data, those collected from the Mayo study demonstrate an increased percentage 
of patients within comparable age groups (i.e., 34-45 v. 40-49), which may be due to the 
inclusion of older patients within those groups, given risk increases with age.   
 Aside from age, race has been implicated as the second most apparent risk factor in 
numerous studies of MM incidence and outcome (68, 71-73).  These studies consistently indicate 
the risk of developing MM in blacks is twice that of whites, while Asians have the lowest 
incidence.  While clear differences among genetic or environmental factors have yet been 
elucidated, these data seem to imply that one or more may exist and contribute to disease 
pathogenesis and progression.  Factors which have been examined so far have ranged from 
obesity (74), socioeconomic status (75), exposure to organochlorine pesticides (76), and 
exposure to ionizing radiation (77).  Of these, experimental groups have shown a slightly 
increased risk to MM, while studies of atomic bomb survivors from Hiroshima and Nagasaki 
have revealed conflicting reports as to a much higher incidence of MM and monoclonal 
gammopathy of unknown significance (MGUS) (77, 78).  In addition, numerous other studies 
have examined tobacco use, occupation, etc. revealing no clear correlation with MM incidence.  
These studies have been summarized previously in several review articles and books (71). 
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Myeloma bone disease 
The most prevalent feature of MM as a consequence of monoclonal plasma cell infiltrates are the 
presence of lytic bone lesions. These lesions occur most often in the spine as well as the 
proximal long bones manifesting as bone pain and compression fractures, and are visible by 
radiograph (79).  Formation of these lesions is due to a decoupling of bone resorption with the 
process of new bone formation.  Under normal circumstances the rate of bone turnover is held at 
a constant rate through degradation by osteoclast activity and formation of new bone by the 
osteoblast activity.  However, the presence of myeloma infiltrates in the bone marrow 
microenvironment upsets this balance to favor bone resorption over bone formation.  Numerous 
studies have demonstrated that MM cells produce a variety of factors that influence osteoclast 
activation, while simultaneously down-regulate osteoblast differentiation and activation (80).  As 
a result of osteolytic activation, MM patients often present with elevated calcium levels (>2.6 
mmol/L in 20-30% of patients) (81).  The elevated Ca++ levels observed in these patients have 
the potential to interfere with cardiac and renal function through the inhibition of Na++ 
reabsorption, and consequential activation of the renin-aldosterone system.  Hypercalcemia may 
also decrease glomerular filtration rate by constriction of afferent glomerular arterioles, as well 
as induce progressive tubular necrosis and renal acidosis.   
 
 Immunoglobulin light chains and disease pathogenesis 
A major consequence of the expansion of monoclonal plasma cells is the overproduction of Ig or 
Ig component protein (i.e. LC or HC).  In the following sections the impact of increased Ig 
paraprotein on renal function (and to a lesser extent other organs) will be examined.  While these 
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pathologies may occur concurrently with MM, it is important to note that they may also occur in 
a pre-malignant state in which the patient may not meet criteria for diagnosis of MM (similar to 
MGUS), thus placing the importance on the paraprotein. 
Synthesis of immunoglobulin protein is a multi-step process; the genes encoding HC and LC 
reside in separate chromosomal regions and are synthesized at different rates (37, 82, 83).  In 
addition, chromosomal translocations and deletions common to myeloproliferative disorders 
often lead to the inactivation of HC translation and synthesis (4q:14).  These factors result in 
disorders involving LC deposition to be over represented in comparison to those involving the 
HC, thus focus will be given to LC involvement with organ dysfunction.  The terms M protein, 
Bence Jones Protein (BJP) and serum or urine free light chain (FLC) will be used 
interchangeably.   
As previously described and increased amount of Ig or Ig component protein in the urine or 
serum is a common finding in PCDs.  This increase in M protein can be exploited during 
diagnosis and staging to provide a measure of clonal expansion through the use of assays 
designed to detect and quantitate the κ or λ isotype of the LC component (84).  A shift in the 
ratio of free LC to either the κ or λ subtype provides a measure to determine the LC isotype 
being expressed by the clonal plasma cell and aids in immunohistochemical and molecular 
analysis of the LC in question (85). 
The function of the kidney is to remove waste products from the blood through the process of 
filtration, reabsorption, and secretion of many chemicals while conserving filtered electrolytes 
and essential metabolites.  Properties of molecules important for interactions with the kidneys 
include; size, isoelectric point, crystal formation, and metal content (86).  Renal function in 
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estimated to be impaired in upwards of 50% of MM patients at time of diagnosis (87), and is a 
negative prognostic indicator of survival when compared to patients admitted without renal 
insufficiency (47, 88, 89).  Conversely, improved renal function in response to treatment is 
correlated to improved outcome (488). In the broadest sense, damage to the kidneys by LC 
protein is brought about by mechanical inhibition by LC aggregates of the kidney’s ability to 
conduct fluid within the renal spaces, and by direct cytotoxicity during the interaction between 
the LC complexes and cells of the kidney (90, 91).  Organizationally, LC aggregate in a variety 
of ways; they may occur amorphously (myeloma kidney Figure 1.5 A), or appear organized in 
fibrillar (light chain or primary amyloidosis; AL) (Figure 1.1 B) or granular (light chain 
deposition disease; LCDD) (Figure 1.1 C) aggregates (refs).  These features are a consequence of 
the folding stability and physical features of the individual LC molecules, which in turn, are a 
direct result of individual LC sequence (92, 93).  These aggregates may be formed from either κ 
or λ LC isotypes, whereas the distribution of the different LC species varies with type of 
depositon (94, 95).  In addition, aggregates may consist of various LC subtypes of either family 
(i.e., Vλ1, Vκ3, etc.)  as well as portions of the LC paraprotein (i.e. V-Jλ, Cκ, etc.), and this 
composition has also been posited to control tissue distribution within an individual patient (96). 
Myeloma cast nephropathy 
While other factors may impact renal performance during MM or other PCD (i.e., 
hypercalcemia, infection, dehydration), a major concern for dysfunction is the production and 
deposition as insoluble aggregates of monoclonal free light chain.  Under normal circumstances, 
0.5-1 g/d polyclonal free LC is produced, secreted into circulation, and processed by the kidneys.   
 Figure 1.5 Images of LC deposits within the renal spaces.
sources and illustrate the variability seen with LC deposits:  A.) Amorphous aggregates seen 
with myeloma kidney, B) Fibrillar aggregates seen with AL amyloidosis, and C) granular 
deposits seen with LCDD. 
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  Images were taken from various 
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Provided no impairment in renal function the kidneys are capable of managing 10-30 g FLC per 
day (48).  This free LC protein may exist either as a 22 kDa monomer or a 44 kDa dimer, both of 
which are small enough to pass through the glomerular basement membrane into the renal 
tubules.  Here free LCs bind to the megalin-cubulin complex (97), are absorbed to proximal renal 
tubule cells by endocytosis, and catabolized to constituent amino acids by hydrolysis following 
binding to lysozomal compartments (98). Of the initial amount of produced LC, only ~0.4 mg/kg 
bw/d is secreted in the urine.  During the course of MM the clonal expansion of the plasma cell 
results in the overproduction of Ig or Ig component protein (i.e., FLC or BJP), drastically 
increasing circulating LC levels, and increasing BJP to levels of 20 g/day or greater (99).  
Increased levels of LC within the proximal tubular space quickly exceed the ability of renal 
epithelial cells to clear excess LC and leading to spillage to the distal renal tubule.   
Following saturation of cubulin-megalin complex, excess LC proceeds along the nephron to the 
distal renal tubule where it may bind with Tamm-Horsfall mucoprotein (THP). THP is a 616 aa, 
70 kDa membrane-bound protein, secreted by epithelial cells within the distal luminal spaces of 
the thick ascending loop of Henle (100-102).  Interaction between LCs and THP were found to 
occur between a conserved 9 aa sequence and the CDR3 region in both κ and λ LCs (100).  
Further, the isoelectric point (pI) is thought to contribute to the binding of LC with THP, as LCs 
with a pI above 5.1 (pH of renal tubule fluid) are conferred with a net positive charge which 
contributes to stability with the anionic THP (103, 104).   These protein complexes accumulate 
to large, fractured, waxy casts in the lumen of distal and collecting tubules.  These casts are 
eosinophillic, polychomatophillic, and are stained by periodic acid-schiff (105).  Infiltration and 
interaction with cast protein by monocytes results in the formation of mononuclear and 
multinuclear giant cells.  The immune response along with the cytotoxic effect of the LC 
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complexes results in diffuse damage within both distal and proximal tubules with areas of 
denuded basement membrane, flattened epithelial cells, and atrophied or necrotic regions (91, 
105).    As the process of deposition continues, fluid volume becomes increasingly reduced, 
further concentrating Ig precursor proteins and enhancing deposition (106).  Evidence also 
suggests that increased NaCl levels renal tubules may increase binding rates between LCs and 
THP, thus potentiating accelerated cast deposition (90).  
In addition, the presence of FLC may also present further challenges to renal function as there 
have been reports that certain LC species may exhibit a cytotoxic inhibition of sodium dependent 
uptake of glucose, alanine, and phosphate by brush border vesicles and proximal renal tubule 
cells (91, 107, 108).    
 
Light chain deposition disease 
Light chain deposition disease (LCDD) is defined as the monotypic deposition of LCs in various 
organs, (109).  While they may occur in any organ, deposits are predominantly localized to 
kidney basal membranes and appear as granular electrodense material, refractory to congo red or 
thioflavin T, but easily stained by immunohistochemistry (95, 110). The most common finding at 
time of presentation is renal insufficiency, proeinuria, and, upon biopsy, nodular sclerosing 
glomerulopathy. This form of LC deposition is relatively rare, in one study of over 5,900 renal 
biopsies LCDD was identified in 6 patients (111). Of LCDD cases, approximately 50% occur in 
concordance with overt MM, with these cases the risk of death is 2.55 times higher than with 
MM alone (110, 112).  In the majority of cases, deposits consist of primarily the C region of κ 
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LCs (68% v 32% Cλ) (95).    Mechanisms of renal damage in LCDD are thought to arise from an 
interaction between LC and a surface receptor found on renal messangial cells (113).  
Interactions between LC and messangial cells result in transformation of cells to a 
myofibroblastic phenotype, followed by the deposition of extracellular matrix material and 
resulting in tubulointerstitial fibrosis (114, 115).  In a multi center study Pozzi et al. reviewed 63 
patients with LCDD.  At the time of presentation ninety-six percent presented with renal 
insufficiency, and by 6 months renal function had deteriorated to the point of proteinuria in 37% 
of participants (95).   
 Therapy for LCDD is similar to that of MM.  Both conventional and high dose 
chemotherapeutics in conjunction with ASCT are utilized to reduce the clonal B-cell population, 
with intent of slowing the rate of deposition, with reports of these interventions showning 
varying success (111, 116-118).   
 
Light Chain Amyloidosis 
 Light chain or primary amyloidosis (AL) refers to the deposition of LC proteins in an 
ordered, fibrillar arrangement.  The term amyloidosis refers to any disease caused by the 
deposition of amyloid fibrils.  Amyloid is defined as an insoluble fibrillar protein, deposited 
within the extracellular matrix, in vivo which can be distinguished from non-amyloid deposits by 
fibrillar appearance upon electron microscopy, typical cross β-sheet pattern by x-ray diffraction, 
and a high affinity to Congo red, with resulting apple green birefringence when viewed under 
polarized light (119).  Heretofore, there have been 25 proteins described which are known to 
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form amyloid fibrils under physiologic conditions and are involved in a range of disease states 
from type II diabetes to Creutzfeldt Jacobs disease (120). Classification of amyloidosis is based 
on two criteria; first, the type of amyloid is determined by the precursor protein that makes up 
the fibrils, and second, the extent and numbers of sites for deposition make up the criteria for 
systemic or localized amyloidosis (121).   
AL is one of the two most common systemic amyloidoses, although on rare occasions it may be 
observed to have a localized site of deposition (122).  While AL may be diagnosed apart from 
hematologic malignancy, it is known to occur in 10-15% of MM patients with a median survival 
of less than 2 years (123).  Conversely, even fewer patients diagnosed with AL progress to 
develop overt lymphoproliferative disorders, likely because the short survival time from 
diagnosis pre-empts the rate of clonal expansion (124).  AL deposits have been described in a 
range of tissues including; kidney, heart, liver, nerve, GI tract, lung, as well as soft tissues (125).  
Diagnosis of AL is reflective of this, as patients often present with vague and disparate 
symptoms, depending on the organ involved (126).  In addition, confirmation of AL requires a 
positive biopsy for amyloid deposition from the organ(s) which are suspected of involvement 
(125).  
During LC amyloid formation, the growing fibril recruits misfolded LC paraproteins and 
arranges them from their native conformation into a well organized β-sheet motif, stabilized by 
the formation of intramolecular H bonds (120).  Unlike LC cast nephropathy, the LCs involved 
in AL are rarely intact, in the majority of amyloids only the N-terminal V and J regions are 
present (525). As amyloids which contain an intact C region, or are composed of C region 
paraprotein are so rare, it is likely that this truncation is a requirement for fibril formation and is 
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reflective of the thermodynamic instability of the VJ region (127). Although all LCs are capable 
of forming amyloid fibrils, those formed from λ LCs are appear at a 3:1 ratio as compared with κ 
LCs (122).  The most common subgroups of LCs involved in AL are the Vκ1 and VλVI groups, 
which are of particular interest in AL studies for their ability to preferentially associate to 
amyloid fibrils (128, 129).  This illustrates the importance of the primary sequence of the LC 
protein, which has been shown to correlate with a variety of features in AL ranging from 
tendency to form fibrils, sites of organ and tissue involvement, and toxicity (92, 114). 
 While any organ other than brain can be involved with systemic AL, the most commonly 
affected are the kidney and heart (129).  Clinical presentation is reflective of the organ involved.  
Findings in patients with renal involvement are proteinuria and other symptoms of nephritic 
syndrome.  Likewise, patients with cardiac amyloid often show an acute onset, and rapidly 
progressing congestive heart failure with abnormal echocardiographic findings upon clinical 
evauation . Patients with AL have a relatively poor prognosis, with a median survival of 1-2 
years (130).   
 Given the grim prognosis for patients with AL, therapeutic intervention focuses on 
affecting either LC concentration or recruitment to fibril formation rather than directly focusing 
on the malignant compartment.  The goal for the former “precursor/product” theory is that 
amyloid formation is a dynamic process of deposition and degradation, whereas concentrations 
of LC precursor protein act as a rate limiting step in fibrillogenesis.  Indeed, scintigraphic 
monitoring of an AL patient with radiolabeled serum amyloid P protein (SAP) demonstrated that 
chemotherapeutic reduction of clonal plasma cell mass resulted in the regression of amyloid 
deposits within organs and tissues (131).   Reduction of myeloid tumor mass in AL relies on the 
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same conventional and high dose chemotherapeutic agents used in MM in conjunction with 
ASCT when permissible (132).  Other groups have evaluated the latter hypothesis of resolving 
amyloid deposition through inhibiting formation or stimulating degradation of amyloid fibrils.  
These studies have ranged from iodinated derivatives of doxyrubicin that bind amyloid fibrils to 
depletion of SAP to hinder fibril formation and immune molecules designed to target amyloid 
fibrils (133-135).   
 
Treatment of multiple myeloma and plasma cell dyscrasia 
Treatment for MM, like all PCDs, focuses mainly on the reduction of the monoclonal plasma cell 
population, with consideration given to addressing bone disease and renal function (which will 
be covered in upcoming sections).  Therapies in MM and related diseases have been slow to 
evolve, with few major turning points in disease management.  In general, agents used in the 
treatment of MM fall into the more broad categories of alkylating agents, inhibitors of mitosis, 
and corticosteroids (136).  Patients diagnosed with MM undergo a series of steps for treatment. 
Figure 1.6 was adapted from Myeloma management guidelines and illustrates the process (135).  
 Listed below are several therapeutic agents used in the treatment of MM.  Although the 
list is not exhaustive, these compounds have been used in many studies as the benchmark to 
which novel therapies are compared, and are representative of the way MM and PCDs in general 
are treated (136-138).  Following this, a brief overview will be given on autologous stem cell 
transfer (ACST) and a few novel compounds used in maintenance therapy. 
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Melphalan 
One of, if not the, oldest compounds described to treat MM is the alkylating chemotherapeutic 
Melphalan (139).  First used in the late 1950’s, Melphalan produced a response of decreased 
tumor mass in 35% of patients.  Subsequently by 1967 the corticosteroid prednisone was also 
shown to effectively reduce MM cell burden, and was considered as an alternate for patients 
refractory to alkylating chemotherapies (140).  Within 2 years combination therapy of Melphalan 
plus prednisone was shown to elicit responses in 70% of patients in a clinical study, subsequently 
adopted for treatment of MM, and remained the gold standard for over 30 years (136).   
Vincristine, adriamycin, dexamethasone and high dose chemotherapeutics 
By the early 1980’s several new therapeutic options had become available for treating MM 
patients refractory to standard chemotherapy regimens, including the combinational therapy of 
Vincristine, Adriamycin, and Dexamethasone (VAD) (141).  In addition, interest was raised in 
the use of high dose chemotherapies (i.e., high dose melphalan) (142, 143).  Although effective, 
with ~25% of patients going to complete remission, these approaches induced profound 
myelosuppression and induced numerous unwanted side effects (465).  To overcome the 
hematotoxic effects of treatments autologous bone marrow transplants were introduced to 
replenish myeloid precursor cells (143-145).   
Autologous Stem Cell Transplant 
From these initial attempts to replenish bone marrow precursor cells autologous stem cell 
transplants were born.  ASCT differs from bone marrow transplants by first mobilizing and then 
 
 Figure 1.6 Schematic representation of the treatment protocol for patients diagnosed with 
PCDs. Adapted from (136) 
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harvesting circulating stem cells a source to replenish the myeloid compartment.  In this process, 
patients first undergo a cytoreduction step using standard chemotherapeutics, avoiding those in 
the alkylator class (136).  Following tumor regression, patient stem cells are mobilized either 
using granulocyte colony stimulating factor either in conjuction with cyclophosphamide, or alone 
(146).  Patient blood is then harvested and white blood cells separated, while sera and red blood 
cells are returned to circulation (145).  This technique, in conjunction with high dose 
chemotherapeutics, remains controversial as various studies have shown either increases in event 
free survival, complete or very good remission, and overall survival, while other studies have 
failed to show improvements over conventional therapies (136, 147-150).    
 Another factor with ASCT is the consideration which must be given to patient selection.  
The primary factors in deciding eligibility are age and renal involvement (138, 149, 150).  ASCT 
is usually limited to patients under 65 years of age with normal renal function (149, 151), 
although some studies have proposed its use in patient populations of up to 75 years of age with 
selective conditioning reagents (152, 153).   
 Renal function in patients may be a more important factor in eligibility for ASCT due to 
the inability to tolerate toxicity induced by chemotherapeutic agents.  In one Spanish study, poor 
renal performance was correlated with increased treatment related mortality by almost ten-fold in 
patients receiving high dose chemotherapy with ASCT as compared with controls (29% v. 3.3%) 
(154).   Findings such as these have led to the conclusion that ASCT in patients with renal 
involvement is contraindicated, and thus limits this vulnerable group from benefits associated 
with transplant (136, 138). 
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Thalidomide 
 One of the more recent advances to gain widespread acceptance in MM therapy occurred 
in the late nineties with the drugs thalidomide.  The drug was originally developed by a German 
pharmaceutical company by a chemist who heated the commercially available chemical 
phthaloylisoglutamine, generating thalidomide (57).  Thalidomide was originally marketed as a 
sleep aid and as an over the counter cure for morning sickness in pregnant women.  It was pulled 
from the shelves within 5 years due to prolific teratogenic effects on the developing fetus (155).  
Due to its ability to intercalate into DNA it was investigated in several oncology studies and 
found to have little effect (156).  Thalidomide was used mainly in refractory or relapsed MM, 
demonstrating at least a partial response in 25-35% of these patients, and has recently been 
proposed as a frontline therapy (138, 149). 
 
Reducing LC precursor 
 The notion of removing LC protein, and thus preventing deposition is not unique to AL.  
As early as 1965 a technique called plasmapheresis was utilized in MM and the related 
Waldenström’s macroglobulenemia (157).  By 1975 the role of BJPs in myeloma kidney were 
more clearly understood, and a case study citing improved renal function in an MM patient was 
published (106, 158).  Subsequently, approaches such as this have been examined in various 
PCDs, typically when renal function has been compromised (95, 159-161).  While the effect of 
this technique on survival in all PCDs remains unclear, a 2003 paper by Lachmann et al. 
demonstrated a positive effect on survival in patients with AL treated with chemotherapy and 
who demonstrated a drop in circulating FLC levels (162).   
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Reducing LC precursor: A molecular approach 
 Over the course of PCD progression the production and increasing concentration of 
circulating FLC can have a profound impact on therapeutic option and patient outcome, through 
aggregation and deposition in vital organs and tissues.  Treatment with chemotherapy is effective 
in some, but not all cases, and the use of conventional alkylating or ACST in conjunction with 
high dose chemotherapeutics may be limited due to organ involvement.  Renal toxicity is of 
particular importance in selection of therapies as high treatment related mortality is associated 
with impaired kidney performance due to BJP deposition.  Further, reliance on high dose 
therapies might not be appropriate in conditions such as AL, when an overt malignancy is not 
present.  Recent advances in the understanding of the process of protein synthesis have revealed 
a previously unknown process, namely RNAi (4), which has been posited as a novel therapeutic 
in a variety of disease states (163, 164).  While the efficacy of this approach remains to be seen, 
owing to issues with delivery and off target gene silencing (25), RNAi offers a promising new 
approach to reducing LC burden in patients with PCD.   
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Chapter 2 
Project Rationale and Summary 
Plasma cell dyscrasias (PCD) occur in a spectrum of disease states (multiple myeloma, light chain 
deposition disease, and light chain amyloidosis) whose differential diagnosis and outcome are 
determined both by the malignancy and the toxic sequalae, which are often related to the 
production and deposition of immunoglobulin light chain (LC).  Overproduction of LC protein and 
their deposition as insoluble aggregates has been indicated as a critical factor in progressive organ 
dysfunction and eventual failure, and the presence of deposits in PCD is indicative of poor 
prognosis.  Reduced circulating LC levels in response to chemotherapeutic intervention, or by 
direct removal of LC with methods such as plasmapheresis results in a recovery of function within 
affected organs, and improved prognosis.  In a number of patients, myelo-ablative chemotherapy in 
conjunction with repopulation of the immune compartment by autologous stem cell transplant has 
shown dramatic improvement and disease remission accompanied with event free survival.  
However, selection to undergo this treatment is stringent, and based, in part, on renal function, 
which is often impaired in PCDs due to the presence of overwhelming LC aggregates.  Each of 
these examples serves to illustrate the negative impact that increased circulating LC levels may 
have on patients with PCDs. 
 While chemotherapeutic intervention is effective, and warranted in patients with 
aggressively expanding plasmacytoid cell populations, it is often harsh and not well tolerated, 
especially in patients with complicating factors such as increased age, or concurrent organ 
dysfunction.  The increased cost to health associated with chemotherapeutics might negate the 
perceived benefits in patients where disease progression resulted mainly from the uncontrolled 
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production of LC proteins (i.e., LCDD, AL).  Thus, it would be rational to devise a treatment 
strategy capable of reducing LC production specifically and directly, rather than indirectly through 
the non-targeted destruction of rapidly dividing cells as with most chemotherapy agents.  Indeed, 
this approach has been pursued elsewhere, most recently in the form of monoclonal antibodies 
which target various forms of LC deposits (135) although there has been at least one study which 
has attempted to reduce the production of LC by interrupting the translation of messenger RNA to 
protein using an approach known as antisense deoxyoligonucleotide interference.   
 Recent advances in the understanding of the way cells manage the expression of self and 
non-self proteins by post-transcriptional regulation have revealed several forms of small interfering 
RNAs (siRNA), which act as initiators for the targeted “silencing” of individual proteins.  This 
process, known as RNA interference (RNAi), is carried out by a conserved family of related 
proteins sharing common RNA-binding and RNase motifs, and which are found in all eukaryotic 
cells.  Exploitation of this natural protein-reducing system offers distinct advantages over earlier 
forms of gene silencing techniques (165).  SiRNAs have been used in a variety of cell systems to 
generate both transient and sustained models of gene knockdown that have been applied in studies 
of gene function and target discovery for pharmaceutical development (31).   Further, their 
application as therapeutic molecules has been proposed for a variety of disease states (166-168).   
 The goals of the present study were to determine if interfering RNA molecules could be 
adapted to reduce LC production by human plasmacytoid cells, and whether these systems may be 
applicable to in vivo in addition to in vitro models of PCD.  To test these hypotheses the following 
specific aims were outlined: 
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Specific Aims 
1) Demonstrate gene knock down in cell cultures following exposure to synthetic siRNAs. 
Human myeloma lines will be selected and screened for production of LC products.  
Synthetic siRNA molecules will be designed to target the V, J, or C regions of LC mRNAs.  
Cell supernatants will be monitored for secreted LC products by ELISA, while cell 
associated LC protein will be measured by flow cytometry.  Finally, levels of LC mRNA will 
be assessed by real time PCR. 
2) Design short-hairpin RNA expressing viral vector construct which are capable of 
transducing human myeloma line and inducing sustained knockdown of LC protein.  
Synthetic siRNA molecules shown effective in transiently reducing LC protein production in 
human myeloma lines will be adapted to include a loop structure which upon transcription 
generated a folded stem-loop structure that was capable of entering the RNAi pathway.  
These shRNA encoding constructs will be ligated into lentiviral expression vectors under 
control of a U6 RNA pol III promoter.  Expression plasmids contain an enhanced green 
fluorescent protein (EGFP) reporter gene under control of a cytolomegalovirus (CMV 
promoter).  Lentiviral expression plasmids will be screened for shRNA insert by DNA 
sequencing and transiently transfected to HEK 293 cells.  Following confirmation of EGFP 
expression lentiviral vectors will be sent to the Viral Vector Core Facility at the University of 
Tennessee Health Science Center in Memphis, TN for packaging to infective, replication 
incompetent lentiviral particles.  Lentiviral particles will be used to infect the human 
myeloma line 8226, and mouse myeloma line SP2/O-λ6.  Cell populations receiving virus 
will be assayed for transduction by identification of cells expressing EGFP by flow 
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cytometry.  Cells shown positive for EGFP expression will be used to generate clonal lines 
and analyzed for LC production by ELISA and real time PCR.  
3) Test the efficacy of shRNA driven gene knockdown using in vivo model systems of PCD.   
Immunocompromised mice (Rag1 -/-, SCID beige) will be recruited as hosts for generation 
of xenograft tumors.  The first series of tumors will be generated from either parental 8226 
cells or clones which have been transduced with either an empty or shRNA expressing 
construct.  Tumors will be administered either intraperitoneally or by sub-cutaneous injection 
within the inguinal region.  Mice will be held for up to 28 days and monitored for presence of 
human LC protein in either sera or urine.  
 Subcutaneous xenograft tumors will be generated in a second group of mice by injection of 
untreated 8226 cells to the inguinal area.  Tumors will be allowed to grow while LC products 
will be measured from the sera or urine.  Mice will receive lentiviral particles with or without 
shRNA expression cassettes at the site of lesions as intra-tumoral injections.  Mouse sera and 
urine will again be collected at 7 and 14 days following administration of virus.  Assay of 
sera and urine for human LC products will be conducted by ELISA, while tumor tissue will 
be analyzed for LC mRNA levels by real time PCR.  Cultured tumor samples will be 
analyzed for LC and mRNA protein expression, while heart, lung, kidney, spleen, and tumor 
samples were analyzed for presence of LC by immunohistochemistry. 
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Chapter 3 
Materials and Methods 
 
The following sections review general methodologies used in these studies.  All materials were 
acquired from sources mentioned below unless specified elsewhere.   
 
3.1 Cell lines and culture conditions 
Unless otherwise specified all cells were maintained in Dulbecco’s modified Eagles medium 
formula 12 (DMEM F-12; Lonza, Wakersville, MD) supplemented with 5% fetal bovine serum 
and 1% penicillin/streptomycin (P/S) with or without 50 µg/mL gentamycin.  Cells were 
maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere.   
 The cell line SP2/O-λ6 was provided by Dr. Alan Solomon (Human Immunology and 
Cancer Program, University of Tennessee Medical Center, Knoxville).  These cells were generated 
by transfecting, by electroporation, the mouse myeloma line SP2/O with an expression construct 
encoding the full length patient derived amyloidogenic λ6 LC protein Wil (Vλ6, Jλ2, Cλ2) (169).   
In this system, expression of LC Wil is regulated by the cytolomegalovirus (CMV) promoter along 
with the sequence under control of the cytomegalovirus promoter and mouse µ enhancer (Figure 
3.1).     
Human myeloma lines RPMI 8226 (CCL-155) U266 (TIB-196) were purchased from American 
Type Culture Collection (ATCC, Manassas, VA).  RPMI 8226 has been previously reported to 
secrete a full length λ2 LC (170).   
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Figure  4.1 Schematic Representation of construct encoding patient derived amyloidogenic 
λ6 LC found in transgenic cell line SP2/O-λ6.  The mouse myeloma cell line SP2/O was stably 
transfected with an expression construct encoding the human λ6 LC Wil by electroporation. LC 
transcription is controlled by the presence of the cytolomegalovirus RNApol III (CMV) promoter.  
Expression of LC Wil is strengthened by presence of the mouse mu enhancer. This map illustrates 
the presence of the full length LC protein including the leader (L), variable (V), joining (J2) and 
constant (Cλ2) regions.   
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The IgG κ1producing human myeloma line, Bur, was provided by the HICP and was shown by 
immunofixation assay to express a full length IgG associated with a κ1 LC (Section 6 Figure 6.2). 
 The human embryonic kidney line HEK 293 was acquired from ATCC (ATCC # CRL-
1573) and maintained as above.  Cells were maintained by removing media and incubating for 5 
min in presence of buffered trypsin, followed by sharply striking side of container. Trypsin was 
neutralized by the addition of 5 x volume of complete media.  Cells were transferred to 15 ml 
conical tubes (BD Falcon) and collected by centrifugation at 600 x g for 5 min. 
 
3.2 Cell counting and viability assays 
Trypan blue dye exclusion assay 
Basic cell counts and viability assays were performed by using trypan blue dye-exclusion assay 
and Neubauer hemacytometer .  At time of count, cell suspensions (usually 20 µl) were collected 
and added to 1.5 ml eppendorf tube (Fisher Scientific) containing trypan blue dye (Sigma-Aldrich) 
at a 1:1 ratio.  Cells were incubated at room temperature for at least 4 min and transferred to 
hemacytometer for counting.   
 
Cell Titer Blue 
In cases where quantification of multiple samples was needed the CellTiter Blue fluorescence 
viability assay (Promega) was used.  Briefly, cells were agitated and 100 µl of culture was 
removed to one well of a black, clear bottom, low-binding polystyrene 96-well microplate 
(Corning).  Standard curves were generated by 1:1 serial dilution of a known quantity of the cells 
being studied starting with 106 cells per well, while blank wells received 100 µl of culture media 
alone.  Each well received 20 µl of CellTiter Blue reagent and plates were incubated for 2-4 h at 
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37°C in a humidified incubator under 5% CO2.  Fluorescent activity was measured at 530ex/645em 
on Synergy HT plate reader (Bio-Tek, Winooski, VT), and viable cell numbers estimated from the 
standard curve.    
 
3.3 Animal models and procedures 
Mice 
Female immunocompromised RAG1-/- knockout mice (595; provided by HICP) and severe 
compromised immune deficient x beige mouse line (SCID/beige; Charles Rivers Laboratory, 
Raleigh, NC) were housed in the animal facility at the University of Tennessee Medical Center, 
Knoxville.  Animals were maintained under a 12 h light/dark cycle and received standard rodent 
chow and water ad libitum.  When required, mice were lightly anesthetized using isoflurane.  
Euthanasia was carried out by isoflurane overdose.  All procedures were approved by the 
University of Tennessee Institutional Animal Care and Use Committee (IACUC) under Protocol 
number 730. 
 
Xenograft tumors 
RAG1-/- or SCID/beige mice were lightly anesthetized and received up to 107 8226 cells as either 
intra-peritoneal (i.p.) or sub-cutaneous injection (s.c.; at shoulder region of right flank or within left 
inguinal region).  Cells were counted and washed 3x in sterile, ice-cold PBS, and immediately 
prior to injection, resuspended in 200 µl PBS for i.p. injection or 50 µl PBS + 50 µl Matrigel 
basement membrane matrix (BD BioSciences San Jose, CA) for s.c. delivery.  In both cases, cells 
were maintained on ice and administered using 1 cc tuberculin syringe, fitted with a ½ inch 27 ½ 
gauge needle.   
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Mice receiving cells s.c. were monitored for tumor development visually and by weekly palpation 
at site of injection.  Samples of sera or urine from mice receiving i.p. injections were monitored for 
presence of human LC using ELISA [Section 3.9]. 
 
Blood collection 
Whole blood was collected from mice via the retro-orbital sinus by first lightly anesthetizing mice 
with isoflurane followed by blood collection using FisherBrand silicate glass capillary tubes 
(Fisher Scientific).  Samples (50-250 µl) were collected in 1.5 ml microcentrifuge tubes and 
allowed to sit for 1 h at RT or overnight at 4° to allow clotting to occur.  Sera were isolated by 
centrifugation at 13, 000 x g on a BiofugePico tabletop centrifuge (Thermo Scientific, Ashville, 
NC) for 10 min, followed by careful aspiration to a clean tube.  Samples were stored at -80° until 
used. 
 
Urine Collection 
Urine was collected from mice by placing a 3 x 6 inch piece of Parafilm underneath a grated 
surface.  Mice were allowed to grip bars and were scruffed, typically resulting in voiding of the 
bladder.  Urine was collected from Parafilm to clean 1.5 ml microcentrifuge tubes and stored at  
-20° until time of analysis.   
 
3.4 Nucleic acid isolation and concentration 
RNA extraction 
Total RNA was isolated from cultured cells and animal tissues using RNeasy plus mini kit 
(Qiagen, Valencia, CA).  For cell lines, 2x105-106 cultured cells were harvested by centrifugation 
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at 3,500 rpm (700 × g) for 5 min in 1.5 ml Eppendorf tubes on a BiofugePico tabletop centrifuge 
(Thermo Scientific, Ashville, NC).  Cells were then lysed in 350 µl RLT Plus buffer, followed by 
passage through QiaShredder spin column (Qiagen) and centrifugation at 10,000 x g for 2 min.  
Flow-through was transferred to gDNA eliminator column (kit), and the sample centrifuged at 
10,000 × g) for 30 sec.  Finally, 1 volume of 80% ethanol/H2O was added to samples.  Mixtures 
were transferred to RNeasy spin column, centrifuged for 30 s at 10,000 x g, and supernatants 
discarded.  Bound RNA was washed once using 700 µl RW1buffer (kit) followed by 2 washes 
with 500 µl RLT buffer (kit).  Residual buffer was removed by centrifugation and the RNA eluted 
to clean tubes by elution in 60 µl RNase/DNase-free water (kit).  RNA yield was determined by 
diluting samples 1:10 in 100 µl distilled water, followed by measuring the A260/A280 on an 
Ultrospec Pro 3300 UV/visible spectrophotometer (GE Healthcare Life Sciences, Piscataway, NJ), 
RNA concentration was estimated by: 
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While purity was estimated according to the following equation: 
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Plasmid Purification 
Transfection-grade plasmid DNA was prepared using Plasmid Midi Kit (Qiagen).  Bacteria from 
overnight cultures (25 or 100 ml) were pelleted by centrifugation for 15 min at 6000 x g and 4° C 
using a Sorvall RC2 centrifuge (ThermoScientific).  Supernatant was removed by decantation and 
bacterial cells disrupted using the supplied alkaline lysis reagents.  First, cells were resuspended in 
4 ml of Buffer P1, supplemented with 100 µg/ml RNase A.  Buffer P2 (Na/OH lysis buffer) was 
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added to cell suspensions (4 ml) followed by 5 min incubation at room temperature.  The lysis 
reaction was neutralized by addition of 4 ml of buffer P3 (pre-chilled to 4° C) and samples were 
placed on ice for 15 min.  Precipitates were removed either by centrifugation at 6,000 x g for 10 
min at 4° C and decanting supernatant through cotton gauze, or by passage through QIAfilter 
cartridge (kit).  Supernatants were passed through a pre-equilibrated QIAtip-100 column (kit) by 
gravity flow to bind plasmid DNA. Columns were washed 2x with 10 ml buffer QC (gravity flow; 
kit) and DNA eluted to a clean Oak Ridge centrifuge tube using 5 ml buffer QF (kit).  Nucleic 
acids were precipitated by addition of 3.5 ml isopropanol followed by holding at 4° C for 30 min.  
After centrifugation at 15,000 x g for 30 min at 4° C, supernatants were decanted, and pellets air 
dried for 10 min at room temperature.  DNA was resuspended in 400 µl DNase free water and 
concentrated by ethanol precipitation.   
 
Ethanol Precipitation of DNA 
For 400 µl of sample in DNase free water, salt content was adjusted to 75 mM with addition of 15 
µl of 5 M NaCl followed by the addition of 2.5 volumes of pure ethanol.  Samples were incubated 
overnight at -80° or for 15-20 min on dry ice.  DNA precipitate was separated from solution by 
centrifugation at 13,000 x g for 20 min at 4° C on a BioFugeFresca refrigerated centrifuge 
(Thermo Scientific).  Pellets were resuspended in 20-50 µl DNase free water.   
 
3.5 First-strand cDNA synthesis and amplification  
Reverse Transcriptase reaction 
For each sample first-strand complimentary DNA (cDNA) was generated using SuperScript III 
Reverse Transcriptase (Invitrogen).  For each 20 µl of reaction, total RNA (200ng-1µg) was added 
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to 0.5 ml snap-top tubes along with 1 µl of 50 µM oligo(dT)20 (Sigma Aldrich, St Louis, MO), 1 µl 
10 mM dNTP mix (Fisher Scientific), and water to a final volume of 13 µl.  Tubes were heated to 
65° C for 5 min to disrupt secondary structure, and rapidly cooled on ice for 1 min.  To this, 4 µl of 
5x first strand buffer (kit) was added along with 1 µl 0.1 M DTT, 1 µl RNasin RNase inhibitor, and 
1 µl Superscript III enzyme (kit).  Reactions were incubated at 55° C for 1h, and heat inactivated 
by increasing temperature to 70° C for 15 min.   
 
Polymerase Chain Reaction (PCR) 
PCR was performed using either Taq DNA polymerase or Phusion DNA polymerase and 
proofreading enzyme (New England Biolabs, Ipswich, MA).  For Taq based PCR, 2x buffer  was 
prepared (100 µl) by the addition of 20 µl 10x Eppendorf PCR buffer (Sigma Aldrich), 40 µl 
Eppendorf PCR enhancer (Sigma Aldrich), 1.6 µl 25 mM dNTP mix, and 38.4 µl water.  PCR 
reactions were typically carried out in 16 µl volumes containing 8 µl 2x mix, 0.5 µl forward primer 
(20mM; Sigma Alrdich), 0.5 µl reverse primer (20mM; Sigma Aldrich), 1-2 µl of template DNA,  
Taq polymerase at a ratio of 1:50 (enzyme: reaction volume), and water was added to final volume. 
 Similarly, Phusion based PCR reactions (20 µl) were prepared with 10 µl Phusion HT 
buffer (New England Biolabs), 0.5 µl forward primer (20 mM), 0.5 µl reverse primer (20 mM), 1-2 
µl template DNA, 1:50 Phusion enzyme, and water to final volume. 
 
Real-time, Quantitative PCR (qPCR) 
Quantitative PCR was conducted using iQ SYBR Green SuperMix (BioRad, Hercules, CA).  
Briefly, each 20 µl reaction contained 10 µl 2x iQ SYBR Green SuperMix, 1 µl forward and 
reverse primer mix (20 µM each) - the cDNAs were diluted to 1:10 or 1:100 in DNase free water 
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and 1 µl added to each reaction.  Primers for LC genes were designed to amplify ~100 bp 
fragments from target genes using Primer-BLAST primer design tool (591), while validated 
primers to human or mouse GAPDH, β-actin, or aldylase served as reference genes (RealTime 
Primers, LLC., Elkins Park, PA).  Amplification efficiencies were determined for each primer set 
by analysis of serial dilution curves and were shown to be between 95-105% (592).  Reactions 
were performed using an iCycler thermocycler base (BioRad) while fluorescence intensity was 
monitored in reaction wells with an iQ5 optical system (BioRad).  Fluorescence data were 
analyzed using the integrated iQ5 control software and relative gene expression levels between 
treated and control cells were calculated using the 2-∆∆CT (Livak) method (592).   
 In all cases, PCR conditions were optimized for each primer set and template and will be 
reported when appropriate.   
 
3.6 Isolation and sequencing of PCR products 
Agarose gel electrophoresis  
Following amplification, PCR amplicons were separated based on size by agarose gel 
electrophoresis, stained with ethidium bromide, and visualized using a UV light box.  Solid 
agarose was prepared as 2% stock solutions (w/v) by adding 2 mg SeaKem low melting point 
agarose per 100 ml Tris acetate-EDTA (TAE) solution.  Agarose was melted by autoclaving for 
one cycle, stocks were aliquoted and stored in closed glass jars.  Gels were prepared by melting 
agarose stocks in a microwave oven and diluting agarose to 1.5% with additional TAE.  Gels were 
poured and allowed to cool.  PCR reactions were mixed with DNA loading buffer and 10-15 µl of 
samples were added to individual lanes.  Hyperladder HI molecular weight marker (Bioline, Inc., 
Tauton MA) was used to estimate product size.  Gels were typically electrophoresed for 70 min at 
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110 volts, or until loading bands had migrated further than 75% of the gel.  Gels were then soaked 
for 10 min in an ethidium bromide bath and visualized by UV trans-illuminator.  Images were 
captured on Canon PowerShot G5 digital camera (Canon USA, Lake Success, NY). 
 
Isolation of PCR products 
Following separation by agarose gel electrophoresis, bands corresponding to predicted PCR 
product size were excised and purified using the Wizard SV PCR and Gel cleanup kit (Promega).  
Gel slices were first dissolved in membrane binding solution (w/v; kit) by incubating for 5-10 min 
at 60° C, until gel slice was no longer visible.  Solutions were transferred to Wizard SV silica mini-
columns and allowed to incubate for 1 min at room temperature.  DNA was bound to columns by 
pulling solution through column membranes by centrifuging at 13,000 × g for 1 min on a 
BiofugePico tabletop centrifuge.  DNA was washed 2x using 200 µl column wash solution, flow 
through was discarded after each wash.  DNA was then eluted into fresh tubes using 400 µl of 
DNase free water (2 elutions of 200 µl each) which had been pre-heated to 60° C.  DNA was 
concentrated by ethanol precipitation as outlined above (Section 3.4).  Concentrations and purity 
were estimated by reading absorbance at A260 and purity by the ratio of A260/A230. 
 
DNA Sequencing 
All gene sequencing was carried out by the University of Tennessee Molecular Biology Resource 
Facility (UTMBRF) at the University of Tennessee, Knoxville.  LC gene sequences were 
compared with published or previously determined sequences using sequence tools found on Basic 
Local Alignment Search Tool (BLAST) website (http://blast.ncbi.nlm.nih.gov/).  LC sequences 
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were also compared against databases at international ImMunoGeneTics (IMGT) information 
system (http://www.imgt.org) to determine Ig germline origin.  
 
3.7 Nucleic Acids 
Synthetic siRNAs Synthesis 
Small interfering RNA duplexes were designed from data acquired by LC gene sequencing.  To 
reduce chances of off target effects, each siRNA (both sense and anti-sense strand) were used to 
generate searches of the BLAST database for non-LC gene products that possessed significant 
nucleotide sequence homology.  Selected sequences were submitted to Sigma-Aldrich for 
synthesis.  RNAs arrived as lyophilized single strand species and were reconstituted to 20 µM 
solutions in siRNA suspension buffer (Sigma Aldrich).  Secondary structures were removed by 
heating RNA solutions to 95°C for 1 min.  Nucleic acids were combined in equimolar amounts in 
1.5 mL microcentrifuge tubes followed by incubation for 1 h at 55° C to allow duplexes to form.  
AllStars non-silencing siRNA duplexes were purchased from Qiagen with or without Alexa488 
fluorescent labels and served as non-silencing controls.  SiRNA duplexes were stored at -20° C 
until the day of experiments. 
 
Short Hairpin RNA Construct Synthesis 
Expression constructs were designed which, when transcribed, generated 50-60 nt RNA sequences, 
which fold to form a stem loop structure consisting of a 21 bp stem duplex with an intervening 6 or 
9 nt single stranded loop region.  Custom DNA oligonucleotides (forward and reverse) encoding 
these sequences were synthesized by Sigma Aldrich and arrived as separate lyophilized 
precipitates.  Forward and reverse strands were resuspended to 20 µM using DNase free water.  
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For annealing, 5 µl of both forward and reverse oligonucleotides were added to a 1.5 ml 
microcentrifuge tube and heated to ~95° C in a glass beaker containing 500 mL boiling water.  
Oligonucleotides were incubated for 4 min and the beaker was removed from heat source and 
annealing occurred as the water to slowly returned to room temperature. 
 
3.8 Lentiviral expression plasmids  
PLKO.1  
The replication incompetent lentiviral expression plasmid pLKO.1-TRC cloning vector (# 8543) 
was acquired from AddGene plasmid repository (www.addgene.org) (171) and arrived as bacterial 
stab cultures (E. coli, Stbl3 competent cells; Invitrogen).  Upon arrival bacteria were transferred to 
Luria Bertani media (LB) agarose plates containing 50 µg /ml Carbenecillin.  Cultures were grown 
overnight, the following day solitary colonies were selected and transferred to 1 L flasks 
containing 250 ml LB media.  Cultures were grown overnight and plasmid recovered by midi-prep 
as above (Section 3.4). 
 
pLB  
The replication incompetent lentiviral expression plasmid pLB was acquired from Addgene 
(plasmid # 11619) (172) as bacterial stock and was propagated as above (Section 3.8).   As with 
pLKO.1 plasmids were recovered from cultures by midi-prep. 
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3.9 Microscopy and Flow Cytometry 
Immunohistochemical and immunofluorescence microscopy 
Tissues and cells were observed using a Leica DMRB epifluorescent microscope, and digital 
images captured by using a SPOT-RT cooled CCD color camera and accompanying SPOT 
Advanced, v. 3.5.2 imaging software (Diagnostic Instruments, Inc., Sterling heights, MI).  The 
microscope was fitted with a DAPI/blue fluorescent protein filter (excitation 360/40 nm, emission 
460/50 nm, with 400 nm bandwidth), and a FITC/GFP filter (excitation 560/40 nm, emission 535/ 
40 nm).  For cells with multiple fluorescent labels SPOT Advanced software was used to correct 
brightness and background for individual channels and generate image overlays. 
 
Flow Cytometry 
Transfection efficiencies, EGFP expression, and immunoglobulin light chain expression were 
monitored using a FACScan flow cytometer (Becton Dickson, San Jose CA).  For each, channel 
FL-1 (488 nm excitation, 530 emission) was used to monitor either Alexa488, EGFP, or FITC 
fluorescence.  In the case of immunoglobulin expression Alexa630 conjugated antibodies were also 
used.  The intensity of red fluorescence was captured on channel FL-2 (630 nm emission) For each 
experiment at least 5,000 events were collected and data analyzed using Cell Quest software v. 1.2 
or Cyflogic v.1.2.1. 
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3.9 Enzyme Linked Immunosorbent Assays (ELISA) 
General ELISA Development and Absorbance  
For all ELISAs used in these studies Horseradish Peroxidase conjugated antibodies were used in 
conjunction with 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid (ABTS) + 0.06% H202 for 
detection of bound antigen.  For each assay, immunoreactivity was visualized by measuring the 
absorbance at 405 nm using a BioTek Synergy HT Luminescence Reader (BioTek Instruments, 
Winooski, VT). 
 
Detection of λ6 LC 
Culture supernatants were collected at 24, 48, or 72 h post-transfection after cell separation by 
centrifugation at 400 × g for 5 min.  For the SP2/O-λ6 cell line supernatants were diluted 1:10 in 
PBS + 1% bovine serum albumin (BSA; w/v) + 0.1% Tween 20 (Sigma-Aldrich) (PBST +BSA).  
High-binding affinity ELISA/RIA plates (Fisher Scientific) were coated overnight at 4°C with 100 
µl of 3.75 µg/ml mouse anti-human Vλ6 monoclonal antibody (173), rinsed and blocked for 1 h at 
37°C with PBS + 1% BSA.  Diluted supernatants were applied to the plate for 1 h at 37°C. A 
standard curve was prepared by serial dilution of purified recombinant λ6Wil VJ(127) over the 
range from 400 µg/ml to 0.3 µg/ml.  Plates were rinsed and 100 µl of rabbit anti-human λ6 LC 
antibody (127) in PBS containing 1% BSA, 0.5% filtered goat serum (Sigma-Aldrich), 0.5% 
filtered mouse serum (Sigma-Aldrich), 0.5% MOPC31c (Sigma-Aldrich), 0.1% tween20 (Sigma-
Aldrich).  Following incubation at 37° C for 1 h plates were rinsed and bound antibody detected by 
addition of HRP-conjugated goat anti-rabbit Ab (Jackson Immunoresearch, West Grove, PA).  
Following 1 h incubation at 37° C the plates were developed using ABTS + 0.06% H202 and 
visualized as above. 
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Detection of Total λ LC 
Total λ ELISA A 
Culture supernatants were diluted 1:100 in PBST before analysis. AO193 Rabbit anti-human 
total λ (11µg/ml; DAKO, Carpinteria, CA) served as the capture antiserum and monoclonal mouse 
anti-human total λ light chain antibody (1 µg/ml; Dako) as the detection reagent.  Bound antibody 
was detected by the addition of HRP-conjugated goat anti-mouse Ig (Jackson Immunoresearch).  
Plates were coated overnight at 4° C and blocked for 1h at 37° C on the day of assay.  All 
antibodies and antigens were allowed to bind for 1 h at 37° C with intermittent washes using 
PBST.   
 
Total λ ELISA B 
Plates were coated either overnight at 4° C or for 2 h at RT with 100 µl of 10 µg/ml 18-9G11 
mouse monoclonal anti-human total λ LC antibody.  Wells were blocked for 1 h at RT by addition 
of 200 µl PBS containing 1% BSA.  The patient-derived BJP Cot was used to generate a standard 
curve, starting with 30 ng protein and proceeding with a 1:1 serial dilution in duplicate wells along 
the first columns of the plate.  Culture supernatants were diluted 1:100 in PBST+BSA, while 
mouse sera and urine were diluted 1:10 in PBST+BSA. Each well received 100 µl of dilute 
sample, and were incubated for 1h at RT.  Plates were washed 3x in PBST followed by the 
addition of 100 µl ABD Star130 HRP-conjugated anti-human total λ LC polyclonal IgG (AbD 
Serotec, Raleigh, NC).  Following final 1 h incubation, plates were again washed and developed 
and absorbance read at 405 nm. 
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Total κ ELISA 
The polyclonal rabbit anti-human total κ antibody AO191 (Dako) was coated (100 µl; 10 µg/ml) to 
each well of a high binding affinity 96-well ELISA/RIA plate overnight at 4° C.  On the day of 
experiments, plates were blocked for 1 h at 37° C with 200 µl PBS + 1% BSA.  Standard curves 
were prepared using purified, patient derived Bur BJP starting with 200 ng protein followed by a 
1:1 serial dilution in PBST + 1% BSA.  Bur supernatants were diluted 1:100 in PBST + BSA and 
100 µl of sample were added to individual wells.  Plates were incubated for 1 h at 37° C and 
washed 3x with TBST.  Bound antigen was detected using a 1:2000 dilution of Star127P HRP-
conjugated goat anti-human total k LC polyclonal IgG (AbD SeroTec).  Plates were developed 
using ABTS and absorbance read at 405 nm. 
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Chapter 4 
Small interfering RNA design and transfection 
4.1 Rationale 
As discussed previously, the introduction of small double-stranded RNA molecules to eukaryotic 
cells will induce the targeted reduction of specific gene products (174).  Utilizing these so-called 
siRNAs, the RISC is capable of locating and degrading mRNA strands which show 
complimentarity to the siRNA guide strand (16).  Several factors may influence the efficiency of 
this process, however, and must be addressed in order to optimize experimental outcomes.  
Perhaps the two most important of these is the proper design of siRNA sequences, and the 
delivery of synthetic RNAs to the cytoplasm of the target cell (35).   
In addressing the former, several authors have demonstrated the robust specificity of RNAi in 
experiments that accomplished a significant reduction in the mutant allele of a targeted protein, 
with little or no effect on wild type levels (125, 167, 175, 176).  Additionally, better 
understanding of the RNAi machinery has led to improved models of siRNA design; for 
example, designing duplex strands that mimic products of the RNase enzyme Dicer, thereby 
increasing the efficiency by which siRNAs are taken into the RNAi pathway, or by altering the 
thermodynamic stability of the guide strand at the 5’ end, ensuring proper strand selection and 
thereby reducing the likelihood of off-target effects (177, 178).   
Delivery of siRNAs to cell in higher eukaryotes also presents a unique challenge, as cellular 
uptake of naked dsRNA molecules was shown to be inefficient in vitro and even more so in vivo 
(45).  As a result, a variety of compounds have been developed to enhance cellular delivery of 
siRNAs (and nucleic acids in general).  Reagents and methods developed for transfection vary, 
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from the use of cationic polymers and lipids to conjugation of siRNA molecules with magnetic 
nanoparticles for transient transfections, or the incorporation of constructs encoding a desired 
siRNA into a viral expression plasmid for stable incorporation (28, 171, 179, 180).   While many 
of these systems remain experimental, varieties of compounds are commercially available and 
are compatible with numerous cell types. 
 The following sections will review the steps taken to identify products of the LC gene 
and in designing siRNA molecules which were later shown effective in reducing LC production 
in the mouse and human myeloma cell lines.  This section will also review the process by which 
appropriate transfection reagents were selected for each cell line and the steps taken to optimize 
transfection efficiency and reduce cytotoxicity.   
 
4.2 Methods 
Cells 
The first step taken in designing siRNAs to target LC genes was the isolation and 
characterizations of the LC protein.  For this, the transgenic mouse myeloma line SP2/O-λ6 and 
human myeloma lines, RPMI 8226 and Bur were selected.  The mouse line SP2/O-λ6 was 
developed by the Human Immunology and Cancer Program, and contains a construct expressing 
a patient-derived amyloidogenic λ6 LC under control of a CMV promoter which is reinforced by 
the presence of a mouse mu enhancer sequence (Figure 3.1).  The human myeloma line RPMI 
8226 has been shown to secrete measurable quantities of a full length λ2 LC containing V-, J-, 
and C-regions (214).  Additionally, the patient-derived human myeloma line Bur was provided 
by the HICP and has been shown to produce a full IgG protein with an associated κ1 LC.  In 
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each case, cells were cultured under standard conditions (Section 3.1).  Cell number and viability 
were assessed as previously described (Section 3.2). 
 
Identification LC gene products 
For each cell line, the full sequence of LC gene was determined by first isolating total RNA 
lysates prepared from 106 cells.  RNA was reverse-transcribed to cDNA as in Section 3.3.  
Primers corresponding to LC Wil (Fwd 5’- CGCGCATGGCCAATTTTTTACT-3’, Rev 5’- 
AGGAATTCAACCTAGGACGGTCAACTTGGT-3’) and Bur (Fwd 5’- GGCTCCCAGG 
TGCCAAATGTGA-3’, Rev 5’- ACAGATGGAGCAGCCACAGTTC-3’) were used to amplify 
the L, V, J regions of each LC.  PCR products were purified and submitted to the DNA 
sequencing laboratory in the Molecular Biology Resource Facility at The University of 
Tennessee, Knoxville using primers LC Wil and Bur. For 8226 cells, the LC sequence was 
acquired from NCBI Nucleotide database (http://www.ncbi.nlm.nih.gov/nuccore/ ; GenBank ID: 
U07992.1).   
 
Design of siRNA 
For each siRNA, 21-bp RNA duplexes containing 3’ 2 nt overhangs were designed based on the 
determined sequence of the expressed LC gene.  The protein and isotype-specific nucleotide 
sequences were compared to others contained in human and mouse mRNA libraries using the 
Nucleotide BLAST suite (http://blast.ncbi.nlm.nih.gov/ ).  Duplexes that possessed significant 
homology >85% base pair identity to non-LC genes were eliminated, while those corresponding 
specifically to LCs were synthesized (Sigma-Aldrich). 
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Transfection conditions 
Transfection media were acquired from several vendors and administered according to 
manufacturer’s instructions.  A summary of each protocol is shown in Table 4.1. In each case,  
cells were incubated for 1-3 days and uptake of fluorescent control siRNA was assessed by 
fluorescence microscopy and/or flow cytometry.  Cell viability was also monitored by trypan 
blue exclusion assay and cell counting by using a hemacytometer. 
 
Optimization of transfection conditions  
To determine optimal transfection conditions for cells, serial dilutions of Alexa488 labeled 
siRNAs were incubated with increasing ratios of delivery reagent.  Following transfection, cells 
were incubated for 24-72 h under standard conditions.  Cells were recovered and viability 
assessed by trypan blue dye exclusion and hemacytometry or by CellTiter Blue assay.  Replicate 
samples were harvested and analyzed for uptake of Alexa488 labeled siRNA by flow cytometry.  
For each treatment group, the healthy cell population was identified by drawing regions in the 
flow cytometer data using untreated populations of 8226 cells.  Marker regions were drawn on 
FL-1 to exclude negative cells.  
 
4.4 Results 
Total RNA extraction and conversion to cDNA was carried out as described in Sections 3.3-3.5.  
PCR primers were designed to amplify LC mRNAs and bands corresponding to ~300 bp were 
excised and isolated as described in Section 3.5.  Results from the UTMBRF were entered into 
the ExPASY Translate program and are shown in Figure 4.1. 
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Table 4.1  Summary of transfection reagents and protocols  
Reagent Manufacturer Protocol summary Notes 
DharmaFect  
reagents 1-4 
Dharmacon/ 
Thermo 
Scientific 
For 96-well format: 1 µM siRNA mixed 1:1 
(moles RNA/ µl Transfection reagent) in 
serum/antibiotic free (s/a-)  media, allowed to 
incubate 5 min. Mixture diluted to 100 ml and 
added to 2x104 cells.   
Small amount of siRNA 
used.  Protocol optimized 
for adherent cell types.  
Incompatible with 
sera/antibiotic containing 
media. 
Lipofectamine 
Invitrogen 
For 24-well format: 0.2 µg siRNA diluted to 25 
µl in s/a- media.  Mixture incubated for 30 min 
at RT and diluted to 200 µL.  2x104 Cells 
washed and transferred to 200 µl s/a- media in 
24 well plate and siRNA/transfection solution 
added slowly.  Cells incubated 6 h under normal 
conditions, collected and media replaced with 
0.6 ml fresh complete DMEM F-12. 
Protocol optimized for 
adherent cells.  
Incompatible with sera or 
antibiotic containing 
media during transfection.  
Media change at 6 h 
cumbersome in 
experiments with large 
number of reps.   
Lipofectamine 
2000 
(L2K) 
Invitrogen 
For 24-well format: Prior to treatment,  2 x 105 
cells added to each well in 500- µl media. 
SiRNAs diluted in 50 µl s/a- media, 1 µl diluted 
likewise, sera and transfectant combined, 
incubated 5 min at RT, siRNA complexes added 
to wells. 
Compatible with sera. 
Relatively small amount of 
siRNA required.  No need 
to change buffer following 
transfection.   
RNAifect Qiagen 
For 96-well format: SiRNA (1 µg) was added to 
100 µl complete media along with 3 µl 
RNAifect.  Solutions were incubated at RT for 
20 min, meanwhile 2x104 cells were collected 
and media removed.  Cells were resuspended in 
100 µl siRNA solutions and transferred to 
individual wells of plate.  
Protocol optimized to 
adherent cells, but 
adaptable to suspension.  
Compatible with serum 
and antibiotics during 
transfection.   
Hiperfect Qiagen 
For 24-well format: 1 µg siRNA was added to a 
tube containing 100 µl s/a- media, to this 3 µl 
hiperfect was added and solutions incubated for 
15 min at RT.  Concurrently, 2x105 cells were 
harvested by centrifugation and transferred to 
individual wells in 100 µl complete media.  
SiRNA solution added to wells and incubated 
for 6 h followed by addition of 400 µl complete 
media. 
Simple protocol, 
compatible with 
suspension cells.  No 
negative effects of serum 
or antibiotics during 
procedure. 
  
Figure 4.1 Sequence of LC gene products and segments
LC gene products from cell lines A) SP2/O
products submitted to UTMBRF.  Results were translated to AA sequences.  Underlined areas 
represent sites to which indicated siRNA s
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 targeted by siRNAs. Sequences for 
-λ6, B) 8226, and C) Bur were acquired from PCR 
equences correspond. 
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 Based on these data short ~21 bp RNA duplexes were designed corresponding to regions 
of hyper-variability (i.e., junctions between complimentarity defining regions and framework 
regions; CDR/FRs, V- J- recombination site).  These regions were chosen as they are sites of 
greatest somatic mutation and therefore have the highest degree of sequence differences from the 
germline gene as well as other LCs of the same isotype.   
Alternately, siRNAs were designed to areas of the LC C-domain to act as tools for isotype-
specific gene silencing (i.e. κ, λ LCs), these sequences were generated by comparing regions 
among the various κ or λ germline genes and selecting those which share homology with their 
respective counterparts.  SiRNA sequences are shown in Table 4.2 while their locations along the 
LC gene products are noted as underlined areas in Figure 4.1. 
 
Selection and optimization of transfection system 
Given the variety of transfection systems available, it was important to determine which method 
of delivery would yield the best results for each myeloma line.  It was decided to limit 
transfection reagents to cationic lipid based systems, as they are the most commonly used 
reagents in the literature and are readily available from a number of sources.  To avoid 
complicating the results of experiments with artifacts generated by different transfectant 
formulations it was also desirable to identify transfection media that were compatible with all 
cell lines. To achieve this, media from several commercial vendors were acquired and used to 
transfect Alexa488-labeled “AllStars”, non-silencing control siRNA (Qiagen), while unlabeled 
Allstars, and separately, untreated cells served as controls.  A summary of the results for each 
reagent and cell line is shown in Table 4.3. 
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Table 4.2 Sequence of siRNA oligonucleotides  
Oligonucleotide  Length (bp)                      Sequence   
SP2/O-1 a     
Wil C1  21      AACAACUAUGUUCACUGGUAC     
CAUUGUUGAUACAAGUGACCA  
Wil C2  21      AAGUUGACCGUCCUGGGUCAG        
GAUUCAACUGGCAGGACCCAG         
Wil J1  21     AAGUUGACCGUCCUGGGUCAG                
GAUUCAACUGGCAGGACCCAG  
RPMI8226 b     
8226 V1  21     GUGACAUUGGUGACUAUCAUU                     
UUCACUGUAACCACUGAUAGU   
8226 V2  21      CCUGCAGAAUGUUCUUAGUUU            
UUGGACGUCUUACAAGAAUCA  
SP2/O-1  
RPMI8226 c  
   
 
  
C1  21      GUCUCCAUAAGUGACUUCUAUU               
UUCAGAGGUAUUCACUGAAGAU  
C2  21      CCAAACAAAGCAACAACAAUU          
UUGGUUUGUUUCGUUGUUGUU  
Bur d    
Bur V1 21     UAUUAACAUUUACGGGACUGAUU             
UUAUAAUUGUAAAUGCCCUGACU 
κ C1 21           AGUCAACCCGGGUUGUACAACUU 
        UUUCAGUUGGCGGGAAGAUGUUG 
aSequence bridges the FR1/CDR1, FR2/CDR2, or J/C region of IgLC protein Wil. 
bAgainst CDR1,2 site of Vλ regions of RPMI8226 cells. cAgainst shared homology 
sequences in constant domain of λ IgLC. dSequence to V region of LC Bur or to C 
region of κ LCs 
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Table 4.3 Results of transfection reagent selection trials 
Cell line Reagent Uptake of siRNA Method of 
detection 
Cytotoxicity 
SP2/O-
λ6 
Dharmafect (1-4) ND  FM ND 
Lipofectamine ND FM ND 
Lipofectamine 2000 Yes FM, FC ND 
RNAifect Yes FM, FC Only at higher 
ratios of 
reagent:siRNA 
HiperFect Yes FM, FC ND 
RPMI 
8226 
Dharmafect NT NT NT 
Lipofectamine NT NT NT 
Lipofectaimine 2000 Yes FM, FC ND 
RNAifect Very low FM, FC Yes 
Hiperfect Yes FM, FC ND 
Bur Dharmafect NT NT NT 
Lipofectamine NT NT NT 
Lipofectamine 2000 NT NT NT 
RNAifect NT NT NT 
 HiperFect Yes FC ND 
Legend:  ND = Not detected, NT = Not tested, FM = Fluorescent microscopy, FC = Flow 
Cytometry 
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 Of the reagents tested, 3 were effective at delivering their siRNA payload to the mouse 
line SP2/O-λ6, and of these, RNAifect was initially selected for use; however, it was shown later 
to be cytotoxic to the human line 8226 and its use was discontinued.  This led to our use of 
HiperFect and Lipofectamine 2000 as effective, non-toxic, transfection reagents.   
 Both HiperFect and Lipofectamine 2000 were capable of delivering labeled siRNAs to 
either SP2/O-λ6 or RPMI 8226 myeloma lines over a range of concentrations (Figures 4.2 and 
4.3).  While Lipofectamine 2000 was successful at transfecting 8226 and SP2/O-λ6 cells over a 
wide range of siRNA concentrations cell counts taken following treatments were lower than 
expected for a 48 culture of 8226 cells given that 2 x 105 cells were plated initially (Table 4.4).  
Forward (FSC) and side scatter (SSC) from flow cytometry studies also revealed an increased 
number of events falling away from the gated population, demonstrating decreased size and 
increased complexity, a possible indicator of increased cell death.  
Treatment of cells with HiperFect resulted in an increased uptake of Alexa488 labeled siRNAs as 
compared with controls as measured by Flow cytometry (Figure 4.3).  Cell counts revealed that 
cell growth and viability were dependant on the ratio of siRNA to reagent, with siRNAs 
delivered at a ratio of 1:3 (siRNA:reagent) being well tolerated, while delivery with the higher 
1:6 ratio reducing cell viability (Table 4.4).  These results were mirrored in data collected from 
flow cytometry experiments, where cells receiving higher ratios of reagent were observed to 
have altered FSC/SSC profiles, indicating increased cell death (Figure 4.3).  Figure 4.4 illustrates 
a typical fluorescent image and flow cytometry histogram observed following transfection with  
1 µg Alexa488 labeled siRNA with HiperFect reagent using the 1:3 ratio at both 24 and 48 h (the 
final conditions selected for experiments). 
 Figure 4.2 Alexa488 Labeled SiRNA Uptake in RPMI 8226 cells Duri
Optimizations.  Forward scatter (FSC) and Side scatter (SSC) plots of A) untreated 8226 cells 
with FL-1 (green fluorescence) histogram shown underneath following 48 h incubation. Marker 
region M1 was drawn around untreated cells and w
positive.  B) 8226 cells treated with 1.5 
Lipofectamine 2000 resulted in uptake of labeled siRNA, however cells begin to show signs of 
cytotoxicity as noted by spread in FSC and SSC.  C) Exposure of 8226 cells to 1 
0.5 µl Lipofectamine 2000 resulted in loss of cell population.
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ng Lipofectamine 2000 
as used to estimate percent of cells considered 
µg Alexa488 labeled AllStars control siRNA with 1.5 
 
 
µl 
µg siRNA and 
 Figure 4.3 Alexa488 Labeled SiRNA Uptake in RPMI 8226 cells During HiperFect 
Optimizations.  Forward scatter (FSC) and Side scatter (SSC) plots of A) untreated 8226 cells 
with FL-1 (green fluorescence) hi
region M1 was drawn around untreated cells and was used to estimate percent of cells considered 
positive.  B) 8226 cells treated with 0.75 
µl HiperFect (1:3) resulted in uptake of labeled siRNA.  C) Exposure of 8226 cells to 0.75 
siRNA and 4.5 µl HiperFect (1:6) resulted in increased cell death.
 
 
 
 
 
 
 
 
 
68 
stogram shown underneath following 48 h incubation. Marker 
µg Alexa488 labeled AllStars control siRNA with 2.25 
 
 
 
 
µg 
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Table 4.4 Optimization of Hiperfect and Lipofectamine 2000 in RPMI 8226 cells (48h) 
Reagent siRNA 
(µg) 
Volume 
reagent 
Ratio % positive  Total 
cells/well 
% viable 
Lipofectamine 
2000 
1.5 0.5 3:1 NA 63,000 86 
 1 3:2 98 110,000 90 
  1.5 1:1 79 193,000 79 
 1 0.5 2:1 94 64,000 85 
  1 1:1 96 147,000 93 
  1.5 1:1.5 86 142,000 77 
 0 0.5 NA 7 165,600 81 
  1 NA 1 182,400 84 
  1.5 NA 1 420,800 88 
HiperFect 1.5 4.5 1:3 95 297,000 88 
  9 1:6 98 205,000 47 
 0.75 2.25 1:3 91 313,000 87 
  5.5 1:6 97 175,000 44 
 0.375 1.125 1:3 79 344,000 96 
  2.25 1:6 93 181,000 74 
 0 3 NA 1 195,000 88 
  6 NA 1 259,000 92 
Legend: NA= Not Applicable    
 Figure 4.4 Transfection of RPMI 8226 Cells With Alexa488 Labeled Control SiRNA Using 
HiperFect Transfection Reagent.
AllStars non-silencing control siRNA with 3 
were cytospun to glass slides, fixed, permeablized and treated with Hoescht stain (blue) for 
visualization of nucleus. B) RPMI 8226 cells were treated with either 1 
unlabeled AllStars non-silencing control siRNA along with 3 
for 24-48 h and uptake of labeled Alexa488 assessed by flow cytometry.  Populations of 8226 
cells were gated and histograms generated using channel FL
population treated with unlabeled siRNAs while open histograms represent cells receiving 
labeled siRNAs.  Region M-1 was drawn on the negative control cells and p
percent of cells considered positive for Alexa488 uptake. 
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  A) RPMI 8226 cells were treated with 1 µg Alexa488 labeled 
µl HiperFect reagent and harvested at 24 h.  Cells 
µg Alexa488 labeled or 
µl HiperFect.  Cells were incubated 
-1.  Green histograms represent cell 
ercentages are the 
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4.4 Discussion 
Two major challenges in designing RNAi based experiments are the development of siRNA 
oligonucleotides and the selection of an appropriately safe and effective method of transfection.  
Individual LCs expressed by different plasma cells may differ significantly from the germline, 
owing to hypermutation events that occur during the maturation of individual plasma cells.  
While this presents an added level of challenge to designing interfering RNAs to a LC of 
interest, it also provides a unique opportunity to selectively target a pathologic LC for silencing, 
while in theory, avoiding collateral damage to the remaining immune repertoire.  As illustrated 
here, obtaining an siRNA sequence specific for an individual LC is possible, and these sequences 
may be used to design functional siRNA duplexes. 
Transfection of myeloma cell lines with siRNAs also requires planning, and testing of numerous 
products as different lines exhibit varying levels of tolerance to given products.  For example, the 
earliest studies conducted for this dissertation utilized the mouse myeloma line SP2/O-λ6 
exclusively and the transfection reagent RNAifect offered an efficient and non-toxic means of 
transfection.  However, with the inclusion of the human myeloma line 8226, RNAifect was 
shown to be ineffective and cytotoxic.   Further screenings identified the reagents 
Lipofectamine2000 and HiperFect, both of which were well tolerated and resulted in efficient 
transfection rates.  However, exposure of the 8226 line to Lipfectamine 2000 resulted in lower 
cell numbers than expected as compared with controls and with HiperFect treated counterparts.  
Exposure of 8226 cells to HiperFect also had the potential to induce cell death when used at 
jphihigher transfectant: siRNAs ratios (i.e., 1:6 siRNA: reagent); however these complications 
were avoided easily enough by adhering to the 1:3 ratio of siRNA: reagent. 
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 These results provide evidence that it is possible to identify LC gene products from 
different myeloma lines and use this data to rationally design siRNA sequences from of these 
isolates.  Further, that efficient delivery of siRNAs to human and mouse myeloma lines is 
possible using neutral lipid based reagents, and that this delivery can be accomplished without 
inducing cell death. 
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Chapter 5 
Inhibition of Pathologic Immunoglobulin Light Chain Production by Small 
Interfering RNA Molecules 
5.1 Abstract 
A main contributing factor to the morbidity and mortality of patients with plasma cell dyscrasias results 
from the pathologic deposition of monoclonal Ig light chains, i.e., BJPs within organs and soft tissues.  As 
an alternative to plasma cell chemotherapy to reduce BJP synthesis and thus prevent aggregate formation 
we have investigated another means to achieve this objective, namely, RNAi.   
 Experimentally, we have stably transfected the SP2/O mouse myeloma cells with a construct 
containing the V, J, and C region of a λ BJP (Wil) under the control of a CMV promoter and have shown 
that they constitutively express measurable quantities of mRNA and protein Wil.  Concurrently, we have 
also recruited the human myeloma cell line RPMI8226 to this study as a robust and clinically relevant 
model cell line.  Treatment of these cells with synthetic, small double stranded RNA based on the Wil 
protein sequence or RPMI8226 IgLC protein sequence reduced both target mRNA levels by 24h and 
protein production by 50% in each cell line over the 72 h experimental period as compared with controls.  
These data provide conclusive evidence that RNAi can effectively reduce BJP production in vitro and 
provide the base for testing the clinical potential of this strategy using a relevant in vivo murine model of 
plasma cell dyscrasia.   
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5.2 Introduction 
Under normal circumstances the polyclonal expansion of B-cell clones is a critical feature in the 
adaptive immune response to pathogens.  Plasma cell dyscrasias however, are characterized by the 
proliferation of monoclonal B-cells that secrete an  Ig or free HC, or LC protein which often 
aggregates and deposits, in vital tissues and organs (181-183).  This results in a loss of compliance 
within tissues and progressive organ failure which contributes significantly to the morbidity and 
mortality of patients. Deposition of free LC, manifests as amorphous aggregates, crystals, or 
structured fibrils most commonly in the kidneys, heart, liver, or nerve fibers.  Manifestations of 
plasma cell dyscrasias in which the LC aggregation and deposition dominates the pathology 
include: cast nephropathy or “myeloma kidney” in multiple myeloma (99); intracellular crystals 
in patients with Fanconi syndrome (184, 185); LCDD (186), and; fibrillar matrices in AL 
amyloidosis (122).   
Current treatment of plasma cell dyscrasia relies on ablative chemotherapeutic approaches with 
alkylating agents and high dose steroids to reduce the monoclonal B-cell component sometimes 
followed by autologous stem cell transplant if warranted (146, 187).  Often the use of non-
steroidal anti-inflammatory drugs and chemotherapeutic agents can exacerbate the acute tubular 
necrosis that is observed in patients with plasma cell dyscrasia (188).  Furthermore, although 
strict criteria are applied when determining eligibility for autologous stem cell transplant, this 
treatment is associated with a high incidence of mortality (159).  Supportive therapy for patients 
often includes increased hydration to assist with clearance of LC from the kidneys as well as 
dialysis and plasmapheresis to further reduce serum monoclonal LC protein levels (52, 99).  
Recent reports have shown an improved outcome in myeloma patients with LC cast nephropathy 
was observed by reducing serum free LC by plasma exchange (189). 
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Previously, it has been shown using a human myeloma cell line, that targeted depletion of LC 
synthesis in vitro could be achieved using post-transcriptional gene silencing (190).  Although 
initially demonstrated using antisense olignucleotides, the same effect has never been 
demonstrated using small interfering RNA technology, which has superseded antisense 
technology.  RNAi exploits an evolutionarily conserved mechanism of post-transcriptional gene 
silencing (4).  The presence of double stranded RNA molecules within the cytoplasm of 
eukaryotic cells triggers an enzymatic cascade resulting in the specific degradation of target 
mRNA, thus inhibiting the production of the encoded protein (13, 191).  RNAi has been shown 
to be a robust and specific tool to selectively “silence” protein synthesis in a variety of cell types 
(192, 193).  Furthermore, RNAi has been shown effective in reducing target protein 
concentrations in animal models of disease (194-196).  Currently RNAi-based therapies are 
being evaluated in humans for the treatment of macular degeneration and respiratory syncytial 
virus infection (197, 198). 
 Building on these observation, herein we describe the treatment of three cell lines; 
SP2/O-λ6, a mouse myeloma cell line stably transfected and expressing the human λ6 Bence 
Jones protein (BJP) Wil, the plasma cell line RPMI 8226 (human λ2) and Bur (human IgG κ1) 
with synthetic siRNA molecules that target the V, J and C domains of the LC proteins.  SiRNA 
delivered by lipid based transfection media was shown to be non-toxic and efficiently reduced 
target LC mRNA as well as intracellular and secreted protein levels by up to 50% as compared 
with controls. 
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5.3 Materials and Methods 
Cell lines 
Mouse myeloma (SP2/O-λ6) cells expressing the human λ6 Wil BJP and the patient derived 
myeloma line Bur were provided by Dr. Alan Solomon (University of Tennessee Medical 
Center, Knoxville).  SP2/O-λ6 cells were stably transfected by electroporation with a construct 
containing the λ6 Wil VJC sequence under control of the cytomegalovirus promoter and mouse 
mu enhancer sequence (Chapter 3, Figure 3.1).  Sequence identity of the Wil insert was 
confirmed by DNA sequencing.  The human myeloma cell line RPMI 8226 was purchased from 
American Type Culture Collection (ATCC).  Cell lines were cultured as described in Section 3.1. 
 
Small-interfering RNA (siRNA) 
SiRNA duplexes corresponding to nucleotide sequences within the variable domain of λ6Wil 
and RPMI 8226 were purchased from Sigma Aldrich. In addition, siRNA oligonucleotides were 
designed to regions of conserved homology within the C domain of λ LCs (Sigma-Aldrich).  All 
sequences were verified and checked for homology with non-LC proteins using BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and are shown in Chapter 4, Table 4.2.  AllStars non-
silencing siRNA (Qiagen) served as a negative control. 
 
Cell Culture and Viability 
On day of experiments, cell numbers and viability were determined by trypan blue dye exclusion 
assay and counting on hemacytometer.  Cells were washed by centrifugation and resuspended in 
100 µl phenol red-free DMEM F-12 (Sigma Aldrich) containing 5% FBS and P/S.   
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A volume containing 2×105 cells was added to each well of a 24-well microplate to which was 
added 1.5 µg siRNA complexed with 4.5 µl HiPerFect siRNA transfection reagent (Qiagen) in 
100 µl phenol red free DMEM F-12 lacking serum or antibiotics.  As a control, cells were treated 
with AllStars siRNA formulated with HiPerFect as above. Cells were incubated at 37°C for 24, 
48, or 72 h.  At each timepoint cell viability was assessed using the Cell Titer Blue assay 
(Promega) according to manufacturer’s instructions. 
 
Transfection Efficiency  
Cellular uptake of siRNA was measured by flow cytometry using a FACScan flow cytometer 
(BD Immunocytometry systems) and employing CellQuest Pro software. Optimal transfection 
conditions were determined for each cell line by titrating the concentration of AllStars siRNA 
labeled with Alexa488 (Qiagen) and HiperFect transfection reagent (Qiagen), non-labeled 
AllStars siRNA (Qiagen) served as a control.  Alexa488-labeled AllStars treated cells were 
incorporated during each experiment to monitor transfection efficiency.   Steps taken in 
determining these conditions are outlined in Chapter 4. 
 
RNA Isolation and Analysis 
Following treatment with siRNA as previously described total RNA was isolated from either 
SP2/O-λ6 or RPMI 8226 cells using RNAeasy Plus RNA isolation kit (Qiagen) according to 
manufacturer’s instructions and the integrity of product was assessed by agarose gel 
electrophoresis.  RNA concentration was determined by UV spectroscopy at 260nm and 280nm. 
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Reverse Transcriptase Real Time PCR 
Analysis of LC gene expression was carried out by RT qPCR (Chapter3.5) using the following 
primers (Sigma-Genosys): Wil (forward) 5΄ -ACGGTAACCATCTCCTGCA-3΄, (reverse) 5΄-
AGGGTCTGTGGTCATCCTC-3΄, 121-bp product; RPMI 8226 LC (forward) 5΄-
CAAAGCCCCCAAACTCATAA-3΄, (reverse) 5΄-AACACCACCTCGAAAAGTGC-3΄, 180-bp 
product. Primers to human and mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 
Real Time Primers LLC) were used to amplify the calibrator gene; human GAPDH (forward) 5΄-
GAGTCAACGCGGATTTGGTCGT-3΄, (reverse) 5΄-TTGATTTTGGAGGGATCTCG-3΄, 238-
bp product; murine GAPDH (forward) 5΄-CTGGAGAAACCTGCCAAGTA-3΄, (reverse) 5΄-
TGTTGCTGTAGCCGTATTCA-3΄, 223-bp product.  For each primer set amplification 
efficiency was shown to be ~100%.  Relative LC mRNA levels for cells in each experimental 
siRNA treatment group were calculated using the 2∆∆CT method and reported using cells 
receiving AllStars siRNA as the reference group.   
 
ELISA of Secreted LC 
Culture supernatants were collected at 24, 48, or 72 h post-transfection after cell separation by 
centrifugation at 400 × g for 5 min. For the SP2/O-λ6 cell line supernatants were diluted 1:10 in 
PBS + 1% bovine serum albumin (BSA; w/v) + 0.1% Tween 20 (Sigma-Aldrich) and analyzed 
using l6 LC ELISA (Chapter 3.9).  A standard curve was prepared by serial dilution of purified 
recombinant λ6Wil VJ(127) over the range from 0.3 µg/ml to 400 µg/ml.   
For LC 8226, supernatants were diluted 1:100 in PBST before analysis using total λ LC ELISA 
A (Chapter 3.9). In this case the patient derived λ2 LC Rhea was used to generated a standard 
curve which ranged from 300 ng/mL to 40 µg/ml.  
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Detection of LC Bur was accomplished using the total κ ELISA (Chapter 3.9). Standard curves 
were prepared using purified, patient derived Bur BJP starting with 200 ng protein followed by a 
1:1 serial dilution in PBST + 1% BSA.  Bur supernatants were diluted 1:100 in PBST + BSA and 
100 µl of sample were added to individual wells.  
 
Flow Cytometry of Cellular LC 
The concentration of cellular LC was measured by flow cytometry (199). RPMI 8226 cells 
treated with experimental or control siRNA were cultured and transfected as previously 
described.  At 24, 48, or 72 h cells were isolated by centrifugation at 500 × g, the supernatant 
removed, and the cells washed in PBS + 1% BSA.  Cells were treated with fixative and 
permeablization buffer (BD Cytofix/Cytoperm; BD Biosciences) according to manufacutrer’s 
instructions, blocked for 20 minutes in Cytoperm solution (BD Biosciences) containing 1% BSA. 
Cells were then resuspended in CytoPerm solution containing 11 µg/ml FITC labeled rabbit anti-
human total λ antisera (DAKO) or unlabeled rabbit anti-human total λ antisera (DAKO), which 
served as a control. After a 1 h incubation at RT cells were washed 3× in PBS and resuspended 
in 0.5 ml PBS for analysis by flow cytometry (FACScan; BD Biosciences). 
 
Statistical Analysis 
ELISA results were normalized and expressed as percent control siRNA treated cells.  For each 
set, data were pooled and analyzed for significance by One-Way ANOVA using Dunnett’s 
Multiple Comparisons test (GraphPad Prism; GraphPad Software Inc.).     
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5.4 Results 
Transfection efficiency 
Optimal transfection conditions for both SP2/O-λ6 and 8226 cells were determined by flow 
cytometry.  For each experiment, incorporation of Alexa488-labeled AllStars siRNA and trypan 
blue was used to document transfection efficiency and monitor cytotoxicity, respectively. In the 
case of SP2/O-λ6, ~97% of the cells were transfected by 24 h, and at 48 h and 72 h this value 
decreased to ~59% and ~40%, respectively (Figure 5.1). 8226 cells were similarly transfected at 
24 h, but remained ~95% labeled at 72 h (Figure 5.1).  The mean fluorescence intensity of the 
transfected cell populations decreased in both cell lines over the 72- h period of study, due most 
likely to the dilution of the fluorescent oligonucleotide in the dividing cells (this was  more 
evident in SP2O-λ6 cells, due to their more rapid, doubling time, i.e., ~12 h). 
 
Effect of siRNA treatment on LC mRNA levels 
Using appropriate primers, the PCR reaction products from SP2/O-λ6 and 8226 cells had the 
expected bands at ~115bp and ~180 bp, respectively, as evidenced by agarose gel 
electrophoresis; no secondary low molecular weight products were observed (data not shown).    
At 24 h SP2O-λ6 cells exposed to V1, V2, and J1 Wil elicited a 23, 32 and 20% reduction in LC 
mRNA levels, as compared to the sham-treated cells, whereas treatment with C1 λ and C2 λ 
induced a 39 and 35% reduction.  By 48 h, cells exposed to V1, V2, and J1 Wil siRNA had 24, 
40, and 34% reductions in mRNA levels, as compared with cells treated with sham siRNA. The 
values after treatment with C1λ and C2 λ remained similar to those at 24h. At 72 h post-
transfection, the results were erratic, presumably due to cell doubling and cell death; however, in  
 Figure 5.1 SP2/O-λ6 and RPMI8226 cells demonstrated positive uptake of siRNA. 
SP2/O-λ6 and B, RPMI8226 were transfected alexa488
siRNA and analyzed by flow cytometry at 24, 48, or 72 h.  Regional markers were set 
based on cells transfected with non
percentage of positively transfected cells.  For all data, percentages indicated are from a 
representative experimental group.
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general, the levels were equivalent to those of untreated cells with exception of V2 Wil and C2 λ 
in the SP2/O-λ6 line which remained 21 and 30%, respectively, below levels found in the 
controls (Figure 5.2).   
Treatment of RPMI 8226 cells with V1 8226 and C3 8226 decreased target LC mRNA by 61 and 
43%. A lesser degree of suppression was observed after treatment with C1 λ and C2 λ (32 and 
39% respectively).  However, by 48h mRNA levels in cells exposed to C1 λ siRNA was reduced 
by 51%.  In contrast, in cells treated with V1 8226, C2 λ and C3 8226 there was a less (32-35%) 
reduction at 48h.  By 72h, the exposure of cells to V1 8226, C1 λ, and C2 λ siRNAs these values 
reverted to near control levels, whereas mRNA levels in C3 8226 treated cells remained 
suppressed (Figure 5.3).  
 
Effect of siRNAs on LC production. 
 1 x 106 of untreated SP2/O-λ6 cells generated ~180 ng of λ6 LC Wil per day.  Treatment with 
siRNA had no effect on cell viability or number throughout the 72 h experimental period, as 
evidenced in the Cell Titer Blue viability assay (Fig. 5.3).  When these cells were treated with 
siRNAs targeting the V, J, or C regions, the amount of secreted LC in the culture supernatants at 
all three time points was significantly reduced (p<0.05) (Figure 5.4), whereas exposure to siRNA 
specific to LC 8226 had no effect (data not shown).  This response was most pronounced at 72 h 
post-transfection, where V- and J-region-specific siRNAs produced an ~50% decrease in λ6 LC 
Wil secretion relative to sham-treated cells (C-region siRNA treatment reduced secretion by 
40%).    
 
 
 Figure 5.2 Transfection with experimental siRNAs reduced LC mRNA in human and m
myeloma cells.  A, SP2/O-λ6 cells were treated with siRNA directed to either the V or J region 
of IgLC Wil or with siRNA targeting C domain of 
quantitated by real-time PCR using murine GAPDH as a reference g
triplicate, columns show expression relative to sham siRNA treated cells as mean ± SEM of 3 
representative experiments.  B, RPMI8226 cells were treated with siRNA directed to either the V 
region of the  RPMI8226 LC or with siRNA 
above. Data were normalized to human GAPDH.  PCR was performed in triplicate, columns 
show expression relative to 8226 LC mRNA from sham siRNA treated cells.
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 Figure 5.3 Treatment with siRNA had little effect on cell via
transfection with siRNA 100 
by CellTiter Blue assay.  Cell numbers were estimated using serially diluted SP2/O
cells.  Data were pooled among 5 experimental replicates and a
ANOVA. B) RPMI 8226 cells were sampled and viability assessed as above.  
C) Likewise, viability for cell line Bur was assessed. Data were pooled among 6 
experimental replicates and analyzed by one
0.05) 
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 Figure 5.4 Cell culture supernatant IgLC concentration was reduced following 
treatment with experimental siRNA.
cells were cultured for 24, 48 or 72 hrs along with indicated siRNA oligonucleotides.  At 
given timepoints supernatant was collected, cleared by centrifugation, and analyzed by 
ELISA.  For each experimental replicate, su
concentration from cells receiving experimental siRNA to cells receiving AllStars 
siRNA.  For each group ratios were pooled and analyzed by one
mean ±SEM; *, p < 0.05). 
6; mean ±SEM; *, p < 0.05).
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  A) SP2/O-λ6, B) RPMI 8226, or C) Bur myeloma 
pernatant LC was reported as the ratio of LC 
-way ANOVA (n = 6; 
B, RPMI8226 cells were cultured and analyzed as above (n = 
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 In the case of RPMI 8226, 1 x 106 untreated cells produced ~13.4 µg of LC per day.  
Treatment with the siRNAs had no effect on cell viability or number (Figure 5.4).    At 24 h post-
transfection, exposure to V1 8226, C1, and C2 siRNA constructs significantly reduced (p < 0.05) 
LC secretion by 40, 39, and 61% respectively as compared with untreated controls. Treatment 
with AllStars non-silencing control siRNA had no effect on LC concentration (Fig. 5.4).  At 48 
h, LC secretion decreased by 54 and 60% respectively.  The C1 and C2 siRNA constructs also 
significantly reduced (p < 0.05) protein production by 40 and 65%, respectively, and this effect 
was still apparent at 72 h.  In contrast, treatment of 8226 cells with siRNA specific to LC Wil 
had no effect on LC production at any timepoint (data not shown).   
 Exposure to siRNAs targeting cell line Bur were also successful in reducing secreted LC, 
however, unlike with the other myeloma lines, this reduction was only seen after 48 h and 
remained strongly evident at 72 h (Figure 5.4). Additionally, these data illustrate the specificity 
of siRNAs as exposure of cell line Bur to siRNA molecules targeting C1 λ had no effect on LC 
production as compared with controls.  Interestingly, cells exposed to either κ targeting siRNA 
were found to have significantly higher cell numbers at 48 and 72 h as compared with non-
silencing controls, however it is not clear why this may have occurred (Figure 5.3) 
 Reduction in cytoplasmic LC production by siRNA-treated 8226 cells was also 
documented by flow cytometry (Figure 5.5).  To determine treatment effect on cellular LC 
content, a gate region was drawn that excluded control siRNA-treated cells (cells within this 
gated region were considered negative for cellular LC staining). The geometric mean of each 
population also was used to estimate relative fluorescent intensity between cells exposed to 
experimental and control siRNAs.  Data collected from the gated region at 24 and 48h revealed  
 Figure 5.5 A sub-population of cells containing lower cellular IgLC concentration 
emerged following transfection with experimental siRNA.
transfected with C1 λ, C2, 
stained with FITC conjugated rabbit anti
cytometry.  Regional markers excluding sham treated cells were set for FL
panel, the geometric mean of th
within the marker region are reported. Open histograms represent cells treated with C1 or 
C2 siRNA and closed histograms represent sham treated cells.  Histograms are taken 
from an example flow cytom
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etry experiment. 
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that 21.3 and 63% of C1 λ treated cells fell within the region considered negative, as compared 
with controls where 1.8 and 2.3% of the population fell within the marker region.  Comparison 
of geometric means revealed that exposure to C1 λ siRNA elicited at 24 and 48 h, respectively, 
58 and 33% reduction in fluorescence intensity, as compared with controls (Figure 5.5).  C2 λ 
siRNA effected an even greater reduction in cellular LC concentration at 24h, resulting in a 70% 
loss of fluorescence as estimated by comparison of geometric means of control cells.  By 24 h, 
42% of the population fell within the gated negative region as compared with controls where 
only 2% fell within the marker region. This effect was more pronounced at 48h where there was 
a 70% loss of fluorescence. In addition, 83% of the population of C2 λ treated cells fell within 
the negative gated region, as compared with controls where only 2% were gated. 
 
6.5 Discussion 
A major contributing factor to the morbidity and mortality of plasma cell dyscrasias is the 
overproduction of immunoglobulin free LC proteins and their subsequent aggregation and 
deposition in tissues and organs.  Current standard of care calls for dose-intensive 
chemotherapeutic intervention to reduce the monoclonal B cell population and thereby effect a 
decrease in circulating LC protein concentration.  A recent retrospective survey of patients 
diagnosed with myeloma and LC cast nephropathy indicated that a reduction of circulating free 
LC levels of ~50% correlated with an improved clinical outcome in patients who responded to 
treatments as compared with non-responders (189).  It is also reasonable to assume that reduction 
in free LC concentration in patients with AL will reduce the growth of the pathologic fibrils, to 
the benefit of the patient.  Thus, methods that decrease free LC production are potentially 
clinically beneficial and highly desirable. 
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 Previously, antisense deoxyoligonucleotides were shown capable of achieving a modest 
reduction in the secretion of free LC by human myeloma cells in vitro and in human myeloma 
cell line xenograft tumor models (190).  Recently, interfering RNA has superseded antisense 
technology in regards to efficiency(200), and specificity (175, 201) as the method of choice for 
post-transcriptional “silencing” of protein expression (165, 200, 202, 203).    Although there 
have been incidences of cytotoxicity and non-specific activation of the host innate immune 
system following RNAi treatment in animals (204, 205) these effects can be avoided, or at least 
lessened, with proper siRNA sequence design and careful selection of delivery system(206-208). 
We have evaluated the ability siRNA treatment to reduce secreted LC concentration using 2 cell 
lines.  SP2/O-λ6 cells that secrete Vλ6Wil BJp were chosen as we have recently developed a 
transgenic mouse stably expressing the λ6Wil BJp into which these studies could translate (JW 
and AS, unpublished data).  However, this system is somewhat artificial we included also the 
well-characterized human myeloma cell line RPMI 8226, while cell line Bur served to test RNAi 
on a cell line expressing the κ LC isotype.  Treatment of each of these cell lines with 
experimental siRNAs targeting nucleotide sequences within the V, J, and C regions resulted in 
significant decreases in the secreted LC protein concentration and mRNA levels as compared to 
cells transfected with benign siRNA.  Interestringly, the C1 and C2 siRNA constructs depleted 
LC secretion by the RPMI 8226 much more effectively than the λ6Wil LC-producing SP2/O-λ6 
cell line.  Since these siRNAs were designed with the goal of targeting highly conserved, and 
therefore universal, regions within the C domain of all λ LC subgroups is somewhat 
counterintuitive that C region siRNAs would be more efficacious for one cell type as compared 
with another.  This decrease may be due to differences in the secondary structure of the SP2/O-
λ6 (Cλ2) and RPMI 8226 (Cλ3) mRNA molecules affecting the annealing efficiency as has been 
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posited elsewhere (209).   Cell counts and viability assays demonstrated no significant difference 
in cell number following transfection with siRNA using a lipid based reagent.  Studies in vivo 
using similar lipid transfection systems have produced little or no toxicity in animal models (168, 
190, 210, 211).   
Immunostaining of fixed and permeabilized RPMI 8226 cells that had been treated with C1, C2, 
or AllStars siRNA revealed a substantial population of cells at 24 h (21-63%) and 48 h (41-82%) 
with reduced intracellular LC.  This sub-population was not observed in untreated cells or those 
transfected with AllStars control siRNA.  Intracellular LC reached a minimal point at 48 h, as 
evidenced by the 82% decrease in positively stained cells.  This is likely due to the fact that 
siRNA treatment is most effective during the initial 48 h post transfection in addition to the 
secretion of intracellular LC pool into the culture supernatant over this time.  The combination of 
these 2 effects - blockage of LC gene translation and loss of cytoplasmic protein by secretion - 
likely resulted in the population of LC-negative cells.  At 72 h post-transfection however, the 
effect of the siRNA treatment was diminished significantly by inactivation and dilution of the 
reagent following cell division, thereby allowing the intracellular pool of LC protein to replenish.  
This is supported by the fact that the doubling time for the RPMI 8226 cell line was ~72 h, as 
evidenced in the flow cytometric analysis of cells transfected with Alexa488-labeled AllStars 
siRNA. 
 Since RNA interference operates in a specific fashion by degrading mature mRNA 
sequences post-transcriptionally we expected that a reduction in LC protein would be 
accompanied by a reduction in target mRNA levels.  Indeed, when treated with siRNA molecules 
targeting the LC V, J, or C regions both SP2/O-λ6 and RPMI 8226 cell lines exhibited a 
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reduction in target mRNA levels as compared with their respective control siRNA treated 
counterparts.   
 Because aggregation and deposition of the free LC component secreted by neoplastic 
plasma cells contributes to the poor prognostic outcome of patients diagnosed with LC diseases 
treatment using RNA interference offers a novel method of therapeutic intervention for a patient 
population with historically limited options.  The results presented herein demonstrate the high 
degree of efficiency by which siRNA reduces intracellular and secreted LC protein.  In both the 
SP2/O-λ6 and RPMI 8226 cell lines reduction in secreted LC reached >50% of normal, which is 
within a range that is considered to be clinically beneficial.  Thus, RNAi offers a targeted 
approach to reducing LC secretion in plasma cell dyscrasias and with careful design and 
implementation may circumvent undesirable non-specific responses.  These findings support the 
hypothesis that RNAi therapy could provide a valuable tool for the treatment of patients with 
plasma cell dyscrasia, as an adjuvant to traditional chemotherapies. 
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Chapter 6 
Design and Synthesis of ShRNA Bearing Lentivirus Constructs 
6.1  Rationale 
Delivery of exogenous interfering RNAs to myeloma cells was effective in reducing the 
production of pathologic LC protein (Chapter 5).  However this reduction was transient, likely 
resulting from the dilution of internalized siRNAs with each cell division and degradation of the 
siRNA molecules.  It has been reported that delivery of shRNAs expression constructs by viral 
particles results in a sustained reduction of target proteins (31, 35, 212).  In particular, viral 
vectors derived from the lentivirus family have been shown effective in transducing slowly 
dividing cell types including human myeloma lines (171, 213).  Separation and truncation of key 
elements of lentivirus genes have produced self inactivating vectors which retain the ability to 
integrate to the host genome and produced a sustainable expression of gene products (390).  
Further, vesicular stomatitis virus g-protein (VSVG)-pseudotyped lentiviral vectors have 
demonstrated the potential to infect bone marrow stem cells in vivo (214).   
 While these studies indicate that it is possible to transduce myeloma cells with shRNA 
expression systems by using lentiviral particle delivery systems it remained to be seen whether 
the level of silencing generated by these interfering RNAs would be robust enough to reduce a 
pathologic LC produced in high quantities by plasmacytoid cells.  To address this, siRNAs 
previously shown effective in reducing LC production in the transgenic mouse myeloma line 
SP2/O-λ6 and the human myeloma line RPMI 8226 were modified by first linearizing the guide 
and passenger strands followed by addition of an intervening sequence of nucleotides, which 
when transcribed, through complimentarity of the two siRNA strands would self-anneal to form 
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the characteristic stem-loop structure of a shRNA molecule (215).  These shRNA cassettes were 
then ligated into a self inactivating lentivirus expression plasmids and functional lentiviral 
particles generated.  Mouse or human myeloma lines were then exposed to the particles and the 
transfection efficiency and stability determined.  This Chapter describes the steps taken in 
designing and generating these particles (see the schematic provided in Figure 6.1). 
 
6.2 Materials and Methods    
Propagation of Vector pLB  
The self inactivating (SIN) lentiviral expression plasmid pLB cloning vector was acquired from 
AddGene plasmid repository (www.addgene.org; vector11619) (Figure 6.2 A).  Viral plasmids 
were handled and purified as previously described (Chapter 3.4). 
 
Propagation of Vector PLKO.1 
The SIN lentiviral expression plasmid 8543 (pLKO.1) was acquired from Addgene as bacterial 
stock and was propagated as above (Figure 6.2 B).   As with pLB plasmids were recovered from 
cultures by midi-prep and ethanol precipitation (Chapter 3.4). 
 
Design of shRNAs 
Short hairpin RNAs (shRNA) were designed based on small interfering RNA (siRNA) sequences 
targeting the V region of λ6 LC Wil (Wil V1) and LC 8226 (8226 V1) (Table 4.1). For plasmid 
pLB, these were modified according to the following format: 5’T (sense oligo)-TTCAAGAGA-
(antisense oligo) TTTTTTC 3’ to generate both the 5’ and 3’restriction enzyme sites as well as to 
produce a stem-loop structure during synthesis (Table 6.1).   
 Figure 6.1 Schematic of the experimental design for generation shRNA
Vectors.  Lentiviral plasmid expression vectors we
encoding shRNA sequences.  Expression vectors were cloned into bacterial colonies and 
amplified.  Following colony screening, plasmids were tested for functionality and ability to be 
packaged to lentiviral vector partic
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 Figure 6.2 Maps of Lentivirus Expression Plasmids pLB and pLKO.1.
B) pLKO.1 were acquired from Addgene.  Maps depict plasmid size and locations of functional 
genetic elements. 
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Table 6.1 Sequence of shRNA inserts 
Vector Dir 5’ siRNA sense loop siRNA antisense 3’ 
pLB 
 
 
Wil V1 Fwd t-GCCAACAACTATGTTCACT-ttcaagaga-GTGAACATAGTTGTTGGC-ttttttc 
 
Rev tcgaaaaaaa-GCCAACTATGTTCA-tctctgaa-GTGAACATAGTTGTTG-a 
8226 V1 Fwd t-GTGACATTGGTGACTATC-ttcaagaga-CACTGTAACCACTGATAG-ttttttc 
 
Rev tcgaaaaaaa-CTATCAGTGGTTACAGTG-tctctgaa-GATTGTCACCAATGTCAC-a 
Bur V1 Fwd t-AGTCAGGGCATTTACAATTA-ttcaagaga-TAATTGTAAATGCCCTGAC-ttttttc 
 
Rev tcgaaaaaaa-GTCAGGGCATTTACAATTAT-tctctgaa-TAATTGTAAATGCCTGAC-a 
pLKO.1 
 
 
Wil V1 Fwd ccgg-AACAACTATGTTCACT-ctcgag-GTGAACATAGTTGTTGGC-tttttg 
 
Rev aattcaaaaa-GCCAACTATGTTCA-gagctc-GTGAACATAGTTGTTG-ccgg 
8226 V1 Fwd ccgg-GTGACATTGGTGACTATC-ctcgag-CACTGTAACCACTGATAG-tttttg 
 
Rev aattcaaaaa- CTATCAGTGGTTACAGTG-gagctc-GATTGTCACCAATGTCAC-ccgg 
Legend: Bold Text represents siRNA portion of insert 
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For plasmid pLKO.1, sequences were modified to include 5' CCGG-(sense oligo)-CTCGAG-
(antisense oligo)-TTTTTG 3' (Table 6.1), to generate a loop region and restriction sites. DNA 
oligonucleotides were ordered from Sigma Aldrich and were phosphorylated using T4 
polynucleotide kinase (New England Biolabs, Ipswich, MA).  Oligonucleotides were 
resuspended at 20 µM in TE buffer and annealed by first heating to 90°C for 4 min, followed by 
cooling slowly to room temperature over several hours. 
 
Digestion of Expression Vectors 
Vector pLB 
The lentivirus expression vector pLB (6 µg) was digested for 2 h at 37° in a 50 µl reaction 
containing 1 µl each XhoI and HpaI restriction enzymes (New England Biolabs) and 5 µl 10X 
NEbuffer 4 (New England Biolabs).  Linearized fragment was isolated by agarose gel 
electrophoresis and Wizard PCR clean-up kit (Promega, Madison, WI). For each reaction, 25 
pmol of vector was removed and treated with Antarctic phosphatase (New England Biolabs) 
according to manufacturer’s instructions. 
 
Vector pLKO.1 
Vector pLKO.1 (6 µg) was resuspended in 5 µl 10x NEbuffer 1 (New England Biolabs) along 
with 1 µl of AgeI and 1 µL of EcoRI restriction enzymes.  Water was added to each reaction to a 
final volume of 50 µl and tubes were incubated for 2h at 37°C.  Following the reaction, 
linearized fragments were isolated and purified as above.    
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Ligation of shRNA constructs 
For each plasmid, 2 µl annealed shRNA oligonucleotides were added to a reaction containing 1 
µl DNA ligase (New England Biolabs), 5 µL 10x T4 Ligase buffer (New England Biolabs), and 
20 ng digested pLB or pLKO.1 vector.  Ligation reactions were carried out overnight at 16° C. 
 
Transformation of competent cells 
XL-1 Blue supercompetent cells were prepared according to manufacturer’s instructions and 
were treated with ligated pLB or pLKO.1 vector at increasing ratios (from 1:1 to 1:6).  Cells 
were incubated on ice for 30 min and heat shocked at 42°C for 45 sec before being returned to 
ice for 1 min.  Starter cultures were prepared by incubating cells at 37°C with constant shaking 
before being plated overnight on LB agarose supplemented with 50 µg/ml carbenicillin (Sigma 
Aldrich) as a selection agent.  Colonies were selected and again grown overnight in 5 ml LB 
media supplemented with 50 mg/ml carbenicillin. 
 
Colony Screening for Ligated insert 
Screening of Crude Lysate by Restriction Enzyme Digest 
For each culture, 1ml bacteria were harvested by centrifugation at 13,000 x g using a Biofuge 
Pico tabletop centrifuge for 5 min.  Cells were resuspended in 300 µl of a STET solution (8% 
sucrose, 0.5% tritonx100, 50 mM EDTA, and 50 mM tris HCl), held on ice for 10 min, and 
boiled at > 90°C for 90 sec.  Bacterial debris was removed following centrifugation at 14,000 
rpm 13,000 x g for 30 min by aspirating supernatants into clean tubes.  Nucleic acids were 
precipitated by the addition of 1 volume isopropanol and 30 min incubation at -20°C.  DNA was 
pelleted by centrifugation at 14,000 rpm at 4° C on a Biofuge Fresca tabletop centrifuge for 20 
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min and resuspended in 50 µl Tris EDTA buffer (TE; 10 mM tris, 1 mM EDTA).  For vector 
pLB, 45 ml of DNA was added to a clean tube along with 5 µl NEbuffer 4 and 1 µl each 
XhoI/HPAI (expected product size 60 bp) or NotI/Xba (~500  bp).  Likewise for vector pLKO.1, 
45 µl DNA was adjusted with 5 µl 10x Nebuffer 1 and 1 µl each AgeI/EcoRI added to each tube.  
Restriction enzyme reactions were allowed to proceed for 2 h at 37°C and 10 µl product 
separated by gel electrophoresis. 
 
Screening of lysates by PCR and Sequencing 
For samples that were suspected to contain ligated plasmid, 2 µl of DNA from each colony was 
amplified by PCR using vector-specific primers that flanked the insertion site for the shRNA 
construct.  For vector pLB fwd primer, 5’ TAGTAACTATAGAGGCTTA-ATGTGCG-3’ and 
reverse 5’TGGGCTATGAACTAATGACCCCGTA-3’ were used which would generate an 
expected product 0f 394 bp for an empty vector and 454 bp for a vector containing an shRNA 
insert.  For vector pLKO.1, forward 5’CAAGGCTGTTAGAGAGATAA-TTGGA-3’ and 
reverse 5’TATTCTTTCCCCTGCACTGT-3’ were used and were expected to generate a 350 bp 
product for empty vectors or 410 bp products for those containing shRNA inserts.  Amplification 
was carried out using the Phusion DNA polymerase enzyme (New England Biolabs) in 20 µl 
volumes following manufacturer’s instructions.  Amplification was achieved using the PCR 
protocol described in Chapter 3.5. PCR products (10 µLwere separated by agarose gel 
electrophoresis.  Products were purified using Wizard kits and presence of shRNA inserts 
confirmed by DNA sequencing (UT MBRF). 
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Vector Purification 
Vectors were purified from 125 ml of bacterial culture using polyethylene glycol (PEG)/ 
chloroform precipitation.  Bacteria were grown overnight and collected the following day by 
centrifugation at 1,000 x g for 5 min.  Supernatants were removed, pellets dried for 3 min, and 
the bacteria lysed by addition of alkaline lysis solutions taken from the Qiagen plasmid midiprep 
kit.  Following lysis, the solutions were centrifuged at 10,000 x g for 20 minutes at 4°C, and 
supernatants containing plasmid DNA were removed and placed in a clean tube.  DNA was 
precipitated by adding ammonium acetate to a final concentration of 2M, followed by 2 volumes 
of 100% ethanol.  Tubes were placed on dry ice for 10 min and DNA was isolated as a pellet by 
centrifugation at 14,000 x g for 20 min at 4°C.  DNA was transferred to a clean 1.5 ml 
microcentrifuge tube in 0.4 ml buffer TE to which an equal volume of saturated phenol -
chloroform; isoamyl alcohol solution (25:24:1) - was added. Solutions were mixed and allowed 
to settle briefly before centrifugation at 13,000 x g on Biofuge Pico tabletop centrifuge for 2 min.  
Aqueous layers were removed and placed in clean tubes.  Extractions were repeated twice.  DNA 
was precipitated by the addition of 0.8 ml PEG solution (30% PEG 8000, 1.6M NaCl) to each 
tube and incubation overnight at -20°C before collection by centrifugation at 14,000 x g for 20 
min at 4°C. 
 
Transient transfection of cells with lentivirus expression vectors 
HEK 293t and RPMI 8226 cells were acquired from the ATCC (Manassas, VA) and grown in 
DMEM F-12 containing 10% or 5% FBS, respectively, along with antibiotics.  Cells were 
housed in a 37°C humidified chamber containing 5% CO2.  For each line, either empty or 
shRNA expressing pLB vector was combined with FuGeneHD transfection reagent (Roche).  
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The optimal ratio of DNA-to-transfection reagent was determined for each line according to 
manufacturer’s instruction. 
 
Generation of lentiviral particles 
HEK 293t cells were grown in DMEM F-12 containing 10% FBS and antibiotics.  Cells were 
housed in a 37°C humidified chamber containing 5% CO2.  For transfection experiments, cells 
were grown to ~80% confluence in 6 mm dishes or 24 well plates.  On the day of transfection, 
media was exchanged to serum containing DMEM F-12 without antibiotics.  ShRNA containing 
pLB expression vectors (1 µg) along with PMD2.G (0.5 µg; Addgene vector number 12259) and 
psPAX (0.5 µg; Addgene vector number 12260) were introduced to HEK 293t cells using 
Fugene HD transfection reagent (Roche) at a ratio of 2:6 (µg total DNA: µl FuGene HD).  Cells 
were examined for EGFP expression under an inverted fluorescence microscope following 24 h 
incubation.   At 48 and 72 h cell supernatants were harvested and filtered through 0.45 µm nylon 
filters and stored at -80°C. 
 
Transduction of cells with low titer virus 
HEK 293t cells were plated and grown to ~80% confluence in 10 mm dishes using DMEM F-12 
with serum and antibiotics.  On the day of transduction media was removed and cells washed in 
serum and antibiotic free DMEM F-12.  1 -1.9 ml Antibiotic free DMEM F-12 containing 10% 
FBS along with 10 µg/ml polybrene (Millipore) was then added to each plate.  0.1-1 ml viral 
supernatant was then added to each plate, bringing the final volume to 2 ml.  Cells were 
incubated with virus for 6 h before supernatants removed and were replaced with fresh media.  
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At 24-72 h Cells were removed from plates by trypsinization and EGFP expression was 
measured by flow cytometry and fluorescence microscopy. 
 Similarly, RPMI 8226 and SP2/O-λ6 cells were exposed to increasing (0.1-1 ml) amounts 
of viral supernatant in presence of polybrene (10 µg/ml).  Cells were incubated for 6 h in 
presence of virus before centrifugation and removal to fresh media.  
 
6.3 Results 
Recovered plasmids were visualized by gel electrophoresis and ethidium bromide staining; 
plasmid pLB is shown (Figure 6.3 A).  For each plasmid, several glycerol stocks were prepared 
and were stored at -80° C.  As needed, stocks were expanded and plasmid DNA purified using 
the Qiagen plasmid midiprep kit.  Following annealing reactions shRNA inserts were visualized 
by gel electrophoresis and presence of double stranded oligonucleotides are evidenced by 
appearance of a ~120 bp band (Figure 6.3 B).   
Following ligation reactions, plasmid preps were analyzed by gel electrophoresis.  For plasmid 
pLB, several colonies were identified which contained bands of 450 bp in size, indicating non-
ligated plasmids while others contained bands of ~500 bp indicating a ligated plasmid. Likewise, 
digestion of colonies generated from pLKO.1 with NotI/EcoRI restriction enzymes produced 
bands which were shifted by ~ 60 bp with shRNA inserts (Figure 6.4 A).  These steps were 
repeated for each plasmid/insert combination, an example for both pLB 8226V1 and pLKO.1 
Wil V1 are shown (Figure 6.4 A, B).   
 Figure 6.3. Lentiviral Vector pLB and A
transformed with plasmid pLB were grown overnight.  The following day cells were lysed, 
plasmid DNA extracted, and linearized by restriction enzyme digest using HpaI and NotI.  
Products visualized by agarose gel electrophoresis and ethidium bromide staining, Hyperladder I 
was used as molecular marker.  B) Plasmid inserts encoding shRNA sequences were annealed 
and visualized on agarose gel.  Lanes demonstrate annealed forward and reverse oligonucleotides 
(120 bp), forward alone or reverse alone (60 bp).  Hyperladder II was used as a molecular 
marker.   
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 Figure 6.4 Restriction Enzyme Digests of Ligated Expression Vectors.
encoding shRNA 8226 V1 was ligated to expression plasmid pLB.  P
transform XL-1 Blue E.coli.  Bacteria were grown on selective agar plates and selected colonies 
expanded to 5 ml starter cultures. Crude lysates were prepared and digested with NotI/Xba, 
producing a 450 bp band for plasmids without shR
inserts.  B) Likewise, plasmid plko1 Wil V1 was prepared and digested with NcoI/EcoRI.  Since 
the EcoRI site was degraded during initial digestions it was expected that a single cut would 
occur without presence of the insert producing a single 8 kb band.  Restoration of the EcoRI site 
allows a double digest to occur producing a 2 kb and 6 kb fragment.
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Results of digest were confirmed by PCR amplification of plasmid DNA.  In the case of pLB two 
sets of primers were designed; one to flank the regions surrounding the shRNA insert (product 
sizes of 400 or 460 bp without or with inserts, respectively), and another in which the forward 
and reverse primers were located internally of the shRNA expression insert.  Products were 
separated by gel electrophoresis and visualized by staining with ethidium bromide. 
As shown, primers flanking the insertion site as well as those used in combination with primers 
targeting sequences along the 8226 V1 insert along plasmid pLB amplified a target of the 
expected size for presence of the 8226 V1 insert (Figure 6.5 A).  No product was observed when 
both forward and reverse primers targeting insert 8226 V1 were used (Figure 6.5 A).    
Amplification of plasmid PLKO.1 with primers located upstream of the shRNA insertion site in 
combination with those internal to Wil V1 revealed several colonies which contained ligated 
expression plasmid.   In each case, bands were submitted to UTMBRF for sequencing 
Purified plasmids were acquired using phenol chloroform extraction method and purity and yield 
were assessed by reading absorbance values for A260/A280 and functionality tested by transfecting 
HEK 293, RPMI 8226 or SP2/O-λ6 cells using FuGene HD (not shown).   
 Plasmids pLB, pLB 8226 V1, and pLB Wil V1 were shown capable of producing 
infective viral particles by co-transfection with plasmids encoding packaging signals and coat 
protein genes to HEK 293t cells.  Following a 3 day window for virus production, supernatants 
from these cells were removed and added to cultures of either naïve 293t cells, 8226 cells, or 
SP2/O-λ6 cells.  Infectivity of viral particles was assessed by EGFP expression using 
fluorescence microscopy (Figure 6.6).  While low in number, 293t cells were observed which 
demonstrated EGFP expression from cultures receiving  8226 V1, Wil V1, and empty vector 
viral particles.   
 Figure 6.5 Purified Plasmid DNA was Screened for Presence of ShRNA Expression 
Constructs by PCR.  A) Primers were designed to amplify regions of pLB plasmid which flank 
shRNA inserts (pLB external) or which require presence of inser
the reaction to occur (pLB internal, or internal/external).  B) Similarly, plasmid DNA for 
pLKO.1 Wil V1 was screened using a forward primer to Wil V1 construct and a reverse primer 
for pLKO.1. In plasmids containing the insert
106 
t encoding 8226 V1 shRNA for 
s a 250 bp band was produced. 
 
 Figure 6.6 Transduction of HEK 293t Cells with Lentivirus Supernatants Results in 
Expression of EGFP.  Supernatants (2 mL) from co
µg/ml polybrene were used to infect naïve HEK 293 ce
empty pLB vector B) pLB 8226 V1 or C) pLB Wil V1 shRNAs 
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A lack of fluorescence was observed in cytospin preparations of either myeloma cell line.  
Plasmids used in preparing viral particles were sent to the UT Viral Vector Core Facility for 
generation of high titer viral vectors. 
 
6.4 Discussion 
While both vectors pLKO.1 and pLB were amenable to the generation of lentiviral vectors, it 
was decided to utilize vector pLB for these studies due to the presence of a CMV driven EGFP  
reporter protein, allowing for easy identification of transduced cells by flow cytometry, 
fluorescence microscopy, or immunohistochemical detection of EGFP.  Digestion and ligation of  
vectors to shRNA constructs provided an ample number of transformed colonies from which to 
generate starting materials.  Purification of plasmids from these bacteria proved difficult, 
however, and was unsuccessful using a variety of plasmid mini-, and midi-prep kits.  Of these 
methods, a straightforward phenol chloroform reaction provided the best results and was adopted 
over the previously used Qiagen midi-prep kit for purification of plasmid DNA.   
 Plasmid functionality was tested in two ways; first, by transfection of HEK293t cells with 
pLB based plasmids to show EGFP expression and by co-transfections to generated infective 
lentiviral particles.  Transfection of kidney cells with either shRNA-expressing or empty 
expression plasmid of the kidney line HEK293t was successful in generating a large population 
of cells which were positive for EGFP, although similar treatment of myeloma lines failed to 
replicate this response. The ability of each of the pLB constructs to produce viral particles was 
successful, and demonstrated that these particles could infect naïve HEK293t cells.  While not as 
striking, a few SP2/O-λ6 and RPMI 8226 cells were seen to express EGFP following exposure to 
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virus.  The relatively lower efficiency of transduction was thought to be a consequence of using 
low titer amounts of virus, although reasons for this were not examined further.   
 These studies provide evidence that a functional lentiviral particle which encodes a 
construct for the expression of an anti LC shRNA molecule can be generated.  Further, these 
materials were used by the UT Viral Vector Core Facility to generate a high titer (1 x 109 
infectious units/ ml) production run of lentiviral particles containing empty pLB expression 
vector or pLB vectors expressing 8226 V1 or Wil V1 shRNAs.   
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Chapter 7 
Transduction of myeloma cell lines with shRNA expressing lentiviral particles 
 
7.1 Introduction 
Previous work has shown that production of toxic LC species can be reduced by delivery of 
synthetic siRNA molecules to human and mouse myeloma lines (Chapter 6).  Exposure of 
cultured cells to siRNAs directed against their LC product in the presence of lipid based 
transfection reagents resulted in decreased LC mRNA and protein, without reducing cell number 
or viability (Chapter 6).  These responses were transient, however, and lipid based media are not 
easily adaptable for administration in vivo.  To address this, an alternate means of delivering 
silencing RNAs was explored.  Short-hairpin RNAs (shRNA) that mimic the naturally occurring 
RNA substrates (i.e., endogenous siRNAs, pre-miRNAs) for the enzyme Dicer are effective in 
reducing protein production (For review see Chapter 1.1).  These shRNAs are synthesized as a 
single-stranded RNA transcript which self-anneals to form the characteristic stem-loop structure 
of shRNAs and include 3’-2 nt overhanging regions (for illustration see Chapter 1, Figure 1.3).  
As these molecules do not require post-transcriptional modifications by the cell to function they 
are amenable to incorporation into plasmids such as those found in retro- or lentiviral expression 
systems (171).  Packaging of these expression constructs into non-replicative viral particles 
affords an effective means of delivery to eukaryotic cells both in vitro and, to a limited extent, in 
vivo. Exposure of cells to these particles which encode targeted shRNAs resulted in a stable 
reduction of target gene products (171, 216).   
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 Stable transduction of myeloma lines has been demonstrated using lentiviral expression 
systems in several studies although none have targeted products of LC genes specifically (213, 
217, 218).  Based on our earlier data demonstrating transient knockdown of LC genes by siRNAs 
(Chapter 5) we posit that lentiviral mediated delivery of a shRNA-expressing plasmid to 
myeloma lines will reduce target LC production, and that this approach may offer the advantage 
of more robust, stable, and long-term knockdown of LC gene products as compared with gene 
silencing using synthetic siRNAs.  
 To test this hypothesis, the siRNA sequences Wil V1 and 8226 V1 (previously shown 
effective in reducing LC production – Fig 5.5) were adapted for expression as shRNAs.  These 
constructs were then cloned into lentiviral expression plasmids containing an EGFP reporter 
construct.  Plasmids were first shown capable of expressing EGFP in the human embryonic 
kidney line HEK293 and were later packaged by the Viral Vector Core Facility into replication 
incompetent self inactivating (SIN) lentiviral particles.   
 Exposure of the human myeloma line RPMI 8226 to increasing amounts of either 8226 
V1 shRNA-expressing or empty vector lentiviral particles resulted in a mixed population of 
transduced cells as measured by EGFP expression and the presence of green fluorescence in the 
cells.  Several clones were generated from these initial transduction which were shown to be 
>95% positive for EGFP expression.  Measurement of LC secretions from supernatants of clonal 
populations demonstrated reduced levels of LC mRNA and protein as compared with untreated 
8226 and empty vector control treated cells.   
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7.2 Methods 
Cells 
SP2/O-λ6 and RPMI 8226 cells were maintained as described in Chapter 3.1.  During sub-
cloning by limiting dilution cell line RPMI 8226 was maintained in an enriched DMEM-F12 
based media which was supplemented with 20% filter-sterilized RPMI 8226 conditioned media 
(harvested from “heavy” 8226 culture after centrifugation) as well as 15% FBS, 0.2 µg/ml 
human insulin, and antibiotics (penicillin, streptomycin, gentamicin).   
 
Lentiviral Vectors 
The SIN lentiviral expression plasmid pLB was acquired from AddGene plasmid repository 
(vector11619) (593). Plasmids were subjected to digestion by the restriction enzymes NotI and 
XhoI. DNA sequences encoding shRNAs directed against the λ2 LC 8226 or the λ6 LC Wil 
were ligated to linearized expression plasmid (Chapter 3.7).   ShRNA-encoding expression 
plasmids were purified using Qiagen plasmid Midi-Prep kit (Chapter 3.4) and supplied with the 
pLB (without inserts) to the UT Viral Vector Core Facility (University of Tennessee Health 
Science Center, Memphis, TN) for packaging as VSVG-pseudotyped lentiviral vectors in viral 
particles. Preparations of virus were returned for analysis with titers of 1 x 109 infectious units 
(IFU) per mL (219).   
 
Transduction of myeloma cell lines 
Cells were counted by hemacytometer and collected by centrifugation (600 x g for 5 min).  Cells 
were added to each well of a 24-well microplate at a concentration of 1 x 106, for low 
multiplicity of infection (MOI) exposure, or 1 x 105 cells per well for high MOI exposure in 1 ml 
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antibiotic-free DMEM F-12 containing 5% fetal bovine serum and 10 µg/ml polybrene. Viral 
particles ranging from 0.05 x 106 - 1 x 107 IFU were added to each well and cells were incubated 
for 6 h at 37°C under 5% CO2.  Cells were collected by centrifugation at 500 x g for 5 min and 
washed 3x in fresh DMEM F-12.  Cells were resuspended in growth media and returned to 
incubator for 24-72h.   
 
Generation of clonal myeloma populations by limiting dilution.   
8226 cells were infected with either 8226 V1 shRNA-expressing virus or those containing the 
empty pLB vector as a control.  Cell cultures shown positive for EGFP expression by fluorescent 
microscopy were counted by hemacytometer and collected by centrifugation (600 x g for 5 min).  
For limiting dilution cloning, a sample of 1 x 105 8226 cells was resuspended in 1 mL fresh 
DMEM F12 containing 5% FBS and penicillin/streptomycin, or 15% FBS, 0.2 mg/ml human 
insulin, and 20% conditioned media. In each case, 200 µl of 8226 cells in suspension was added 
to each well of the first column of a tissue culture-treated 96-well microplate (BD Falcon).  A 1:1 
serial dilution (100 µl cells) was then diluted across each plate.  Cells were housed in a 
humidified incubator at 37°C under 5% CO2 for 4-6 weeks.  Wells were observed for colony 
formation, and screened for EGFP expression by fluorescent microscopy.  Colonies found to be 
positive for EGFP fluorescence were further re-cloned or expanded by growth in 24 well plates, 
then 6 well plates. 
 
Flow Cytometry 
Cells transduced with pLB vectors were analyzed for expression of EGFP by flow cytometry.  
Cells were counted, collected by centrifugation, and washed 3x in PBS containing 1% bovine 
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serum albumin.  Cells were then resuspended in PBS/BSA and cell size, complexity, and 
fluorescence were analyzed on FACScan flow cytometer (BD Biosciences).   
To detect LC expression, cells were harvested and washed as above, then fixed for 20 min using 
BDcytofix solution followed by permeablization using BDcytoperm buffer (Beckton Dickson).  
Human λ LC was detected using an Alexa594-conjugated rabbit anti-total human lambda 
polyclonal IgG (Invitrogen).  Antibody was diluted 1:2000 in BDcytoperm and incubated with 
cells for 1h at room temperature.  Cells were washed 3x as above and analyzed by FACS. 
Regions of interest were drawn around populations of untreated cells, and no fewer than 5,000 
events were collected for analysis.  
 
Analysis of LC expression by ELISA  
Secreted λ LC was detected from cell supernatants using either Total human λ ELISA A or total 
human λ ELISA B as indicated.  For detailed descriptions please see Chapter 3.9. 
 
Real Time PCR 
Levels of LC mRNA were assessed using real time PCR analysis of cDNA acquired by reverse 
transcriptase of total RNA extracted from 8226 cells following the protocol found in Chapter 3.5. 
 
Statistical Analysis 
Data concerning LC production from ELISAs were pooled, entered into GraphPad Prism version 
4 (GraphPad Software, Inc.) and analyzed for statistical significance by One-Way ANOVA.   
Dunnett’s Multiple Comparisons test was used to determine which groups were significantly 
different as compared to controls. 
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7.3 Results 
Transduction of cell line 8226 
By 24 h, exposure of 8226 cells to increasing titers (MOI 0.5, 1, 2.5, 5, 10) of lentiviral vectors 
encoding shRNA 8226 V1 yielded a corresponding increase in the proportion of cells expressing 
EGFP as measured by flow cytometry (Figure 7.1).  Following initial evaluation, transduced 
cells were expanded to 10 ml tissue culture flasks and maintained under standard conditions.  
Cells were re-evaluated repeatedly up to14 d by flow cytometry and showed slight variances in 
the population of positive cells as compared with analysis at 24 h.  While EGFP positive cells 
were still observed in cultures exposed to 0.5-5 MOI lentivirus a slight decreases the proportion 
of EGFP expressing cells was seen, while those transduced at an MOI of 10 demonstrated an 
increased number of positive cells as compared with samples taken at 24 h (Figure 7.2).  
 At 7 and 21 days post-transduction, 24 h cell culture supernatants from 8226 cells were 
collected and analyzed for secreted LC by ELISA.  Analysis of cell supernatants on day 7 
demonstrated a trend toward reduced LC secretion in cells exposed to shRNA expressing 
lentiviral vectors as compared with untreated 8226 cells.  In supernatants from cells exposed to 
MOI values of 0.5, 1.25, and 2.5, secreted LC was found at 89, 79, and 62% of that seen in 
untreated control cells.  Supernatants from cells exposed to MOI 5 or 10 contained LC levels 
74% and 83% of untreated control cells.  As cultures were sparse on d 7, only single replicates of 
wells were prepared so no statistical analysis was performed (Figure 7.3 A).   
When experiments were repeated on d 21 a similar trend was observed with supernatants from 
cells exposed to MOI 0.5, 1.25, and 2.5 pLB 8226 V1 lentiviral vectors with 73%, 75%, and 89% 
levels of LC protein as compared to that found in untreated 8226 cells, while those exposed to  
 
  
Figure 7.1.  Evaluation of enhanced green fluorescent protein at 24 h following exposure to 
pLB 8226V1 expressing lentiviral particles.
well along with increasing amounts of viral titer in presence of 
transduction cells were washed and cultured overnight before samples were analyzed for EGFP 
by flow cytometry.  A) Forward (FSC) and side scatter (SSC) analysis of untreated 8226 cells 
were used to generate regions of interest. B) 
channel FL-1 allowing for selection of cells positive for EGFP expression. Viral titer is noted at 
top of histogram while percentage represents the proportion of positive cells in each culture.
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polybrene. 6 h following 
Markers were drawn to exclude negative cells on 
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 Figure 7.2. Evaluation of enhanced green fluorescent protein 14 d following exposure to pLB 
8226 V1 expressing lentiviral particles.
culture for 14 d.  A) Forward (FSC) and side scatter (SSC) analysis of untreated 8226
used to generate regions of interest. B) Markers were drawn to exclude negative cells on channel 
FL-1 allowing for selection of cells positive for EGFP expression. Viral titer is noted at top of 
histogram while percentage represents the proport
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 cells were 
 
 Figure 7.3 Secreted LC from 8226 cells exposed to pLB 8226 V1 lentiviral vectors.
(n=1) and B.) 21 d (n=3) following transduction with increasing concentrations of lentivirus pLB 
8226 V1 cells were cultured and supernatants analyzed for secreted LC by ELISA.  Data were 
expressed as percent untreated 8226 LC and at d 21 data were analyzed by One
denotes significance; p <0.05) 
 
 
118 
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MOI 5 or 10 of the same viral construct were shown to contain 86 and 90% of controls, 
respectively (Figure 7.3 B). 
 To test whether exposure to higher levels of virus would improve results viral titers were 
raised 10-fold by reducing the number of 8226 cells plated from 1x106 - 1x105 cells per well 
while retaining the amount of virus added (Figure 7.4 A-B). Additionally, cells exposed to 
lentiviral particles containing empty expression vector pLB were included in these experiments 
(Figure 7.4 C).   
In cells that received a 10-fold increase in viral particles, no corresponding increase in EGFP-
positive cells was observed. The singular exception to this was seen in cells exposed to an MOI 
50 of pLB 8226 V1 lentiviral particles, and in this case the increase was modest (30% v. 25%) 
when compared with cells previously exposed to the same particles at an MOI of 5 (Figure 7.1).  
These results were mirrored in 8226 cells which received empty pLB vector bearing particles 
with 31% of these cells considered positive for EGFP expression at 24 h.   
 Similar to cells transduced with lower titer shRNA-expressing lentiviral particles, cells 
from the high MOI treatment group were plated to 24-well plates at 2 x 105 in fresh media and 
incubated overnight at 7 d post-transduction.  The following day, supernatants were harvested 
and secreted LC was measured by ELISA.  Significantly (p<0.05) reduced amounts of LC 
protein were found in cells which had received lentiviral particles at MOI of 10 (42% decrease) 
and 50 (41% decrease) as compared with those treated with particles containing empty pLB 
plasmid (vector control) (Figure 7.5).  The cells treated with an MOI of 25 showed reduced LC 
secretion relative to empty vector control cells, but this change did not reach significance (Figure 
7.5). 
 
 
  
Figure 7.4. Evaluation of enhanced green fluores
MOI pLB 8226 V1 or control lentiviral particles.
higher amounts of lentiviral particles and evaluated for EGFP expression at 24 h.  A) FSC and 
SSC profiles of untreated 8226 cells cultured under similar conditions to those exposed to viral 
vectors were used to draw regions around cell populations.  B) Untreated cells were used to set 
marker regions for cells considered positive for EGFP.  Each panel represents an individua
transduction experiment, in which cells were exposed to shRNA expressing lentiviral particles at 
increasing MOI.  Percentages above marker region represent the proportion of EGFP positive 
cells from the total population.  Similarly, in C) 8226 cells were
encoding empty pLB expression vector.
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 Figure 7.5 Exposure to higher levels of shRNA expressing lentiviral particles.
cells exposed to either MOI 10 or 50 shRNA 8226 V1 expressing lentiviral particles 
demonstrated a significant (n=3; *denotes significance p < 0.05) reduction in secreted LC protein 
as compared with control cells which had received MOI 50 lentiviral particles when analyzed by 
One-way ANOVA. 
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Transduction of cell line SP2/O-λ6    
Initial transductions of the cell line SP2/O-λ6 were performed using lower concentrations of 
lentiviral particles.  Surprisingly, analysis of the transduced cells 24 h post exposure revealed no 
EGFP expression in the cells even at the highest concentrations of virus used in this study (i.e., 
MOI 5-10) (Figure 7.6).  Following this, SP2/O-λ6 cells were plated at a lower number of cells 
per well (1 x105 cells) and were exposed to 10-fold increased amounts of pLB Wil V1 virus from 
a new, unopened stock.   
As with the earlier results, SP2/O-λ6 cells receiving Wil Vλ lentivirus at MOI 12.5 and 25 
demonstrated no increase in fluorescence as compared with controls (Figure 7.7 A-B).  Those 
receiving viral particles at an MOI of 50 demonstrated a small population (1.8 v. 0.9%, 
respectively) of cells exhibiting an increased fluorescence as compared to controls.  It was only 
when cells were exposed to the highest amount of virus tested in these studies, MOI 100, that a 
substantial (6.87%) population of cells were evidenced by EGFP expression (Figure 7.7 B).  
Examination of FSC and SSC for this population also revealed an increased number of dying 
cells as assessed by size and complexity (Figure 7.7 C).   
 To determine if the differences observed in transduction efficiency as compared with the 
8226 line were a function of the SP2/O-λ6 line, or the pLB Wil V1 virus a series of cross 
exposure experiments were conducted.  In the first series of studies, SP2/O-λ6 cells were plated 
as above and received either lentiviral vectors expressing pLB 8226 V1 plasmid or empty pLB 
plasmid at an MOI of 50, followed by analysis by flow cytometery.  Evaluation of those exposed 
to pLB 8226 V1 revealed 12.33% of cells expressing EGFP, while exposure to the same levels of 
particles expressing pLB empty vector resulted in 1.25% of the population being positive for 
green fluorescence (Figure 7.8 A-B). 
 Figure 7.6 Evaluation of enhanced green fluorescent protein 14 d following exposure to pLB 
Wil V1 expressing lentiviral particles.
culture for 14 d.  A) Regions of interest were drawn based on FSC and SSC profiles of untreated 
SP2/O-λ6 cells. B) Evaluation of fluorescence from untreated populations was used to generate a 
marker region to exclude negative cells on channel FL
from untreated or treated cells. Viral titer is noted at top of histogram while percentage 
represents the proportion of positive cells in each culture.
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  pLB Wil V1 transduced SP2/O-λ6 cells were held in 
-1.  Panels illustrate EGFP expression 
 
 
 Figure 7.7 Evaluation of enhanced green fluorescent protein 24 h following exposure to high 
MOI pLB Wil V1 lentiviral particles.
of lentiviral particles and evaluated for EGFP expression at 24 h.  A) FSC and SSC profiles of 
untreated SP2/O-λ6  cells cultured under similar conditions to those exposed to viral vectors 
were used to draw regions around cell populations.  B) Untreated cells were used to set marker 
regions for cells considered positive for EGFP.  Each panel represents an individual transduction 
experiment, in which cells were exposed to shRNA expressing lentiviral particles a
MOI.  Percentages above marker region represent the proportion of EGFP positive cells from the 
total population.  C.) FSC and SSC profiles of SP2/O
cells considered non-viable (Blue) with increasing concentration of viral particles.
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-λ6 demonstrate an increased population of 
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 Figure 7.8 Evaluation of EGFP expression in SP2/O
pLB Wil V1, 8226 V1 or pLB empty len
SP2/O-λ6 cells were used to generate regions of interest. B.) 
efficiency was caused by lentiviral particles 
8226 V1 lentiviral particles at MOI 50.  Fluorescence was assessed at 24h by flow cytometry.  
C.) Lentiviral particles (MOI 50) encoding pLB Wil V1 were used to infect 8226 cells alongside 
pLB empty and pLB 8226 particles.  Panels illustrate FSC and SSC profil
experiment, with regions colored red considered the primary 8226 population while those in blue 
considered non-viable (denoted by percentages).   Below, FL
treatment, where percentages represent EGFP p
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In a parallel series of experiments, the human myeloma line 8226 was exposed to viral particles 
encoding  pLB Wil Vλ (MOI 50), while cells exposed to particles encoding pLB vector  were 
used as a positive control population.  From evaluation by flow cytometry it is evident that 
transductions with the pLB empty vector viral particles was successful, with 22.29% of cells 
expressing EGFP. Conversely, exposure to pLB Wil V1 resulted in a much lower proportion of 
EGFP positive cells with only 1.34% of cells demonstrating increased fluorescence.   
 The difference in viability observed in cell line SP2/O-λ6 was also mirrored in 8226 cells 
exposed to Wil Vλ viral particles where 55.8% of cells were considered non-viable as compared 
with 11% and 17% in untreated and vector control treated cells, respectively (Figure 7.8 C).  
 
Generation of stably transduced 8226 clones 
While exposure to the 8226 line to shRNA expressing lentivirus produced a population of cells 
positive for EGFP expression and elicited, a modest, but significant reduction in secreted LC 
protein (Figure 7.4) it was of interest to know what the maximal level of LC silencing might be.  
To approach this, samples of 8226 cells transduced with either pLB 8226 V1 or pLB empty 
lentiviral expression systems were collected and clonal populations generated by limiting 
dilution.  For cells exposed to pLB 8226V18226 V1, 8 clones were generated which 
demonstrated a >90% population of cells shown to express EGFP as measured by flow 
cytometry (Figure 7.9).  Likewise, 3 clones were generated from 8266 cells exposed to pLB 
empty vector which were shown to exhibit equivalent levels of EGFP positive cells.   
Initial screening of secreted LC protein from clones was measured following 24 hour incubations 
in 24-well plates in 1 ml DMEM-F12 of 200,000 cells per well by using the total λ ELISA A 
(Chapter 3.9).  Analysis of ELISA results by One-way ANOVA demonstrate that clones  
  
Figure 7.9 RPMI 8226 cells exposed to 8226 V1 shRNA bearing lentiviral particles were 
analyzed for EGFP expression by flow cytometry.
populations of untreated 8226 cells based of FSC and SSC profiles.  A Marker (EGFP +) was 
drawn on histograms based on fluorescence channel FL
Screening of 8226 clones from cells exposed to lentivirus pLB
near homogenous population of cells expressing EGFP.
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expressing the 8226 V1 shRNA produced a significantly reduced amount of LC 8226 with a 
mean ~20% of that seen with untreated control cells (n = 2; * p< 0.05).  Of these, clones 13A2, 
13B2, and 13A5 demonstrated the most striking reductions of secreted LC; generating 13%, 
21%, and 22% of LC protein relative to untreated control cells.    Following these, clones 13C7, 
16B2, 13A3, and 13B9 also secreted significantly reduced (25% - 39%) amounts of LC protein 
as compared to untreated 8226 cells (Figure 7.10 A).    
In contrast, with singular exception (clone E1D4), no significant reduction in secreted LC 
product was detected in clones generated from cells transduced with lentivirus bearing empty 
pLB vector (Figure 7.10 B).  In clone E1D4, secreted LC product was found at levels which were 
reduced by 44% to those found in the untreated parental line, possibly owing to a general 
reduction in protein synthesis as a consequence of the site of insertion of the pLB construct 
within the DNA of this clone.  
Cell growth and viability were assessed for individual clones following overnight incubation of  
2 x 105 cells in fresh DMEM F-12 by trypan blue dye exclusion assay and counting on a  
hemacytometer.  Analysis of these data by One-way ANOVA revealed no significant differences 
in the number of viable cells from treated or control population (Figure 7.11 A).  However, the 
percentage of viable cells was slightly reduced (10%) in clone 13A2 as compared with the 
untreated 8226 line (Figure 7.11 B).  Similarly, clones derived from empty vector treated cells 
showed no difference in cell number (Figure 7.11 C) or viability (Figure 7.11 D) as compared 
with untreated control cells. 
From these initial characterization studies, three clones (13A2, 13C7, 16B2) were selected from 
the 8226 V1 shRNA-transduced group, and one (E1G3) from the pLB empty vector group and  
 
  
Figure 7.10 Measurement of secreted LC from lentiviral 8226 clones.
exposed to A.) 8226 V1 shRNA (n=2) or B.)
UT n=15) lentiviral particles were cultured overnight in 24
measured by ELISA and results expressed as percent LC as compa
were analyzed for significant differences by One
comparison test (* denotes significance; p<0.05).
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 Figure 7.11 Cell number and viability of pLB 8226V1 and pLB empty clones following 
overnight incubation. Selected clones from cells exposed to either pLB 8226 V1 or pLB empty 
infected cells were plated at 2 x 10
were counted and viability assessed by trypan blue dye exclusion and coun
hemacytometer.  Data were pooled and analyzed for differences using One
Dunnett’s Multiple Comparisons tests (n=9; * denotes significance p < 0.05) A.) No differences 
were found in clones 13C7 or 16B2, while clone 13A2 was found to ha
significant decrease in viability as compared with untreated cells. B) no differences were found 
in cell numbers of clones exposed to pLB 8226 V1 as compared with untreated cells. Likewise, 
no differences were found in C.) viability,
as compared with controls.   
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were maintained under standard conditions (Chapter 3.1), while the remaining clones were stored 
at -80°C.   
 
LC mRNA levels 
For the shRNA 8226 V1 expressing clones 13A2, 13C7, and 16B2 and clone E1G3, derived 
from cells transduced with the empty pLB vector, total RNA was extracted and analyzed for 
relative LC 8226 gene expression by real time PCR using primers specific to LC 8226, while 
human β-actin served as a reference gene (Chapter 3.5) (Figure 7.12 A).  As compared to 
untreated 8226 cells, samples collected from clones 13A2, 13C7, and 16B2 demonstrated 
significantly reduced (25, 30, 45%, respectively) levels of LC 8226-encoding messenger RNA as 
compared to the parental 8226 line.  In contrast, no differences were found in cells from group 
E1G3 as compared to untreated cells. 
 
Secreted LC protein 
As before, clones 13A2, 13C7, 16B2 were transferred to individual wells of a 24-well plate in 1 
mL fresh media. Untreated 8226 cells and the empty vector clone E1G3 were cultured alongside  
shRNA-expressing clones and served as untreated and vector controls, respectively.  Following 
a24 h incubation, cells were harvested and supernatants analyzed for human LC, this time, 
because of technical difficulties with total λ ELISA A,  using total λ ELISA B (Chapter 3.9). 
Data were expressed as percent untreated 8226 LC and analyzed by one-way ANOVA. As with 
the previous ELISA (Figure 8.10), 8226 shRNA clones were shown to produce significantly 
reduced levels of LC 8226 as compared with controls (n = 9; p >0.01).   As shown in Figure  
 Figure 7.12 Real time PCR analysis of LC 8226 mRNA and ELISA analysis of protein LC 
8226 in clones exposed to either pLB 8226 
from cells exposed to 8226 V1 shRNA expressing lentiviral particles were evaluated for LC 
8226 gene products by Real-time PCR, and demonstrate a trend towards reduced LC 8226 
mRNA levels (n=3). B.) To confi
supernatants analyzed using total 
LC and analyzed by One-way ANOVA and Dunnett’s Multiple Comparisons test (n=9; * 
denotes significance p < 0.01).  Clone E1G3 was generated from 8226 cells receiving pLB empty 
lentiviral particles and demonstrates no differences in secreted LC protein as compared with 
controls.  Whereas, clones 13A2, 13C7, and 16B2 demonstrate significant reductions in LC
compared with untreated 8226 cells.
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7.10, supernatants taken from wells containing clones 13A2, 13C7, and 16B2 had LC protein 
levels that were reduced by 58%, 66%, and 70% as compared to the untreated parental 8226 line.  
As expected, no difference was detected in LC concentrations from supernatants collected from 
wells containing clone E1G3 as compared with untreated 8226 cells (Figure 7.12 B). 
 
7.4 Discussion 
Transduction of myeloma cell lines 
As shown in Chapter 6, the introduction of synthetic siRNA molecules which are designed to 
target products of the LC gene to the human myeloma line 8226 and the mouse myeloma line 
SP2/O-λ6 resulted in reductions of LC protein.  While significant, these reductions were 
transient, and levels of LC protein and messenger RNA recovered by ~ 72 h post transfection.  In 
addition, the chemical transfectants utilized in these experiments are not amenable for 
administering siRNAs in vivo. To address these issues, several options were considered for 
delivery of silencing RNAs.  A review of the literature revealed several publications in which 
viral vectors were used to deliver shRNAs to B-lineage cells or for inducing RNAi in vivo (212, 
220, 221).  From these searches it was found that in a comparison among viral vectors systems 
based on lentiviral particles were most successful at transducing human myeloma lines in vitro 
(213).  Further, in a biodistribution study it was reported that mice receiving EGFP expressing 
lentiviral particles demonstrated presence of expression cassettes in both primary bone marrow 
stem cells and populations of circulating B-cells (214).  Based on these earlier studies it was 
determined that a lentiviral delivery system might be appropriate for delivery of anti-LC 
shRNAs, although it remained to be seen whether the expression of the silencing RNAs would be 
robust enough to effect LC production.   
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 As described in Chapter 6, lentiviral expression constructs were designed to express 
shRNA molecules targeting LC 8226 and LC Wil.  These constructs along with a lentiviral 
expression vector lacking an shRNA expression construct were prepared and packaged by the 
UT Viral Vector Core Facility at the University of Tennessee, Memphis (219).  In a series of 
experiments, both the 8226 line and the SP2/O-λ6 line were exposed to these lentiviral vectors at 
a range of concentrations.  It was found that 8226 cells exposed to lentiviral particles 
demonstrated effective transduction as evidenced by both an increased number of cells 
expressing the EGFP reporter protein and decreased levels of LC as compared to controls.  
 Conversely, and for reasons that are not understood, exposure of the cell line SP2/O-λ6 to 
lentiviral particles containing the pLB Wil V1 vector elicited no increase in fluorescence or 
decrease in LC production.  It was initially thought that the cell line may be refractory to 
transduction with the selected lentiviral system, so a series of experiments were conducted in 
which the SP2/O line was exposed to either 8226 V1 shRNA-expressing or pLB empty lentiviral 
particles.  Results from these seemed to confirm our hypothesis; however in parallel experiments 
in which 8226 cells were treated with pLB Wil expressing lentivirus it was found that these cells 
too had failed to be effectively transduced by the viral particles.  In both cases, increasing levels 
of viral particles failed to increase the number of transduced cells, but did however generate a 
cytotoxic response as evidenced by using flow cytometery.  Because of these findings both the 
SP2/O-λ6 line and the pLB Wil V1 lentiviral groups were dropped from the remaining 
experiments. 
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Generation of stably transduced RPMI 8226 clones 
While a modest reduction in LC was noted with 8226 cells receiving higher levels of lentiviral 
particles, these data were collected on mixed populations of cells containing at best ~30% 
transduced cells.   To determine the amount of silencing that may be expected with a 
homogenous population of infected cells it was decided to generate several clones from these 
initial groups.  Indeed, when assayed in the absence of untransfected cells, those 8226 clones 
exposed to pLB 8226 V1 shRNA-expressing lentiviral particles were shown to express lower 
quantities of LC protein to their untreated 8226 cohorts, while those generated from cells treated 
with particles expressing empty pLB vector retained the ability to produce normal levels of LC 
protein.  Further, this reduction was not due to a decreased tolerance of infected cells as cell 
viability was not compromised.    
 Taken together, these data demonstrate that exposure of myeloma lines to shRNA-
expressing lentiviral systems can elicit a similar response to that seen when cells were exposed to 
synthetic siRNAs.  A >60% reduction in LC protein secretion appears to be the maximum 
attainable from a population of > 90% virally-transduced cells.  It is possible that the rate of 
transcription for LC gene products is outpacing the production of shRNA molecules, resulting in 
only a portion of target being degraded.  Alternately, the rate of LC mRNA turnover is greater 
than that of the rate of degradation within the RNAi process, allowing some mRNAs to bypass 
the RNAi pathway.  While these are both possibilities, further study would be required to 
determine the true cause of partial silencing in these cases. 
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Chapter 8 
Mouse models of LC expression 
 
8.1 Introduction 
While earlier experiments demonstrated the silencing effects of administering siRNA molecules 
to cells in vitro [Chapters 5, 6, 7], these studies did not address whether a similar reduction in LC 
gene products may be attained in an in vivo model system.  Several published reports have 
shown that synthetic siRNAs or vector-delivered shRNA molecules can be used, but with 
varying degrees of success (172, 214, 222).  While none of these studies specifically targeted the 
LC protein, there is at least one example in which shRNA bearing lentiviral vectors were shown 
to infect both bone marrow and circulating b-lymphocytes in mice (214).   
 To test the hypothesis that RNAi therapy affords a rational approach to reducing free LC 
burden in vivo, human 8226 plasma cell tumors were generated in severely compromised 
immuno-deficient beige (SCID) or mice deficient in active Recombinase Activating Gene 1 
(RAG1 -/-).  The SCID/beige model was first identified in the early 1980’s by Bosma et al. and 
is deficient in both B and T cell responses.  There is a lack of immunoglobulin production due to 
a deficiency in the recombinase activity within the IgL gene locus; while mice retain normal 
macrophage and natural killer cell function (223, 224).  Similarly, the RAG1 -/- knockout mice 
are immunodeficient due to a lack of the RAG1gene, which is crucial for B and T cell 
maturation, and thus these animals contain no mature B or T lymphocytes (225).   
For these studies both mouse strains were implanted with either pLB empty vector clones or pLB 
8226 V1 shRNA clones (Chapter 7), and LC production monitored over a period of 4 weeks.   
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 To study the effects of treating an established tumor with siRNAs, immunocompromised 
mice were implanted with 8226 cells and monitored for tumor growth.  Mice were then treated 
with lentiviral expression vectors encoding either 8226V1 shRNA transcript or empty pLB 
vector by direct tumoral injection.  Mouse sera was collected prior to and post-injection with 
viral vectors and the secretion of LC monitored by various techniques over the course of these 
studies. 
 
8.2 Methods 
Mice 
Fox Chase SCID/beige (SCID) mice were acquired from Charles Rivers Laboratories 
(Wilmington, MA) and were housed in the animal care facilities at the University of Tennessee 
Medical Center, Knoxville.  RAG1 -/- mice were a gift from the HICP and were housed as 
above. Animals were maintained under 12 hour light/dark cycles while food and water were 
given ad libitum.    All care and animal manipulations were approved by the University of 
Tennessee Animal Care and Use Committee. 
 
Cells 
Clones of cell line 8226 containing either pLB empty or pLB shRNA 8226 V1 expression 
constructs were generated as described in Chapter 9.  For this series of experiments the 8226 V1 
shRNA-expressing clones 13A2 and 13C7 were used, while cells generated from the pLB empty 
vector clone E1G3 were used as a control.  In addition, the parental cell line 8226 was included 
as control for LC expression. 
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Lentiviral vectors 
Lentiviral vectors pLB 8226 V1 and pLB empty were characterized as described in Chapter 6. 
 
Xenograft models and treatment 
On the day of experiment, cells were counted and viability assessed by trypan blue dye exclusion 
assay as described in Chapter 4.  Cells from line 8226 or the stably transfected clones 13A2, 
13C7 and E1G3 were harvested by centrifugation.  Cells were washed 3x and resuspended in ice 
cold sterile 200 µl PBS. For intraperitoneal (I.P.) injections, female SCID mice (n = 4) were 
lightly anesthetized using isoflurane and received 1 x 107 8226 or 8226 lentivirus-transduced 
clone (n = 4 per group) cells by direct introduction of cells to the intraperitoneal cavity using a ½ 
inch 30 gauge needle.   
 Subcutaneous (S.C.) injections of 1 x 107 either 8226 untreated, pLB 8226 V1, or pLB 
empty clones were administered to the left inguinal region in the mammary fat pads of female 
RAG1 -/- mice (n = 4) using ½ inch 30 gauge needles.  On days 7, 14, and 28 blood was 
collected via the retroorbital sinus from anesthetized mice.  Samples were held for 1 h at RT to 
generate serum.   When possible, urine was also collected from animals by first placing them 
over squares of parafilm™ and gently scruffing the animal.  Sera and urine samples were stored 
at 0°C until time of analysis.  On day 28, mice were euthanized and spleen, kidney, heart, and 
liver tissues harvested at necropsy.  Samples of each organ were preserved in buffered formalin 
solution for microscopic analysis.  Solid tumor, when present, was also harvested and preserved 
in formalin.  Samples of spleen and tumor tissue were also stored in RNA later solution for 
molecular analysis (Ambion, Austin, TX). 
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 In a separate series of experiments, 8 female SCID mice received 1 x 107 8226 cells 
suspended in 100 µl ice cold PBS, injected to the inguinal mammary fat pad as above.  Mice 
were monitored for tumor development.  Once tumors formed, measurements of height, length, 
and width were taken using calipers.  When the tumor volume reached ~5 mm3, mice received 
107 of either pLB 8226 V1 or pLB empty expressing lentiviral particles.  Particles were diluted 
in100 µl ice cold PBS and injections were given directly into tumor mass (intratumoral; I.T.).  
Mouse sera were harvested both immediately prior to administration of virus and at 7 and 14 
days following treatment.  Tumor size was assessed on the day of each collection.  On day 14 
animals were euthanized and tissue harvested as above.   
 
ELISA of sera LC 
Mouse sera was diluted 1:10 in PBS + 0.5% tween and analyzed by total λ ELISA B as 
described in Chapter 3.9. Serial dilutions of the patient derived human BJP (Cott) was used to 
generate standard curves.  Filtered mouse sera (Sigma-Aldrich) was used as a negative control.   
 
Immunohistochemistry 
Tissue was fixed in 10% neutral-buffered formalin for ~24 h, embedded in paraffin and 4 µm-
thick sections cut.  Sections were placed on Tissue Path Superfrost Plus Gold Slides (Fisher 
Scientific).  For each animal, one slide was prepared with hematoxylin and eosin stain.  At the 
time of analysis slides were de-paraffinized and antigen retrieval performed using Target 
Retrieval Solution S1700 (Dako) as directed. For detection of LC, rabbit anti-human total λ pAB 
(Dako) was applied at a 1:15,000 dilution and the sections incubated overnight at 4°C. For 
detection of EGFP, Rabbit monoclonal anti-EGFP (Invitrogen) was applied at a 1:250 dilution 
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and incubated overnight at 4°C.   Reactivity was visualized with the IHC for Rabbit antibodies 
on Mouse/Rat tissues kit (Biogenex, San Ramon, CA) following manufacturer’s instructions.  
Color development was achieved using ImmPACT™ DAB peroxidase substrate (Vector 
Laboratories, Burlingame, CA) following manufacturer’s instructions.  Images were captured by 
microscopy as described in Chapter 3.8. 
 
Statistical Analysis 
For data sets with comparisons between more than two groups data were analyzed by One-Way 
ANOVA followed by Dunnett’s Multiple Comparisons Test.  In cases where comparisons were 
made between two groups data were analyzed by Non-Paired Student’s T-test.  All analyses were 
conducted using GraphPad Prism version 4.0 (GraphPad Software Inc.).  Data are reported as 
mean ± standard error.  
 
8.3 Results  
I.P. injection of SCID mice 
SCID mice were randomly assigned to receive pLB shRNA expressing clones 13A2, 13C7 or 
pLB empty expression vector clone E1G3 (vector control; VC), while those receiving untreated 
8226 cells served as no treatment control (n = 4 per group). Animals from groups SCID 8226 UT 
and SCID 13A2 were the first to receive myeloma cells, with groups SCID VC and SCID 13C7 
exposed on a separate day.  Sera collected from SCID 8226 or SCID 13A2 mice demonstrated 
detectable levels of human λ LC (289.8 ± 87.21 µg/mL; n = 3 and 85.54 ± 34.35 µg/mL; n = 4, 
respectively) when analyzed by ELISA (Figure 8.1 A).  In the case of mouse SCID 8226 UT 1, 
repeated ELISA of sera revealed no increased LC production, and the animal was excluded from   
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analysis.  Although at day 7 post tumor implantation there appeared to be a trend towards 
decreased LC production in group SCID 13A2 (85.54 ± 34.35 µg/mL; n = 4) as compared with 
SCID UT (289.8 ± 87.21 µg/mL; n = 3) this did not reach significance (p = 0.11). 
 On day 14 there was also a similar trend toward decreased LC production in sera from 
mice in the SCID 13A2 group with mean concentrations of serum LC 86.88 ± 23.00 µg/mL (n = 
4) as compared to 312.5 µg/mL ± 71.90 (n = 3) in animals from group SCID UT (8.1 B),  
although, due to the low animal numbers per group, the data failed to achieve significance (p = 
0.06),  Because 2 animals from group 13A2 (mice 13A2 1 and 13A2 3) expired while under 
anesthesia, we limited LC analysis of sera to day 28 for the remaining animals to avoid further 
losses.  As an alternative, mouse urine was analyzed as a metric of LC production, although as 
assay of urine from individuals taken on the same day yielded highly disparate results, this 
approach was also dismissed.  
 Analysis of mean LC production from sera collected from animals in groups SCID UT 
and SCID 13A2 revealed a high level of variability as evidenced by large standard errors within 
groups.  As such, LC data were graphed for individual animals from groups SCIT UT and SCID 
13A2 over time (Figure 8.2 A, B). Likewise, sera LC values for individuals from groups SCID 
13C7 and SCID VC were graphed from samples collected at day 28 (Figure 8.2 C, D). 
 These data demonstrated an overall > 2-fold increase of LC protein within the sera of 
animals from group SCID 8226 with a minimum value of ~ 250 µg/ml (mouse SCID UT 2).  A 
similar increase in serum light chain concentration was observed in 2 of the 13A2 mice (SCID 
13A2 1 and SCID 13A2 3); however the maximum level attained by these animals at day 28 pi  
 Figure 8.1 Mean Serum LC concentration of SCID mice at 7 and 14 days following I.P. 
injection of myeloma cells.  Female SCID/beige mice received either 1 x 107 RPMI 8226 or 
clone 13A2 cells by intraperitoneal injection.  Serum was
analyzed for total human l LC by ELISA.  Data were analyzed using a Student’s t
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 harvested at A.) 7 or B.) 14 days and 
-test.   
 Figure 8.2 Serum concentration of human LC in individual mice.
for mice from groups A.) SCID UT and B
increased in 3 of 4 animals from group SCID UT over the course of the study, while increasing 
LC was observed in 2 of 4 mice from group SCID 13A2.  C.) In Animals from group SCID VC 
two animals were found to have serum LC concentrations above 100 mg/mL, while two were 
near 0.  D.) Three mice from group SCID 13C7 were shown to lack or have low levels of human 
LC protein in the serum, while mouse 13C7 1 was shown to have 89 mg/mL.
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was only ~130 µg/ml (Figure 8.2 A, B).  Exclusion of the non-responding animals from group 
SCID 13A2 at day 14 increased the mean LC concentration from 86 ± 23.00 µg/mL (n = 4) to  
124.4 ± 7.500 µg/mL (n = 2) and reduced the standard error (SEM 7.5 v. 73.5), but did not affect 
significance (p=0.061) when compared with group SCID UT 8226 (312.5 ± 71.90 µg/mL; n = 
3).Analysis of mean LC concentration in sera collected at 28 d pi indicated a significant 
difference (p < 0.05) between the untreated control group SCID UT (648.3 ± 222.3 µg/mL; n = 
3) and the treated group SCID 13C7 (19.55± 1.667; n = 3) (Figure 9.3). While no differences 
were detected between SCID UT and SCID VC (267 ± 116 µg/mL; n = 2).   
 Tissue samples harvested at day 28 pi mice were studied by using IHC.  In the case of 
animals SCID UT 2 - 4, tumor cells were observed outside the abdominal wall of the peritoneal 
cavity near the site of injection.  Regardless, the lesion size, presence or absence of tumors 
corresponded well with whether serum LC was detectable for the given animal.  It was not 
known whether the extra-peritoneal lesions resulted from inadvertent S.C. injection of cells, or 
due to implantation of a small number of cells from backflow at the time of injection.   
 
S.C. injection of RAG1 -/- mice 
While data from I.P implantation of SCID mice appeared compelling, a major concern with the 
model was the lack of visible tumor.  Further, the single parameter which might offer a measure 
of tumor burden in the mice, sera LC concentration, was also the protein which should be 
affected by treatment, and could therefore not be used as surrogate marker of tumor size or 
growth in an in vivo silencing experiment.  Additionally, due to loss of animals, group sizes were 
smaller than desirable, likely contributing to the lack of statistical significance.  To address these 
issues, a second mouse model was developed.  For this, the clones 13A2, 13C7, and E1G3 (VC)  
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Figure 8.3 Analysis of sera from groups SCID UT, SCID VC, and SCID 13C7 at 28 days 
following I.P. myeloma cell injection.  Serum from taken from animals within each tumor group 
were analyzed for human LC by ELISA.  Mean concentrations were compared among SCID UT 
(n = 3), SCID VC (n = 2), and SCID 13C7 (n = 3).  Data were analyzed by One-way ANOVA.  
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were again utilized, in addition to untreated 8226 cells, to generate S.C. xenograft tumor in the 
inguinal fat pad in RAG1 -/- mice.  As before, mice were held up to 28 days and sera were 
harvested at 7, 14, and 28 d.  At day 28 mice were euthanized, necropsies performed, and tissues 
collected for IHC analysis.  By day 7, small (approximately 33 mm3) tumors were palpable in 3 
of 4 mice receiving untreated 8226 cells (RAG UT 2, 3, and 4), in all vector control animals 
(RAG VC 1, 2, 3), 3 of 4 mice receiving clone 13A2 (RAG 13A2 2, 3, and 4), and all mice 
receiving clone 13C7 (RAG 13C7; n = 4).  The serum LC levels measured on d 7 yielded were 
not significantly different between groups (Figure 8.4A); however, as seen in the SCID mice, the 
8226 tumor-bearing animals had higher mean LC concentrations (106 ± 46.59 µg/ml; n = 4) as 
compared to the silenced clones, 13A2 (21.24 ± 4.27 µg/ml; n = 4), and 13C7 (47.49 ± 13.52; n 
= 4).  Sera from mice bearing vector control cells contained 76.99 ± 23.46 µg/ml human LC.  
Reassessment of sera LC at 14 days revealed a similar, but more dramatic pattern, with 8226 
tumor-bearing mice having 128 ± 48 µg/mL (n = 4), and those bearing clone 13A2 or 13C7 had 
much lower levels (7.490 ± 1.936 µg/mL; n = 3 and 2.493 ± 1.039 µg/mL; n = 4, respectively) 
(Figure 8.4 B). 
 Because of the apparent decrease in serum LC from the clone groups as compared with 
concentrations assayed at day 7 mice were rechecked for tumor lesions. Animals which had been 
found with lesions at site of injection prior to day 7 had retained the lesions, although tumor sizes 
were still below that which could be accurately measured by calipers.  The decrease in serum 
free LC in these mice could therefore not be explained by the loss of tumor mass. 
 Analysis of serum samples collected on day 28 showed that this trend continued (Figure 
8.4 C); however, while there were large differences in mean serum LC concentrations between  
 
 Figure 8.4 ELISA analysis of sera from shRNA treated 8226 clone tumor bearing mice.
each group (N=4), female RAG 1
sera was collected at A.) 7 days post tumor implantation and assaye
ELISA.  This was repeated at B.) 14, and C.) 28 days.  Mean LC concentrations among groups 
were analyzed for each day by One
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groups there were still no significant differences among animals.  At necropsy on d 28, tumor 
lesions were identified in 3 of the control animals (Rag UT1, 3, and 4) and 3 of the vector control 
animals (RAG VC 1, 3).  Interestingly, no evidence of lesions was identified from animals 
bearing 13A2 or 13C7 clones. Results of necropsies are summarized in Table 8.1 for each 
animal, reporting presence of tumors, weight of mass at time of necropsy, and whether each 
animal demonstrated LC production by ELISA from samples collected on day 28. 
 Due to the high variability in LC serum concentrations among animals from the same 
group, the LC production of individual animals were analyzed over time to determine whether 
patterns may emerge which would help explain the above results.  Beginning with animals 
bearing untreated 8226 tumors one of the 4 animals (RAG UT 1) demonstrated the expected 
increase in LC production throughout the experimental period (112, 244, and 1,036 µg/mL at 7, 
14, and 28 d, respectively), while RAG UT 2 began with a higher concentration of LC at day 7 
(236.99 µg/mL) this value decreased to 168 µg/mL by day 14, and disappeared by day 28 
(Figure 8.5 A).  For the remaining animals, assessment of LC production at d 7 revealed much 
lower concentrations of serum LC (35 and 43 µg/mL) compared with the other animals within 
this group.  LC concentrations from mouse RAG UT 4 showed a modest increase in LC at d 14 
(60 µg/mL) which persisted to d 28 (54 µg/mL), and mouse RAG UT 3 exhibited a similar 
pattern at d 14 with LC concentrations of 37 µg/mL, although in this case, there was a drastic 
reduction in detectable LC by d 28 (4.59 µg/mL) (Figure 8.5 A). 
 In animals injected with vector control cells, two animals, VC 1 and VC 3, demonstrated 
increasing amounts of serum LC protein over the experimental period beginning with 65 and 
121 µg/mL LC at day 7.  The concentration of LC assayed from sera collected at day 14 was  
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Table 8.1 Comparisons of tumors and LC data in RAG 1 -/- mice 
Group Mouse LC in sera (µg/mL) Tumor Present Weight (g) 
D 7 D 28 D 7 D 28 
RAG UT 1 112 1215 No Yes 0.189 
 2 236 4 Yes No  
 3 34 8 Yes Yes 0.002 
 4 43 54 Yes Yes 0.002 
Vector Control 1 65 607 Yes Yes 0.118 
 2 42 0 No No  
 3 121 597 Yes Yes 0.102 
13A2 1 11 6 Yes No  
 2 15 0 Yes N/A  
 3 27 0 Yes No  
 4 28 0 Yes N/A  
13C7 1 35 13 Yes No  
 2 87 12 Yes No  
 3 31 2 No No  
 4 33 7 No No  
Legend: No data available for animals marked N/A 
   
  
Figure 8.5 Serum LC concentrations
concentrations were plotted for RAG 1
8226 cells, B.) Vector control clones, C.) shRNA clone 13A2, or D.) shRNA clone 13C7at 7, 14, 
and 28 days  
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.  Sera LC 
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increased in both animals to 85 and 142 µg/mL, and reached peak concentrations at d 28 with 
samples containing 607 and 597 µg/mL, respectively (Figure 8.5 B).  While LC was detectable 
in the sera from the remaining animal at d 7 (42.99 µg/mL), there was a steep reduction by d 14 
(8.99 µg/mL) and no detectable LC by d 28 (Figure 8.5 B).  
 Of the mice injected with clone 13A2, two (RAG 13A2 1 and RAG 13A2 2), showed 
lower serum LC concentrations at d 7 as compared with their cohorts (RAG 13A2 3 and 4) with 
12 and 16 µg/mL versus 27 and 28 µg/mL, respectively.  By day 14 LC concentrations had 
decreased to > 5 µg/mL for all but RAG 13A2 2, which had a reduced sera LC level of 12.9 
µg/mL.  By day 28 serum LC was below detectable limits for all animals from this group (Figure 
8.5 C).   
 Mice bearing 13C7 tumors demonstrated a similar pattern to that of mice from group 
13A2, with the highest levels of LC observed at d 7 (Figure 8.5 D). 
 Since LC was detectable in the sera of animals from all groups at day 7 this data was 
reanalyzed and 2 animals from the RAG UT group removed (RAG UT 3, 4).  The rationale for 
this is that over the experimental period serum LC did not increase appreciably from day 7, 
possibly indicating problems with the tumor cells.  Removal of these animals increased the mean 
LC concentration for the RAG UT group from 106± 49 µg/mL (n = 4) to 172±64 µg/mL (n = 2).  
Comparisons among the groups without these values using One-Way ANOVA followed by 
Dunnett’s Multiple Comparisons Test now revealed significant differences among between both 
animals from both 13A2 and 13C7 groups as compared with untreated controls, while no 
differences were detected between animals bearing untreated 8226 cells and those bearing vector 
control tumors (Figure 8.6).   
 
  
 
Figure 8.6 Analysis of RAG mice bearing myeloma clone tumors.
human LC were reanalyzed by One
RAG UT 4.  Removal of these animals from analysis reveal a significant (p > 0.01) reduction in 
the serum LC concentration of animals from the RAG 13A2 (mean LC 21.24 ± 4.27 mg/mL) 
group as compared with RAG UT controls (Mean LC 172.5 ± 64.5 mg/mL).  These data also 
indicicate a significant (p < 0.05) reduction in the mean LC concentration of animals 
RAG 13C7 (47.49 ± 13.52 mg/mL)
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Treatment of in vivo S.C. human 8226 tumors with shRNA-bearing lentivirus  
To determine the efficacy of administering a shRNA expression vector to pre-established tumors 
8 female SCID mice received 1 x 107 8226 cells S.C in the inguinal mammary fat pad.  
Unfortunately, 2 of the mice expired under anesthesia during implantation.  The remaining 
animals were monitored for up to 25 days for tumor growth, prior to injection of lentivirus and 
for up to 14 days following treatment - these data are summarized in Table 8.2 and Figure 8.7.   
Of these, one mouse (8226 V1 1) was found to have developed a mass of appropriate size 15 
days pi of cells (Table 8.2).  By 21 d two more mice (pLB 1 and 8226 V1 2) had developed 
masses of similar size (Table 8.2).  Tumors were identified in the final 2 mice (8226 UT and pLB 
2) at day 30 and 35, respectively (Table 8.2).  The final animal from this group had no apparent 
tumorigenesis over the course of the study.   
 Animals which had developed tumors (n = 5) were randomly assigned to receive 107 
lentiviral particles containing either pLB empty vector (group pLB; n = 2) or pLB 8226 V1 
shRNA expressing constructs (group 8226V1; n = 2), while the remaining mouse received no 
treatment and served as a control (8226 UT).  In each animal, sera were harvested immediately 
prior to administration of lentivirus, followed by sampling at 14 d.  The presence of human λ LC 
was measured by ELISA (Chapter 3.9; Total λ ELISA B).  Prior to treatment with lentivirus 
(Day 0) animals randomly assigned to the 8226 V1 group had slightly elevated LC concentration 
in the sera (972.4 ± 135.9 µg/mL, n = 2) as compared to those from the pLB group (2167 ± 386.4 
µg/mL, n = 2), although this was not statistically significant (Figure 8.8 A).  By day 14 this trend 
had reversed itself, with animals from the 8226 V1 group having mean sera LC concentrations of 
2,133 ± 1683  µg/mL, while those from the pLB group were found to have mean LC 
concentrations of 3,685 ± 364.3  µg/mL (Figure 8.8 B).   
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Table 8.2 Tumor sizes in SCID mice 
Group Mouse Day 0* Day 7 Day 14 
  L x W x H  mm3 L x W x H  mm3 L x W x H  mm3 W (g) 
pLB 1 4 x 6 x 3 37.7 5 x 9 x 4 188 14 x 9 x 6 395 0.805 
 2 4 x 5 x 4 41.9 7 x 6 x 5 87.9 10 x 7 x 6 219 0.457 
8226 V1 1 7 x 4 x 4 58.6 7 x 4 x 2 29.3 12 x 10 x 6 377 0.790 
 2 7 x 7 x 7 179 9 x 7 x 4 131 14 x 16 x 4 469 0.989 
8226 UT 1   9 x 6 x 4 113 11 x 7 x 12 483 1.01 
* Timing measured relative to injection of  lentivirus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
SCID est tumor size over time
0 5 10 15
0
100
200
300
400
500
600
8226 UT
pLB 1
pLB 2
8226 V1 1
8226 V1 2
Day
 
Tu
m
o
r 
Vo
l m
m
3
 
 
Figure 8.7 Calculated tumor volumes from individual animals over time.  Female SCID mice 
received 1 x 107 8226 cells as S.C. injections to the inguinal mammary fat pads.  Tumor growth 
was estimated in each animal by measuring height, length, and width of tumors using calipers 
and calculating tumor volume using the formula 4/3pi(ABC).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8.8 Serum LC from 8226 xenograft tumor bearing mice pre
lentiviral expression vectors.  Female SCID bearing 8226 xenograft tumors were treated with 
107 lentiviral particles (pLB N=2; 82
For each animal, sera were analyzed for human LC by ELISA.  Mean LC concentrations from 
sera are shown for A.) pre-treatment or C.) 14 days following administration of virus. Data were 
analyzed by One-Way ANOVA. 
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26 V1 N=2), whereas 8226 UT received no injection (N=1).  
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As a reference the 8226 UT mouse was found to have 5,016 µg/mL serum LC (Figure 8.8 B). 
To account for the differences in tumor size among animals, data collected regarding tumor 
volume (Figure 8.7) along with serum LC ELISA results were used to generate ratios of serum 
LC concentration to tumor volumes for animals from each group at day 14, and the mean ratio  
for each of these groups were plotted (Figure 8.9).  From this, it was found that the average ratio 
of LC production per mm3 of tumor volume for group pLB was 12.63 ± 2.375 µg/mL LC/mm3 
tumor, with the single 8226 UT animal producing 10 µg/mL LC/mm3 tumor, and mice injected 
with 8226 V1 vector producing 4.615 ± 3.515 µg/mL LC/mm3 tumor. 
Sections of kidney and tumor tissue taken from mice and stained were stained by IHC using 
antibodies specific to human λ LC. Comparisons of tumors from these animals revealed little 
difference in the intensity of antibody binding, but do reveal that tumor size along with the 
amount of vascularization and necrotic regions were equivalent among mice.  Evaluation of 
kidneys from animals taken from each of the three groups do, however, reveal differences in the 
amount of antibody binding along the luminal surfaces of the renal tubules as well as within the 
cytoplasm of the renal tubule cells (Figure 8.10 A, B, C).  This difference is most apparent in the 
tubules themselves, where heavy binding is observed along the borders with animals from 
control groups (8226 UT or pLB empty) as compared with those treated with 8226 V1 shRNA 
expressing particles. 
 
8.4 Discussion 
While it is difficult to draw definitive conclusions about the results of these experiments, they do 
demonstrate that shRNA expression vectors can continue to exhibit their inhibitory effect in vivo  
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Figure 8.9 Serum LC production normalized to tumor volume.  Serum LC concentrations 
from ELISA for human LC protein were collected from mice at day 14.  Values were normalized 
to estimated tumor size by dividing LC content by tumor volume and data expressed as µg/mL 
LC/ mm3 tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 8.10 Detection of λ LC in mouse kidneys following treatment with shRNA expression 
vectors.  Mice were sacrificed at 14 d p.i. and kidneys stained for human LC.  Images were taken 
from 200X (left column) and 400X (right column) fields for animal bearing
tumors and receiving A.) no treatment (8226 UT), B.) Vector pLB, or C.) pLB 8226 V1 lentiviral 
particles.  Arrows show regions along the luminal borders of tubules or renal tubular epithelial 
cells.    
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following implantation as xenografts in mice; as was the case at the earlier time points from the 
SCID I.P. and the RAG1 S.C. experiments.    
 Some concerns about these models remain, however, and would to need be addressed in 
future studies.  One of the most problematic issues that arose with the tumor models used herein 
was the large degree of variability in tumor development both among and between groups.  In 
some cases, the standard SEM within a given treatment group for serum LC content was almost 
identical to the mean itself, making it difficult to draw conclusions about outcomes with any 
statistical certainty. 
 Another concern was the apparent loss of tumors observed in the RAG1 mouse line after 
the day 14 time point following implantation of shRNA-treated myeloma clones.  While tumors 
were not present in some of the untreated and vector control animals in this group, all mice 
receiving shRNA clones 13A2 and 13C7 were devoid of perceptible lesions at time of necropsy.  
While differences in cell growth and viability were not apparent during in vitro studies [Chapter 
8], these clones appear to be less fit than the untreated or vector control groups regarding 
survival in vivo.   Re-submission of the shRNA sequence used to generate the 8226 V1  
expression vector to the NCBI BLAST algorithm using the RefSeq_RNA database as reference 
revealed no known RNA transcripts with more than ~50% homology to the siRNA sequence 
used.  While this does not remove the possibility that the encoded shRNA sequence could reduce 
survival of the cells in vivo, it does reduce the likelihood that off-target effects are responsible.  
Another possibility is that the selected clones were less hardy than untreated 8226 cells because 
of lack of variability within the cell population.  Although, it would not be expected that two 
unique clones would be equally susceptible, and the findings that vector control clones were 
successful at colonization also argues against this fact.  At least one study has reported 
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hepatotoxicity in mice receiving lentiviral vectors by tail vein injection.  In this case, expression 
of the shRNA construct was controlled by an RNA polymerase III, as is the case with the system 
used here.  It was hypothesized by the authors that the cytotoxic effects were induced when the 
constitutively expressed shRNA construct overwhelmed the cells natural miRNA pathways, 
resulting in loss of essential post-transcriptional gene silencing (204).  A final alternative that 
may explain the fact that many of the mice did not develop tumors is that the RAG1 -/- knockout 
strain has been shown to be “leaky” and that in some cases the mice develop the capacity to 
produce immunoglobulin (Kennel, et. Al. unpublished data).  If this were the case then the lack 
of tumors in many of the mice used in this study may be due to the animals mounting a humoral 
response to the cells of human origin.  
 Regarding the variability among groups, it would be desirable to increase the number of 
animals per group to determine whether statistical significance might be possible with a larger 
sample size, given the apparent trends towards decreased LC seen among both the I.P. and S.C. 
models.  As for the survival issues with shRNA expressing clones, one potential series of 
experiments would be to redesign the shRNA constructs to target various regions along the LC 
gene transcript, and generate several clones based on each of these vectors.  Here, differences in 
survival among clones might offer evidence to whether the loss of tumors is a problem of design 
or inherent to infection with lentiviral vectors. 
 As for the final series of experiments in which established 8226 tumors were treated with 
empty or shRNA expressing lentiviral particles a larger cohort of animals would be crucial to 
assess the efficacy of this approach.  Given the small sample size (n = 2 per treatment), these 
experiments represent a preliminary study, although the data shown in figure 9.9 seem 
promising, given the decrease in the ratio of LC production with given tumor size.  In 
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conclusion, establishing that the effects of silencing LC proteins using siRNA or shRNA 
molecules in vivo is crucial in translating effects observed in the earlier chapters to a clinical 
model.  These data, while limited, provide the impetus for further study along these lines.  
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Chapter 9 
Summary and Conclusions 
 
9.1 Design of siRNA molecules targeting LC products 
Based on sequencing data acquired from PCR amplification of individual LC gene products 
(Figure 4.1), several candidate small interfering RNA molecules were designed which 
corresponded to sequences along the V, J, and C region for the respective targets (Table 4.2).  
SiRNA sequences targeting the V, or J region of each LC were designed to sites such as the 
borders of framework- and complimentarity defining regions, or recombination sites between the 
V and J regions of the LC molecule.  These sites were selected because they represent areas of 
the molecules which are most likely to house sequences that are significantly different to their 
respective LC germline genes or to other LCs within the same isotype sub-class (i.e., λ or κ) 
(226, 227).  Alternately, sites of conserved homology were selected within the C region for both 
λ and κ isotypes.  Selection of these regions allowed for the design and synthesis of class 
specific siRNAs which could target a broad range of LC molecules of a given sub-type.   
 Initial experiments in silencing LC products were carried out in both κ and λ producing 
human myeloma lines (cell lines Bur and RPMI 8226) as well as a transgenic mouse myeloma 
line engineered to produce a patient derived amyloidogenic recombinant λ6 LC molecule 
(SP2/O-λ6; Wil).  Screenings of various transfection reagents using fluorescently labeled non-
silencing siRNA molecules to transfect these lines were conducted (Table 4.3) and a suitable 
reagent (HiperFect) was identified which could efficiently (> 90% of cells transfected; Figure 
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4.3) deliver the nucleic acid cargo to all cell lines used in these studies without inducing a 
cytotoxic response.  
 
9.2 Effect of targeted siRNA molecules on LC synthesis 
 As demonstrated in Chapter 5, exposure of either mouse or human myeloma lines to 
siRNAs targeting V, J, and C regions of their secreted LC gene products elicited significant 
reductions in target mRNA (25-61%) and secreted protein (25-75%) when compared with 
untreated control cells (Figure 5.2, 5.4).  The effect of these interfering RNAs on LC production 
was observable within 24 hrs of exposure, and appeared to be maintained for 48-72 hrs 
afterwards.  Additionally, neither the addition of siRNAs or transfection reagent to cell cultures 
seemed to negatively affect cell growth or viability (Figure 5.3).   
 While these results indicate the potential of siRNAs to affect LC production, it is evident 
that this is a transient reduction in secreted product.  One possible explanation for this loss of 
activity is the loss of siRNA molecules over time.  Supporting this hypothesis, Figure 5.1 depicts 
histograms generated using flow cytometry to detect the presence of a fluorescently labeled 
siRNA molecule at 24 h, 48 h and 72 h following exposure to either mouse (SP2/O-λ6) or human 
(8226) myeloma lines.  In this case, both lines exhibit a high degree of uptake for labeled siRNA 
molecules (> 95% of cells were positive) at 24 hrs.  Following along with line SP2/O-λ6, a 
reduction in positive cells is apparent by 48 h (~60% positive), which is further reduced by 72 h 
(~40% positive).  When these data are compared with those for cell number and viability (Figure 
5.3) it appears that the greatest decrease in the number of positive cells (24-48 hrs; 96%-59%) 
also corresponds to the time period (24-48h) demonstrating the largest increase in cell number (2 
x 105 - > 2 x 106 cells well-1) for this line.   
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 Although the population of 8226 cells remained >90% positive for the duration of the 
experiments, careful examination of the flow cytometry histograms over the time periods 
assayed reveals an apparent decrease in fluorescent intensity among cells.  Although it is unclear 
whether this loss is attributable to decreased signal from the fluorescent label over time or due to 
dilution of the siRNA molecules across cell divisions, it is interesting that a similar population of 
cells appeared as a “shoulder” of cells with decreased fluorescence at 48 h in the SP2/O-λ6 line 
and 72 h in the 8226 line, and that the appearance of this population is most apparent at time 
points when lines were seen to noticeably increase in cell number.   
 A final piece of evidence that the observed loss of effect on LC production was a function 
of loss of siRNA molecules per cell is seen in flow cytometry experiments using clones of cell 
line 8226 which had been stably transfected with constructs which produce both shRNA 
molecules as well as enhanced green fluorescent protein (EGFP) as a reporter molecule (Figure 
7.9).  In this case, the production of EGFP is expected to be maintained among daughter cells 
following division, and as a result, the “shoulder” observed in the previous model system is not 
seen.   
 
9.3 Design and generation of lentiviral expression vectors    
 The data summarized in Section 9.2 are promising, and demonstrate the utility of siRNA 
molecules in reducing LC production in myeloma lines, although the transient nature of this 
reduction remains a concern.  One approach to address this was to alter the delivery system of 
effector molecules from one that provided a single “dose” of siRNAs, to one that offered a 
renewable, and thus, a sustainable supply of silencing molecules.  It has been reported in 
myeloma lines that silencing of various proteins has been achieved using viral mediated delivery 
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of constructs which express shRNA molecules (213, 217).  While these studies did not 
specifically target LC proteins, they do demonstrate the successful transfer of gene expression to 
these cells from viral particles.       
 To test whether the level of silencing mediated by a shRNA expression system would be 
robust enough to effect a reduction in LC protein expression, two constructs (Wil V1 and 8226 
V1), which had been shown effective at reducing LC production (Figure 5.4), were modified to 
incorporate a hairpin-loop structure (Table 6.1) and were cloned into the pLB lentiviral 
expression plasmid (Figure 6.2).  These constructs were shown to effectively produce visible 
quantities of EGFP protein when transiently transfected to the kidney line HEK 293t by 
fluorescent microscopy (not shown).  These constructs were also shown to be functional 
following packaging within lentiviral particles by exposing naïve HEK 293t cells to supernatants 
from cultures which had been previously co-transfected with plasmids encoding viral coat 
proteins and packaging signal sequences along with pLB expression vectors (Figure 6.6).  
A lack of EGFP expression was seen in human myeloma lines following exposure to 
supernatants, although this was likely due to the low amount of virus produced from this system, 
as there was no way to concentrate viral particles to a higher titer solution.   
 
9.4 Effect of shRNA expressing lentiviral vectors on LC production 
 Cell supernatants containing high titers of infective lentiviral particles encoding either the 
empty pLB plasmid (pLB) or plasmids which include constructs encoding shRNAs directed to 
either LC 8226 (pLB 8226V1) or LC Wil (pLB Wil V1).  
 By 24 h exposure of the human myeloma line 8226 to viral particles containing plasmid 
pLB or those encoding pLB 8226V1 induced the expression of the reporter protein EGFP. The 
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proportions of cells expressing EGFP were found to increase for both lentiviral vectors as the 
MOI for each virus was increased over a range of 0.5-50 (Figure 7.2, 7.4).  Assessment by flow 
cytometry revealed that exposure to either virus at levels of MOI 100 resulted in the maximum 
number of EGFP positive cells attainable (~30%) without inducing cytotoxicity (Figure 7.4). 
Among the populations of cells exposed to lower amounts of virus (MOI 0.5-10) there appeared 
to be a dose dependant reduction of secreted LC as compared with control cells when 
supernatants were assayed at day 7, which seemed to peak at around MOI 2.5 (Figure 7.3). When 
supernatants from cells exposed to higher viral titer (MOI 10-50) were assayed, two of the 
groups (MOI 10 and MOI 50), were found to be producing significantly reduced amounts of 
protein when compared with untreated cells (Figure 7.5).  
 Unexpectedly, similar exposures of the mouse myeloma line SP2/O-λ6 to increasing 
levels of virus pLB Wil V1 failed to elicit EGFP expression in cells (Figure 7.7).  This was likely 
a combination of poor virus preparation combined with cells which were refractory to 
transduction as exposure of 8226 cells to pLB Wil V1 yielded no increase in EGFP and exposure 
of the SP2/O line to pLB 8226 V1 resulted in a slight increase in EGFP positive cells 
(Figure7.8). 
 Observations were also made regarding LC productions in clonal populations of 8226 
cells which had been positively transfected with both virus pLB and pLB 8226 V1 (Figure 7.9).  
Several of the lines exposed to the shRNA expressing viral particles were shown to secrete 
reduced amounts of LC mRNA and protein as compared with untreated cells (Figure 7.10, 7.12), 
while, with a single exception, those exposed to pLB were found to secrete equivalent levels 
(Figure 7.10).   
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9.5 LC secretion by shRNA expressing clones in vivo 
 Of the shRNA expressing clones generated, 2 were selected for injection to the peritoneal 
cavity of immunocompromised SCID mice alongside mice receiving either untreated 8226 cells 
or those receiving a clone generated from pLB empty infected cells.  Assay of sera taken from 
one group mice implanted with shRNA clone cells or untreated 8226 cells at 7 and 14 days p.i. 
revealed increased levels of LC (Figure 8.1).  From this figure it also appears that the amount of 
LC in the sera from mice bearing the shRNA expressing cells was lower than that from animals 
bearing the parental line.  While similar results were observed at day 28 in mice receiving the 
alternate shRNA expressing clone, it is difficult to determine if this reduction is due to a 
reduction in LC secretion or due to the loss of clonal cells. 
 Following these studies a second immunocompromised mouse line (RAG1 -/-) received 
either shRNA expressing clones, pLB empty clone, or untreated 8226 cells as s.c. injections.  
From these mice, tumor growth was apparent for up to 14 days post injection, as assessed by 
manual palpation of animals (Table 9.1).  Although, beyond the 14 day timepoint lesions were 
not detectable in animals bearing the shRNA expressing cells (Table 9.1).  While the cause of 
tumor regression is undetermined several possibilities were postulated in Chapter 8.4. 
 Analysis of sera taken from animals at day 7 did reveal reductions in LC content from 
mice receiving either shRNA expressing clones as compared with animals bearing untreated 
8226 tumors (Figure 8.6).    
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9.6 Treatment of established tumors with lentiviral particles 
 In a final series of experiments, xenograft tumors consisting of 8226 cells were generated 
within the mammary fat pad of 5 female SCID mice.  Tumor growth was monitored and when 
lesions reached roughly equivalent sizes mice received intratumoral injections of viral particles 
bearing either pLB empty or pLB 8226 V1 expression plasmids.  While assay of sera from 
animals prior to injection revealed mice from group 8226 V1 had higher levels of LC to those 
receiving pLB empty vector particles, by day 14 this trend appeared to have reversed (Figure 
8.8).  Ratios of tumor size versus sera LC production from day 14 also revealed that tumors from 
animals in group 8226 V1 appeared be producing lower levels of LC per mm3 than animals 
receiving sham injection, or the animal bearing untreated 8226 cells.         
 Perhaps the most compelling data taken from this series of experiments was shown in 
Figure 8.9, which depicts the IHC staining for human λ LC within renal tubules from animals 
receiving pLB 8226 V1 particles versus pLB empty or untreated control animals.  From these 
images it appears that tubules stain more strongly in control animals than in those receiving virus 
bearing functional shRNA expression vectors.  Most striking is the almost lack of staining for LC 
along the luminal epithelia of these animals.  In contrast, animals from both control groups were 
shown to be highly positive for staining along this region. 
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9.7 Conclusions of studies 
 Taken together, these data demonstrate that exposure to myeloma cells to silencing RNAs 
will induce a targeted reduction in LC molecules.  Studies from cells in culture provided positive 
evidence that this reduction can be elicited by either viral or non-viral delivery of interfering 
RNAs and provided the basis for the constructs used for in vivo studies.    While tumors formed 
by these clones generate measureable amounts of LC which is secreted to the sera, further studies 
should be conducted to confirm that these reductions are a result of the shRNA construct and not 
a consequence of viral transduction.  Along those lines, additional RAG1 -/- might be implanted 
with a larger variety of clonal 8226 cells to test whether some cells might be more fit for 
implantation in vivo.  Also, the inclusion of a third control group, composed of cells transduced 
with constructs expressing non-silencing shRNAs should be included to answer whether the 
constitutive expression of shRNA molecules may impact survival.  
 To further strengthen the case that shRNA expressing lentiviral particles can indeed 
effect LC production in established tumors a larger number of mice should be recruited for study.  
In addition, mice could also be given a higher number of viral particles than used in the current 
study in order to account for increased cell numbers found in tumors which are large enough for 
injection.  Further, staining of tumor tissue for presence of EGFP positive cells either by PCR 
amplification of gene products or by IHC staining might provide insight to the efficiency of 
silencing in these mice by determining the proportion of transduced versus non-transduced cells.     
 As the field of siRNA delivery is constantly growing, alternative means to viral delivery 
should be explored for the transfection of cells in vivo.  Although the viral vectors used for these 
studies provided a relatively safe method of treatment for mice bearing established tumors it may 
be desirable to identify a non-viral means to introduce silencing RNAs in a clinical setting.    
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9.8 Closing Remarks 
 The goal of personalized gene therapy using siRNA molecules currently remains 
unrealized, however, as this study has shown RNAi provides a robust and flexible means to 
reducing the production of pathologic moieties.  This section contains a brief narrative of how 
the inclusion of siRNAs might alter the treatment of a patient with AL amyloidosis.   
 Figure 1.6 outlines the current treatment strategy of patients diagnosed with a PCD.  This 
process starts with the diagnosis of pathology along with staging of the disease.  In this case the 
patient presents with elevated serum creatnine levels along with abnormal findings by 
echocardiogram along with the presence of BJP in the urine.  Staining of fat and renal biopsy 
tissue with Congo red reveals congophilic bodies, which exhibit apple green birefringence when 
viewed under polarized light.  N-terminal protein sequencing of this material confirms it is 
composed of λ2 LC, and yields a partial 12 amino acid sequence.  IHC evaluation of bone 
marrow aspirates reveals a small cadre of clonal plasma cells composing ~3% of the total cell 
population.  Whole body CT scans fail to identify presence of lytic bone lesions.   
 The patient begins conventional chemotherapy with a combination of Melphalan and 
Prednisone.  Upon re-evaluation renal function has worsened and BJP content of the urine has 
increased.  Because of the patient’s age (60 yrs) they would be eligible for ASCT (Chapter 1.3) 
however, because of renal involvement they are a poor candidate.  As other studies have shown 
that reduction of serum LC content can lead to improved organ function and outcomes in AL  
(160) the patient elects to receive siRNA therapy to reduce LC production.  As it was previously 
determined that the LC involved in deposition was a member of the λ sub-type the patient 
receives synthetic siRNA molecules designed to the λ C region as an i.v. infusion using a neutral 
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peptide carrier.  Evaluation of patient serum and urine reveals a ~25% reduction in LC levels 2 
days p.i. compared with the pre-injection values and a 15% reduction at 5 days.   
 DNA sequencing of the pathologic LC was conducted by first translating the N-terminal 
protein sequence to nucleotides, which were used to generate an LC specific primer.  Primers 
specific to the λ2 C region provide the reverse template.  The patient LC is sequenced and a 60-
bp shRNA molecule is designed with an 18 bp stem region complimentary to the pathologic LC, 
but shares less than 50% homology to the λ 2 germline gene. This shRNA construct is cloned 
into a tissue specific viral expression vector and is driven by the LC V region promoter and Cµ 
enhancer element.  These expression plasmids are packaged as self-inactivating viral particles, 
which have been pseudotyped with coat proteins which target CD 138, which has been shown to 
be upregulated in neoplastic plasma cells (228).  This system provides both a targeted delivery of 
gene products as well as an expression system which is driven by B-cell specific regulatory 
elements.   
 Following secondary evaluation, the patient receives an injection of viral particles and is 
monitored for unwanted immune responses.  Patient sera is re-evaluated over a 2 week period 
and shown to contain consistently less LC than the pre-injection levels.  Subsequent evaluation 
of renal function shows improvement and the patient begins the process for ASCT.    
 As mentioned in the opening of this section, this scenario is based solely on conjecture 
and provides a “what if?” scenario for illustrative purposes only.   
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Appendix 1 
Detection of immunoglobulin light chain gene products 
A1.1 Rationale 
In order to test the hypotheses put forth for these studies it is important to have reliable systems for 
accurately measuring differences in levels of LC mRNA and proteins.  To do this, several 
methodologies were adapted and developed that produce accurate and reproducible measurements 
of LC gene products following exposures to experimental and control siRNAs and shRNA 
expression systems.  Those used for detection of protein included Immunoprecipitation of 
radiolabeled newly synthesized LC proteins from cell lysates, Enzyme Linked Immunosorbance 
Assay (ELISA), and fluorescent immunolabeling of intact cells for analysis by flow cytometry; LC 
mRNA levels were assessed using PCR and Real Time PCR.   
 
A1.2 Detection of LC Gene Expressionby Real time PCR 
Cells and culture conditions 
Myeloma lines SP2/O-λ6, RPMI 8226, and Bur were maintained as described in Section 3.1.  At 
time of experiments cells were harvested by centrifugation.  Supernatants were removed to clean 
tubes and stored at 4° or -20° until time of assay.  If required, cell washes were carried out by 
resuspending in PBS containing 1% BSA.   
 
Real Time PCR 
For each line, cells were lysed, total RNA extracted, and cDNA synthesized by Reverse 
Transcriptase reaction as described in Sections 3.3 and 3.4. Primers were designed to the LC 
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product of either SP2/O-λ6 (Fwd 5’AATTTTTTACTGACTCAGCCCC-3’, Rev 5’-
ACTTGGTCCCTCCGCCGAAAAC-3’) or RPMI 8226 (Fwd 5’-gCCCTCAGGGGTTTCTAA     
TC-3’, Rev 5’-CTTTGTTTGGAGGGTGTGGT), each of which generated a 100 bp fragment.  For 
the SP2/O-λ6 line, mouse glyceraldehyde 3-phosphate dehydrogenase (mGAPDH; RealTime 
Primers, LLC.; Fwd 5’-CTGGAGAAACCTGCCAAGTA-3΄, Rev 5΄-TGTTGCTGTAGCCGT-
ATTCA-3΄, 223-bp product) was used as reference gene.  Likewise human GAPDH (hGAPDH; 
RealTime Primers, LLC; Fwd 5΄-GAGTCAACGCGGATTTGGTCGT-3΄, Rev 5΄-TTGATT- 
TTGGAGGGATCTCG-3΄, 238-bp product) or human β-actin (hβ-actin; RealTime Primers, LLC; 
Fwd 5’- GGACTTCGAGCAA- GAGATGG-3’, Rev 5’- AgCACTgTgTTggCgTACAg-3’) served 
as the reference genes for the RPMI 8226 line.  Real-time PCR reaction was carried out using IQ 
SYBR Green Supermix (BioRad) containing 400 nM primer mix and 3 µL cDNA following 
manufacturer’s instructions.  Amplification was performed in 96-well PCR plates (BioRad) using 
an ICycler PCR unit and fluorescence detected by an IQ5 Multicolor Real-Time PCR system 
(BioRad).  TAQ activation and denaturation was achieved in 1 cycle at 95°C for 3 minutes which 
was followed by forty 30-second amplification cycles at 95°C, 63°C, and 72°C. Relative LC 
mRNA levels for cells in each experimental siRNA treatment group were calculated using the 
2∆∆CT  method (229) and reported using cells receiving AllStars siRNA as the reference group.   
 
Optimization of Reactions 
The first step in developing the real time PCR conditions used in this study were the design of 
experimental primer sets.  Deduced LC sequences were entered into the NCBI Primer-BLAST 
primer designing tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  For each primer set, 
BLAST search parameters were set to return PCR products with lengths of between 90-110 bp and 
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melting temperatures (TM) ranging from 60-70° C.  Specificity checks were performed using the 
refseq mRNA databases for H. sapiens and M. musculus to avoid amplification of unintended gene 
products, while search stringency was set so that primers must have had at least 2 bp mismatches to 
unintended targets.   
For each gene target 6-8 primer sets were tested for functionality by Reverse Transctiptase-PCR of 
selected myeloma cell total RNAs followed by product separation by agarose gel electrophoresis. 
Amplicons were visualized under UV light following staining with ethidium bromide.  Primer sets 
which failed to amplify any product, or those which generated multiple bands were eliminated 
from consideration. 
Real-time PCR conditions were optimized for the IQ SYBR Green Supermix by ranging the 
annealing temperature from 60-72° using the temperature gradient curve protocol on the ICycler 
PCR unit.  For each LC product, primer sets were selected which achieved target amplification 
above thresh hold levels at the lowest cycle number.  The presence of single PCR products from 
each of these sets were confirmed by analysis of melt curves following each reaction.   
The final step in selection of PCR primers for LC products was to determine amplification 
efficiencies for each primer set.  This was conducted by setting up 10-fold serial dilutions of LC 
cDNA followed by analysis by real-time PCR.  In the case of each primer selected, the 
amplification efficiencies were found to be between 90-110%. 
Discussion 
Real-time PCR was used to determine relative expression of LC mRNA for cell lines SP2/O-λ6 
and RPMI 8226 with or without exposure to LC targeting or non-silencing control siRNAs.  In the 
case of these experiments, the fluorescent dye, SYBR Green, was used to measure the amount of 
double stranded nucleic acids in each reaction.  Because the fluorescent signal generated by SYBR 
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Green is generated as the dye becomes intercalated within double-stranded nucleic acids it is not 
product dependant amplification specificity is critical.  This was initially addressed in the design of 
PCR primers by using the Primer-BLAST design algorithm which recommended primer sets that 
were only expected to amplify the LC genes of interest.  These expectations were later confirmed 
by amplifying cDNA generated from either SP2/O-λ6 or RPMI 8226 cells and visualization on 
agarose gels. 
Because real-time PCR steps are kept relatively short (30 sec each), the length of the PCR product 
can influence reaction efficiency.  Thus, we followed recommendations put forth by Bio-Rad and 
limited our primer sets to generate products of around 100 bp.    
Comparisons among treatment conditions in real-time PCR experiments may be influenced by the 
amount of starting material present in samples.  To control for this, a “reference” gene was selected 
to normalize samples within each experiment.  Typically a reference gene measures product levels 
of a so-called housekeeping gene whose levels may be rationally expected to remain stable among 
cells.  In this case, we used either human or mouse GAPDH and β-actin as our housekeeping 
genes. 
The final consideration in designing a real-time PCR reaction is the relative efficiencies of target 
versus reference gene amplification efficiencies.  This refers to the notion that, under ideal 
conditions, each cycle of a PCR should exactly double the amount of double stranded material 
from that found at the start of the reaction.  Amplification efficiency is accounted for 
mathematically by the base in the formula 2∆∆CT.  For example, if the efficiency of the reaction is  
100%, then the formula for calculating relative expression levels is 2∆∆CT , while if the effiency 
were lower, say 90% then the formula would be 1.9∆∆CT .  If the amplification efficiencies between 
the gene of interest (GOI) and the reference gene differ significantly, the results will be inaccurate.  
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A simple test for primer amplification efficiency is to set up a 1:10 dilution curve of cDNAs.  
Under optimal conditions, subsequent dilutions should generate amplification curves which cross 
the thresh hold value at exactly 2 cycles difference.  In the case of these studies the amplification 
efficiency of LC primers and reference gene primers were between 90-110%.                  
 
A1.3 Detection of LC protein by ELISA 
Antibody Selection 
Lyophilized patient derived BJPs (κ or λ, respectively) were acquired from the HICP and 
reconstituted to ~10 µg/ml in PBS, for list see Table 5.1.  100 µl of diluted BJP were added in 
duplicate wells to the first row of a 96-well high binding ELISA/RIA plates followed by 1:1  
serial dilution down plate. Plates were covered and BJPs bound overnight by incubation at 4°.  
Plates were blocked for 1 h at RT followed by the addition of 100 µl of 10 µg/µl antibody to be 
tested.  Binding to antigen was detected by the addition of either HRP conjugated goat anti-mouse 
or goat anti-rabbit antisera (Jackson Immunoresearch).  Wells with BJP but no antibody served as 
control.    
 In another series of experiments tentative primary antibodies (1 µg/µl; 100 µl) were bound to 
plates as above followed by blocking and addition of serially diluted BJPs.  Unconjugated 
secondary antibodies were added at 1 µg/µl while HRP conjugated secondary antibodies were 
added at dilutions of 1:2,000-10,000. For a list of antibodies tested see Table 5.2. 
 
Standard Curves 
Serial dilution (1:1) of patient derived BJPs with known concentrations were prepared which 
spanned the dynamic range of ELISAs.  Abs405 readings were collected using method described in  
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Table A1.1 BJPs used in developing ELISA assay 
Isotype BJP Isotype BJP 
λ1 Houston κ1 Galyon 
 Locke  Watts 
 Cox  Bur 
λ2 Rhea κ3 Dooley 
 Levin κ4 Lenoir 
λ3 Kirby   
λ6 JTO   
 Wil   
BJPs in bold were used to generate standard curves in final ELISA 
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Table A1.2 Antibodies Tested For ELISA 
 
 Source/ 
specificity 
 Pass/Fail 
Bound 
Sandwich Pass/Fail 
Target Antibody Vendor Primary Secondary 
λ6 
(Wil) 
55-5F5 Mouse α hλ6 mAb HICP NT P NT 
R604 Rabbit α hλ6 pAb HICP NT NT P 
 15A4 Mouse α hλ6 mAb HICP P F F 
 9D2 Mouse α hλ6 mAb HICP F   
 15A4 Mouse α hλ6 mAb HICP P F F 
 14B Mouse α hλ6 mAb HICP F   
 14C Mouse α hλ6 mAb HICP F   
Total λ 
(Rhea) 
(Cott) 
21-3F4 Mouse α hλ mAb HICP P P P 
18-9G11 Mouse α hλ mAb HICP P P P 
AO193 Rabbit α hλ pAb Dako P P P 
 Star130P HRP Rabbit αhλ 
pAb 
AbD 
Serotec 
P NT P 
 AHI1804 HRP Rabbit αhλ 
pAb 
Invitrogen P NT P 
Total κ 
(Bur) 
AO191 Rabbit α hκ pAb Dako P P NT 
Star127P HRP Rabbit αhκ 
pAb 
AbD 
Serotec 
P NT P 
Legend: Antibodies for each ELISA were tested in various combinations using target antigen shown in 
parenthesis. Pass/Fail Bound refers to reactivity to antigen plated antigen. Sandwich Pass/Fail refers to 
reactivity of antibody in sandwich format.  For non-HRP antibodies, binding was detected using species 
specific HRP conjugated goat antisera (Jackson ImmunoResearch).   
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Chapter 3.9 from duplicate wells.  Data were entered into Microsoft Excel and fit to either 
logarithmic or linear regression curves.  Calculated R2 values provided a measure of fit, while the 
formula of the line was used to calculate LC concentrations from cell supernatant or mouse sera. 
 
ELISA Protocol 
For all ELISAs the following standard conditions were used.  Primary antibodies were diluted to 
concentrations of ~10 µg/ml in PBS, and 100 µl of each were added to each well of 96-well high 
binding ELISA/RIA plates.  Antibody binding was accomplished either by incubation overnight at 
4° C or for 2 h at 37° C.  Plates were blocked with PBS + 1% bovine serum albumin (BSA) for 1 h 
at room temperature.  Antigen and further antibody bindings were carried out by adding 100 ml to 
each well followed by 1 h incubations at room temperature.  Between steps plates were washed 3x 
in Tris buffered saline containing 0.1% tween20.  Plates were developed using ABTS and 
absorbance read as described in Chapter 3.9. 
 
Final ELISA Formats 
Figure 5.1 depicts a graphical representation of the antibodies and standards used for detection of 
LC products and are reflective of assays reported in Chapter 3.9 and 6.3. A dilution series of 
standards were included on each plate.  Based on initial test plates, standards diluted to encompass 
either the linear or logarithmic phase of calculated regression curves so that the calculated R2 for a 
given line was > 0.9.  Figure 5.2 depicts several sample standard curves from individual ELISAs.      
  
 Figure A1.1 Final ELISA Configurations.
using A) human λ6 ELISA while the LC product of cell line 8226 were mea
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 LC products of cell line SP2/O-λ6 
 
  
 
were measured 
 
 Figure A.1 2 Sample standard curves from various ELISA formats.
generated from A.) Total λ 6 ELISA using patient derived BJP Wil, B.) Total 
Rhea, Total λ ELISA B with Cot standard curve in C.) the log phase or D.) the linear phase, and 
E.) Total κ ELISA using BJP Bur as a standard.  Curves and standards 
considered valid if unknown samples of interest fell within the dynamic range of the assay and if 
R2 > 0.98 for the curve. 
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  Standard curves were 
λ ELISA A with BJP 
used to generate them were 
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